Antibody-drug conjugates and their use in the treatment of cancer

By employing specific compounds and conjugation methods, ADCs with controlled Drug-to-Antibody Ratio (DAR) are produced, addressing the challenge of variable stoichiometry and reducing toxicity, thus enhancing cancer treatment efficacy.

WO2026234255A1PCT designated stage Publication Date: 2026-11-12BIONTECH SE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063464
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing antibody-drug conjugates (ADCs) face challenges in achieving a controllable and consistent payload stoichiometry, which affects their potency and toxicity, necessitating improved compounds and methods for preparing ADCs.

Method used

Development of compounds with specific structures and conjugation methods, such as selective reduction/oxidation of disulphide bonds, to achieve a Drug-to-Antibody Ratio (DAR) of about 1, resulting in ADCs with reduced toxicity and controlled DAR.

Benefits of technology

The proposed compounds enable the preparation of ADCs with a consistent DAR of 0.5 to 2.0, enhancing potency while minimizing toxicity, thereby improving the therapeutic efficacy of cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026063464_12112026_PF_FP_ABST
    Figure EP2026063464_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Compounds of formula (I-A) or (II-A) are provided: wherein R1, R2, n, m, x, R3, R4, R5, R6, u, v, r, LG1, and LG2 have the meanings defined herein. Also provided are synthetic routes for the production of such compounds and methods of producing antibody-drug conjugates (ADCs) using such compounds. The present invention also relates to the ADCs prepared using such compounds and the use of such ADCs as medicaments, in particular in the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] COMPOUNDS

[0002] FIELD OF THE INVENTION

[0003] This invention relates to compounds which are useful for preparing antibody-drug conjugates (ADCs). The invention also relates to synthetic routes for the production of such compounds and methods of producing ADCs using such compounds. The present invention also relates to the ADCs prepared using such compounds and the use of such ADCs as medicaments.

[0004] BACKGROUND

[0005] Antibody-drug conjugates (ADCs) have prompted a revolution in the treatment of cancer. ADCs, comprising antibodies conjugated to payloads (e.g. cytotoxic agents) via a cleavable linker, have emerged as novel therapeutic options.

[0006] Upon binding with the cell surface antigen targeted by the specific antibody, the ADC is internalized by the tumour cell and processed by the endo-lysosomal system. Within the tumour, cognate antigen-positive cells are bound by the antibody, the payload is released through the cleavable linker technology and results in cytotoxic activity.

[0007] ADCs can induce tumour cell death through the so-called bystander effect, which occurs when the cytotoxic warhead diffuses across the cell membrane to neighbouring cells, thus inducing their apoptosis. ADCs can interact with cancer and immune cells by eliciting mechanisms such as immunogenic cell death, antibody-dependent cell-mediated cytotoxicity and dendritic cell activation. An example of an ADC approved as a human medicine is trastuzumab deruxtecan (Enhertu®), which contains deruxtecan as the linker-payload moiety.

[0008] The payload stoichiometry is known as the drug-to-antibody ratio (DAR), which can greatly affect the potency of the ADC. Variations in the site of payload conjugation and DAR can impact the predictability of the ADC pharmacokinetic profile. For example, while a higher DAR can enhance potency, it might also introduce increased toxicity.

[0009] Thus, there remains a need in the art to develop improved compounds and methods for preparing ADCs, for example compounds and methods which allow for a controllable and consistent payload stoichiometry.

[0010] SUMMARY OF THE INVENTION

[0011] In a first aspect, there is provided a compound having or comprising a structure shown as formula (l-A) or formula (I l-A) or pharmaceutically acceptable salts or solvates thereof:(i) wherein formula (l-A) is:

[0012]

[0013] wherein:

[0014] Ri and R2 are each independently selected from H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, each optionally substituted;

[0015] n and m are each independently from 0 to 20; and

[0016] x is 0, 1, 2, 3, 4, or 5; and

[0017] (ii) wherein formula (ll-A) is:

[0018]

[0019] wherein:

[0020] R3, R4, Rs and R6are each independently H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, each optionally substituted;

[0021] LG1 and LG2 are each independently a leaving group;

[0022] R9 and R10 each independently consist of -(EO)s-(CH2)t-, wherein EG is an ethylene glycol moiety, the terminal carbon of which is attached to the group -N(Rs)- or -N(Re)- and the terminal oxygen of which is attached to the group -(CH2)t, wherein s is from 0 to 10 and t is from 0 to 15, provided that s and t are not both 0;u and v are independently from 0 to 10; and

[0023] r is 0, 1, 2, 3, 4, or 5.

[0024] In some embodiments, the compound of the invention has the structure shown as formula (I-A). In one embodiment, n and m are each independently selected from 1, 2, 3, or 4, preferably wherein n and m are both 1. In one embodiment, x is 0, 1, 2, 3, or 4, preferably wherein x is 1 or 4. In one embodiment, Ri and R2 are each independently selected from H or a C1-3 alkyl, preferably wherein R1 and R2are both H. In one embodiment, the chiral center * is in R configuration. In one embodiment, the compound has the structure shown as formula (l-A-1) or formula (l-A-2) or formula (l-A-3) or pharmaceutically acceptable salts or solvates thereof.

[0025] In other embodiments, the compound of the invention has the structure shown as formula (II-A). In one embodiment, u and v are independently selected from 1, 2, 3, or 4, preferably wherein u and v are both 1. In one embodiment, r is 0, 1, 2, 3, or 4, preferably wherein r is 1. In one embodiment, R3and R4are each independently selected from H or a C1-3 alkyl, preferably wherein R3and R4are both H. In one embodiment, R5and R6are each independently selected from H or a C1-3 alkyl, preferably wherein R5and R6are both methyl. In one embodiment, LG1 is a sulfonate having formula -SO2R7 and LG2 is a sulfonate having formula -SO2R8, wherein R7 and Rs are each independently C1-6 alkyl or substituted C1-6 alkyl, preferably wherein R7 and Rs are each independently selected from H or a C1-3 alkyl, more preferably wherein R7 and Rs are both methyl. In one embodiment, the chiral center * is in R configuration. In one embodiment, s is from 1 to 10 and t is from 0 to 10, preferably wherein s is 2 and t is 1. In other embodiments, R9 and Rware each independently selected from 01-015 alkylene.

[0026] In some embodiments, the compound of the invention has the structure shown as formula (I l-A-1 ) or a pharmaceutically acceptable salt or solvate thereof, wherein R3, R4, Rs, Rs, u, v, r, LG1, and LG2 are as defined for formula (ll-A). In one embodiment, the compound of the invention has the structure shown as formula (I l-A-2) or a pharmaceutically acceptable salt or solvate thereof. In other embodiments, the compound of the invention has the compound has the structure shown as formula (I l-A-3) or a pharmaceutically acceptable salt or solvate thereof wherein R3, R4, Rs, Rs, u, v, r, LG1, and LG2 are as defined for formula (ll-A); and x and y are each independently from 1 to 15, preferably x and y are each independently from 1 to 6, preferably wherein x and y are both 2 or both 3. In one embodiment, the compound of the invention has the structure shown as formula (ll-A-4) or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the compound of the invention has the structure shown as formula (ll-A- 5) or a pharmaceutically acceptable salt or solvate thereof.In some embodiments, the compound of the invention further comprises a payload moiety, preferably wherein the payload moiety is a cytotoxic drug. In one embodiment, the payload moiety is a tubulin polymerisation inhibitor, a DNA damaging agent, a TOPO1 inhibitor, an auristatin, a maytansinoid, or a calicheamicin. In one embodiment, the payload moiety is a TOPO1 inhibitor. In one embodiment, the TOPO1 inhibitor is a camptothecin or an exatecan, or a derivative thereof, preferably wherein the TOPO1 inhibitor is exatecan.

[0027] In some embodiments, the compound of the invention further comprises a linker moiety. In one embodiment, the linker moiety comprises a peptide moiety, preferably wherein the peptide moiety consists of 1 to 10 amino acid residues, more preferably wherein the peptide moiety consists of 1 to 6 amino acid residues. In one embodiment, the linker moiety further comprises a spacer moiety, preferably wherein the spacer moiety is present between the peptide moiety and the payload moiety.

[0028] In one embodiment, the compound of the invention has a structure shown as formula (l-C) or formula (I l-C) or pharmaceutically acceptable salts or solvates thereof:

[0029] (i) wherein formula (l-C) is:

[0030] O

[0031] L - P

[0032]

[0033] (l-C)

[0034] wherein: Ri, R2, n, m, and x are as defined above; L is a linker moiety; and P is a payload moiety; and

[0035] (ii) wherein formula (ll-C) is:

[0036]

[0037] wherein: R3, R4, Rs, Rs, u, v, r, LG1, and LG2 are as defined above; L is a linker moiety; and P is a payload moiety.

[0038] The linker moiety L and the payload moiety P are not particularly limited and any suitable linker-payload moieties may be used in the present invention. In some embodiments, the payload moiety has a structure selected from any of formulas (lll-A) to (Vlll-A). In some embodiments, the compound comprises a linker-payload moiety having a structure selected from any of formulae (lll-B) to (Vl-B).

[0039] In one embodiment, the compound of the invention has a structure shown as formula (l-B) or formula (I l-B) or pharmaceutically acceptable salts or solvates thereof:

[0040] (i) wherein formula (l-B) is:

[0041]

[0042] wherein: R1, R2, n, m, and x are as defined above; and LG3 is a hydroxyl group or a leaving group, for example a halogen; and

[0043] (ii) wherein formula (ll-B) is:

[0044]

[0045] wherein: R3, R4, Rs, Rs, R9, R10, u, v, r, LG1, LG2 are as defined above; and LG4 is a hydroxyl group or a leaving group, for example a halogen.In another aspect of the invention, there is provided an antibody-drug conjugate obtained or obtainable by conjugating the compound of formula (l-A) to (l-C) or (ll-A) to (ll-C) to an antibody or a fragment thereof, wherein the antibody-drug conjugate has a Drug-to-Antibody Ratio (DAR) of from 0.5 to 2.0, preferably from 0.8 to 1.2, more preferably from 0.9 to 1.1. In another aspect of the invention, there is provided an antibody-drug conjugate having a structure shown as formula (l-D) or formula (I l-D) or pharmaceutically acceptable salts or solvates thereof:

[0046] (i) wherein formula (l-D) is:

[0047]

[0048] (l-D)

[0049] wherein:

[0050] Ri and R2are each independently selected from H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, each optionally substituted;

[0051] n and m are each independently from 0 to 20;

[0052] x is 0, 1, 2, 3, 4, or 5;

[0053] L is a linker moiety;

[0054] P is a payload moiety;

[0055] Ab is a binding molecule or a fragment thereof, preferably an antibody or a fragment thereof; and

[0056] q is 1 or 2, preferably wherein q is 1; and

[0057] (ii) wherein formula (ll-D) is:

[0058]

[0059] wherein:

[0060] R3, R4, Rs and Re are each independently H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, each optionally substituted;

[0061] R9 and R10 each independently consist of -(EO)s-(CH2)t-, wherein EO is an ethylene glycol moiety, the terminal carbon of which is attached to the group -N(Rs)- or -N(Re)- and the terminal oxygen of which is attached to the group -(CH2)t, wherein s is from 0 to 10 and t is from 0 to 15, provided that s and t are not both 0;

[0062] u and v are independently from 0 to 10;

[0063] r is 0, 1, 2, 3, 4, or 5;

[0064] L is a linker moiety;

[0065] P is a payload moiety;

[0066] Ab is a binding molecule or a fragment thereof, preferably an antibody or a fragment thereof; and

[0067] q is 1 or 2, preferably wherein q is 1.

[0068] The antibody or fragment thereof is not particularly limited and any suitable antibody or fragment thereof may be used in the present invention. In one embodiment, the antibody or fragment thereof specifically binds to a target expressed on the surface of a tumour cell. In one embodiment, the target expressed on the surface of a tumour cell is HER2, B7H3, TROP2, HER3, CD30, Nectin-4, TF, B7-H4, and / or ITGB6, preferably HER2, B7H3, TROP2 and / or HER3. In one embodiment, the antibody or fragment thereof is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, a monoclonal antibody, and a polyclonal antibody. In oneembodiment, the antibody or fragment thereof is selected from the group consisting of: a Fab, a Fab', a F(ab')2, an Fv, an ScFv, an Fab'-SH, an sdAb, and a VHH. In one embodiment, the antibody or fragment thereof comprises an immunoglobulin constant region, the immunoglobulin constant region being a human IgG constant region, e.g., a human lgG1 constant region.

[0069] In another aspect of the invention, there is provided a composition comprising one or more antibody-drug conjugates as defined herein. In one embodiment, the composition is a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers, diluents and / or excipients.

[0070] In another aspect of the invention, there is provided an antibody-drug conjugate according to the present invention or a composition according to the present invention, for use as a medicament.

[0071] In another aspect of the invention, there is provided an antibody-drug conjugate according to the present invention or a composition according to the present invention, for use in treating cancer.

[0072] In another aspect of the invention, there is provided use of an antibody-drug conjugate according to the present invention or a composition according to the present invention for the manufacture of a medicament for treating cancer.

[0073] In another aspect of the invention, there is provided a method of treating cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of an antibody-drug conjugate according to the present invention or a composition according to the present invention to the subject.

[0074] In another aspect of the invention, there is provided an antibody-drug conjugate according to the present invention or a composition according to the present invention, for use in treating an autoimmune disease or an inflammatory disease.

[0075] In another aspect of the invention, there is provided use of an antibody-drug conjugate according to the present invention or a composition according to the present invention for the manufacture of a medicament for treating an autoimmune disease or an inflammatory disease.

[0076] In another aspect of the invention, there is provided a method of treating an autoimmune disease or an inflammatory disease in a subject in need thereof, the method comprisingadministering a therapeutically effective amount of an antibody-drug conjugate according to the present invention or a composition according to the present invention to the subject. In another aspect of the invention, there is provided a method of producing an antibody-drug conjugate, the method comprising conjugating a compound of formula (l-A) to (l-C) or (ll-A) to (I l-C) to an antibody or fragment thereof.

[0077] ADVANTAGES

[0078] It has been found by the present inventors that the compounds of the present invention are useful for preparing antibody-drug conjugates (ADCs) with a DAR of about 1, for example, using a method comprising selective reduction / oxidation of the disulphide bonds.

[0079] Thus, the compounds and methods of the present invention are useful for preparing ADCs with a controllable and consistent DAR. The ADCs prepared using the compounds of the present invention may have reduced toxicity.

[0080] BRIEF DESCRIPTION OF THE FIGURES

[0081] Figure 1 shows the drug-to-antibody ratio (DAR) of antibody-drug conjugates (ADCs) that were prepared by the selective reduction / oxidation method described in Example 5, using linker-payloads prepared by Example 4 and the compounds of Examples 1-3. (A) DAR of ADC preparing using the compound of Example 1. (B) DAR of ADC preparing using the compound of Example 2. (C) DAR of ADC preparing using the compound of Example 3. DETAILED DESCRIPTION

[0082] Various preferred features and embodiments of the present invention will now be described by way of non-limiting examples. This disclosure is not limited by the exemplary methods and materials disclosed herein, and any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of this disclosure. The skilled person will understand that they can combine all features of the invention disclosed herein without departing from the scope of the invention as disclosed.

[0083] It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise.

[0084] The terms "comprising", "comprises" and "comprised of' as used herein are synonymous with "including", "includes", "containing", or "contains", and are inclusive or open-ended and do not exclude additional, non-recited members, elements or steps. The terms "comprising", "comprises" and "comprised of" also include the term "consisting of".Numeric ranges are inclusive of the numbers defining the range. As used herein the term “about” means approximately, in the region of, roughly, or around. When the term “about” is used in conjunction with a numerical value or range, it modifies that value or range by extending the boundaries above and below the numerical value(s) set forth. In general, the terms “about” and “approximately” are used herein to modify a numerical value(s) above and below the stated value(s) by 10%.

[0085] Unless otherwise indicated, amino acid sequences are written left to right in amino to carboxy orientation, respectively.

[0086] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that such publications constitute prior art to the claims appended hereto.

[0087] All publications mentioned in the specification are herein incorporated by reference.

[0088] Definitions

[0089] The terms indicated for explanation of the invention and the disclosure have the following meaning, unless otherwise indicated in the description or the claims. Additional definitions are set forth throughout the detailed description.

[0090] The terms used herein may be defined as described in "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", H.G.W. Leuenberger, B. Nagel, and H. Kolbl, Eds., Helvetica Chimica Acta, CH-4010 Basel, Switzerland, (1995).

[0091] The practice of the present disclosure may employ, unless otherwise indicated, conventional chemistry, biochemistry, cell biology, immunology, and recombinant DNA techniques which are explained in the literature in the field. See, for example: Organikum, Deutscher Verlag der Wissenschaften, Berlin 1990; Streitwieser / Heathcook, "Organische Chemie", VCH, 1990; Beyer / Walter, "Lehrbuch der Organischen Chemie", S. Hirzel Verlag Stuttgart, 1988; Carey / Sundberg, "Organische Chemie", VCH, 1995; March, "Advanced Organic Chemistry", John Wiley & Sons, 1985; Rdmpp Chemie Lexikon, Falbe / Regitz (Hrsg.), Skoog, D.A., et al. (2013) Fundamentals of Analytical Chemistry, 9th edition, Cengage learning; Walker J. M. (2009) The Protein Protocols Handbook, 3rd edition, Springer Nature; Green, M.R. and Sambrook, J. (2012) Molecular Cloning: A Laboratory Manual, 4th Edition, Cold Spring Harbor Laboratory Press; Ausubel, F.M., et al. (2003) Current Protocols in Molecular Biology, John Wiley & Sons. Each of these general texts is herein incorporated by reference.The term "binding molecule" or “binding agent” in the context of the present disclosure refers to any molecule capable of binding to desired antigens. In certain embodiments, the binding molecule is an antibody, antibody fragment, or construct thereof. The binding molecule may also comprise synthetic, modified or non-naturally occurring moieties, in particular nonpeptide moieties. Such moieties may, for example, link desired antigen-binding functionalities or regions such as antibodies or antibody fragments. In one embodiment, the binding molecule is a synthetic construct comprising antigen-binding CDRs or variable regions. In one embodiment, the binding molecule comprises an immunoglobulin constant region.

[0092] “Antibodies” are glycoproteins belonging to the immunoglobulin superfamily. The term "full-length antibody" may refer to an immunoglobulin molecule that binds to a target molecule and contains four peptide chains: two heavy chains and two light chains which are connected to each other through disulphide bonds. Antibodies may comprise several “regions” or “domains” and the terms may be used interchangeably herein. An antibody may recognise an antigen via the fragment antigen-binding (Fab) variable region. The fragment crystallizable region (Fc region) is the tail region of an antibody that may allow antibodies to activate the immune system. The hinge region is a stretch of heavy chains linking the Fab and Fc regions. The heavy chain and light chain may each comprise a variable domain and one or more constant domains. For example, in IgG antibodies, a heavy chain comprises a variable domain (VH) and three constant domains (CH1, CH2, and CH3) and a light chain comprises a variable domain (VL) and one constant domain (CL). Examples antibodies include a human antibody, a mouse antibody, a camelid antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, a monoclonal antibody, and a polyclonal antibody.

[0093] The term “antibody fragment” may refer to a fragment of an antibody, or a genetically engineered product of one of more fragments of an antibody, which fragment is involved in binding with the target molecule. Examples of antibody fragments include an antigen-binding fragment (Fab), a Fab', a Fab'-SH, a fragment antibody (F(ab’)2), a variable region (Fv), a single chain antibody, such as a single chain variable fragment (scFv), a single-domain antibody (sdAb), a nanobody, and a VHH. The term “Antigen-binding fragment” or “Fab” refers to a region of an antibody that binds to antigens and is composed of one constant and one variable region of each of the heavy and the light chain. The term “fragment antibody” or “F(ab’)2” refers to a region of an antibody that remains following digestion of the Fc region while leaving intact some of the hinge region. The term “Fab”’ refers to a fragment formed by the reduction of a F(ab')2 fragment. The term “Fab’-SH” refers to a Fab’ fragment with a free sulfhydryl group. The term “Single chain variable fragment” or “scFv” refers to an engineeredantibody consisting of a light chain variable region and a heavy chain variable region which are connected to each other.

[0094] “CDR” or “CDRs” means complementarity determining region(s) in an immunoglobulin variable region. The variable regions of the heavy and light chains each contain three CDRs, designated CDR1, CDR2 and CDR3. The precise boundaries of these CDRs can be defined according to various numbering systems known in the art (see e.g. Dondelinger, M., et al., 2018. Frontiers in immunology, 9, p.2278), such as the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991; Kabat et al., 1992, Sequences of Proteins of Immunological Interest, DIANE Publishing: 2719), the Chothia numbering system (Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; Chothia et al. (1989) Nature 342:878-883) or the IMGT numbering system (Lefranc et al., Dev. Comparat.lmmunol.27:55-77, 2003;

[0095] Ehrenmann F, Kaas Q, Lefranc M P. IMGT / 3Dstructure-DB and IMGT / DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF[J], Nucleic acids research, 2009;38(suppl_1):D301-D307). Fora given antibody, those skilled in the art will readily identify the CDRs defined by each numbering system. Also, the correspondence between different numbering systems is well known to those skilled in the art (for example, see Lefranc et al., Dev. Comparat. Immunol. 27:55-77, 2003). “Variable regions” as used herein means a segment of an antibody which contains three CDRs, designated CDR1, CDR2 and CDR3. A “variable region” of an antibody refers to the variable region of the antibody light chain or the variable region of the antibody heavy chain, either alone or in combination. The variable region of the heavy chain may be referred to as “VH.” The variable region of the light chain may be referred to as “VL.” Typically, the variable regions of both the heavy and light chains comprise three hypervariable regions, the CDRs, which are located within relatively conserved framework regions (FR). The CDRs are usually aligned by the framework regions, enabling binding to a specific epitope. In general, from N-terminal to C-terminal, both light and heavy chains variable domains comprise FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

[0096] An antibody that “specifically binds to” a specified target protein is an antibody that exhibits preferential binding to that target as compared to other proteins, but this specificity does not require absolute binding specificity. An antibody is considered “specific” for its intended target if its binding is determinative of the presence of the target protein in a sample, e.g., without producing undesired results such as false positives. Antibodies, or binding fragments thereof, useful in the present invention will bind to the target protein with an affinity that is at least two-fold greater, preferably at least ten times greater, more preferably at least 20-timesgreater, and most preferably at least 100-times greater than the affinity with non-target proteins. As used herein, an antibody is said to bind specifically to a polypeptide comprising a given amino acid sequence, e.g., the amino acid sequence of a mature human PD-L1 molecule, if it binds to polypeptides comprising that sequence but does not bind to proteins lacking that sequence.

[0097] The term “human antibody” may refer to an antibody that comprises human immunoglobulin protein sequences only. A human antibody may contain murine carbohydrate chains if produced in a mouse, in a mouse cell, or in a hybridoma derived from a mouse cell.

[0098] Similarly, “mouse antibody” or “rat antibody” refer to an antibody that comprises only mouse or rat immunoglobulin sequences, respectively.

[0099] The term “humanized antibody” may refer to forms of antibodies that contain sequences from non-human (e.g., murine) antibodies as well as human antibodies. Such antibodies contain minimal sequence derived from non-human immunoglobulin. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence.

[0100] The term “chimeric antibody” may refer to an antibody in which a portion of the heavy and / or light chain is identical with or homologous to corresponding sequences in an antibody derived from a particular species (e.g., human) or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in an antibody derived from another species (e.g., mouse) or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.

[0101] The term "monoclonal antibody" may refer to an antibody obtained from a substantially homogeneous population of antibodies. The individual antibodies composing the population may be identical except for possible naturally occurring mutations, which may be present in minor amounts. Monoclonal antibodies are highly specific and target a single antigenic epitope. In contrast, polyclonal antibody preparations typically include a large number of antibodies which are specific for different epitopes.

[0102] The term "alkyl" refers to a monoradical of a saturated straight or branched hydrocarbon. Preferably, the alkyl group comprises from 1 to 40, i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40, carbon atoms, such as 1 to 30, such as 1 to 20 carbon atoms, such as 1 to 12carbon atoms, such as 1 to 10 carbon atoms, such as 1 to 8 carbon atoms, such as 1 to 6 or 1 to 4 carbon atoms. Exemplary alkyl groups include methyl, ethyl, propyl, iso-propyl (also called 2-propyl or 1 methylethyl), butyl, iso-butyl, tert-butyl, n-pentyl, iso-pentyl, sec-pentyl, neo-pentyl, 1,2-dimethylpropyl, iso-amyl, n-hexyl, iso-hexyl, sec-hexyl, n-heptyl, iso-heptyl, n-octyl, 2-ethyl-hexyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl, n-octadecyl, n-nonadecyl, n-icosyl, n-triacontyl, n-tetracontyl, and the like. A "substituted alkyl" means that one or more (such as 1 to the maximum number of hydrogen atoms bound to an alkyl group, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10, such as between 1 to 5, 1 to 4, or 1 to 3, or 1 or 2) hydrogen atoms of the alkyl group are replaced with a substituent other than hydrogen (when more than one hydrogen atom is replaced the substituents may be the same or different). In one embodiment, the alkyl is substituted with one or more, such as 1, 2 or 3, such as 1 or 2, such as 1 substituents selected from List A. Examples of a substituted alkyl include chloromethyl, dichloromethyl, fluoromethyl, and difluoromethyl.

[0103] The term "alkenyl" refers to a monoradical of an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond. Generally, the maximal number of carbon-carbon double bonds in the alkenyl group can be equal to the integer which is calculated by dividing the number of carbon atoms in the alkenyl group by 2 and, if the number of carbon atoms in the alkenyl group is uneven, rounding the result of the division down to the next integer. For example, for an alkenyl group having 9 carbon atoms, the maximum number of carbon-carbon double bonds is 4. Preferably, the alkenyl group has 1 to 6 (such as 1 to 4), i.e., 1, 2, 3, 4, 5, or 6, carbon-carbon double bonds. Preferably, the alkenyl group comprises from 2 to 40 carbon atoms, such as 2 to 30 carbon atoms, such as 2 to 20 carbon atoms, such as 2 to 12 carbon atoms, such as 2 to 10 carbon atoms, such as 2 to 8 carbon atoms, such as 2 to 6 carbon atoms or 2 to 4 carbon atoms. Thus, in a preferred embodiment, the alkenyl group comprises from 2 to 40, such as 2 to 30, such as 2 to 20, such as 2 to 12, such as 2 to 10 carbon atoms and 1, 2, 3, 4, 5, or 6 (e.g., 1, 2, 3, 4, or 5) carbon-carbon double bonds, such as comprises 2 to 8 carbon atoms and 1 , 2, 3, or 4 carbon-carbon double bonds, such as 2 to 6 carbon atoms and 1, 2, or 3 carbon-carbon double bonds or 2 to 4 carbon atoms and 1 or 2 carbon-carbon double bonds. The carboncarbon double bond(s) may be in cis (Z) or trans (E) configuration. Exemplary alkenyl groups include vinyl, 1-propenyl, 2-propenyl (i.e., allyl), 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1 -octenyl, 2-octenyl, 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, 8-nonenyl, 1-decenyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 6-decenyl, 7-decenyl, 8-decenyl, 9-decenyl, 1-undecenyl, 2-undecenyl, 3-undecenyl, 4-undecenyl, 5-undecenyl, 6-undecenyl, 7-undecenyl, 8-undecenyl, 9-undecenyl, 10-undecenyl, 1-dodecenyl, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-dodecenyl, 6-dodecenyl, 7-dodecenyl, 8-dodecenyl, 9-dodecenyl, 10-dodecenyl, 11-dodecenyl, and the like. A "substituted alkenyl" means that one or more (such as 1 to the maximum number of hydrogen atoms bound to an alkenyl group, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10, such as between 1 to 5, 1 to 4, or 1 to 3, or 1 or 2) hydrogen atoms of the alkenyl group are replaced with a substituent other than hydrogen (when more than one hydrogen atom is replaced the substituents may be the same or different). In one embodiment, the alkenyl is substituted with one or more, such as 1 , 2 or 3, such as 1 or 2, such as 1 substituents selected from List A.

[0104] The term "alkynyl" refers to a linear or branched monovalent hydrocarbon moiety having at least one carbon-carbon triple bond in which the total carbon atoms may be two to forty, such as two to thirty, typically two to twenty, such as two to eighteen. Alkynyl groups can optionally have one or more carbon-carbon triple bonds. Generally, the maximal number of carbon-carbon triple bonds in the alkynyl group can be equal to the integer which is calculated by dividing the number of carbon atoms in the alkynyl group by 2 and, if the number of carbon atoms in the alkynyl group is uneven, rounding the result of the division down to the next integer. For example, for an alkynyl group having 9 carbon atoms, the maximum number of carbon-carbon triple bonds is 4. Preferably, the alkynyl group has 1 to 6 (such as 1 to 4), i.e., 1, 2, 3, 4, 5, or 6, more preferably 1 or 2 carbon-carbon triple bonds. A "substituted alkynyl" means that one or more (such as 1 to the maximum number of hydrogen atoms bound to an alkynyl group, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10, such as between 1 to 5, 1 to 4, or 1 to 3, or 1 or 2) hydrogen atoms of the alkynyl group are replaced with a substituent other than hydrogen (when more than one hydrogen atom is replaced the substituents may be the same or different). In one embodiment, the alkynyl is substituted with one or more, such as 1, 2 or 3, such as 1 or 2, such as 1 substituents selected from List A.

[0105] The terms "cycloalkyl" and “cycloalkenyl” represents cyclic non-aromatic versions of "alkyl" and "alkenyl" with preferably 3 to 40, such as 3 to 30, such as 3 to 20, such as 3 to 14 carbon atoms, such as 3 to 12 or 3 to 10 carbon atoms, i.e., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 carbon atoms (such as 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms), more preferably 3 to 7 carbon atoms. Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, and adamantyl. Exemplary cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, and cyclodecenyl. The cycloalkyl or cycloalkenylgroup may consist of one ring (monocyclic), two rings (bicyclic), or more than two rings (polycyclic). A "substituted cycloalkyl" means that one or more (such as 1 to the maximum number of hydrogen atoms bound to a cycloalkyl group, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10, such as between 1 to 5, 1 to 4, or 1 to 3, or 1 or 2) hydrogen atoms of the cycloalkyl group are replaced with a substituent other than hydrogen (when more than one hydrogen atom is replaced the substituents may be the same or different). In one embodiment, the cycloalkyl or cycloalkenyl is substituted with one or more, such as 1, 2 or 3, such as 1 or 2, such as 1 substituents selected from List A.

[0106] The term "aryl" refers to a monoradical of an aromatic cyclic hydrocarbon. Preferably, the aryl group contains 3 to 14 (e.g., 5, 6, 7, 8, 9, or 10, such as 5, 6, or 10) carbon atoms which can be arranged in one ring (e.g., phenyl) or two or more condensed rings (e.g., naphthyl). Exemplary aryl groups include cyclopropenylium, cyclopentadienyl, phenyl, indenyl, naphthyl, azulenyl, fluorenyl, anthryl, and phenanthryl. Preferably, "aryl" refers to a monocyclic ring containing 6 carbon atoms or an aromatic bicyclic ring system containing 10 carbon atoms. Preferred examples are phenyl and naphthyl. Aryl does not encompass fullerenes. A "substituted aryl" means that one or more (such as 1 to the maximum number of hydrogen atoms bound to an aryl group, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 5 or up to 10, such as between 1 to 5, 1 to 4, or 1 to 3, or 1 or 2) hydrogen atoms of the aryl group are replaced with a substituent other than hydrogen (when more than one hydrogen atom is replaced the substituents may be the same or different). In one embodiment, the aryl is substituted with one or more, such as 1 , 2 or 3, such as 1 or 2, such as 1 substituents selected from List A. Examples of a substituted aryl include biphenyl, 2-fluorophenyl, 2-chloro-6-methylphenyl, anilinyl, 4-hydroxyphenyl, and methoxyphenyl (i.e., 2-, 3-, or 4-methoxyphenyl).

[0107] The term "heteroaryl" or "heteroaromatic ring" means an aryl group as defined above in which one or more carbon atoms in the aryl group are replaced by heteroatoms of O, S, or N. Preferably, heteroaryl refers to a five or six-membered aromatic monocyclic ring wherein 1, 2, or 3 carbon atoms are replaced by the same or different heteroatoms of O, N, or S. Alternatively, it means an aromatic bicyclic or tricyclic ring system wherein 1, 2, 3, 4, or 5 carbon atoms are replaced with the same or different heteroatoms of O, N, or S. Preferably, in each ring of the heteroaryl group the maximum number of O atoms is 1, the maximum number of S atoms is 1, and the maximum total number of O and S atoms is 2. Exemplary heteroaryl groups include furanyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, triazinyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, 1H-indazolyl, benzimidazolyl, benzoxazolyl, indoxazinyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl, benzodiazinyl, quinoxalinyl, quinazolinyl,benzotriazinyl, pyridazinyl, phenoxazinyl, thiazolopyridinyl, pyrrolothiazolyl, phenothiazinyl, isobenzofuranyl, chromenyl, xanthenyl, pyrrolizinyl, indolizinyl, indazolyl, purinyl, quinolizinyl, phthalazinyl, naphthyridinyl, cinnolinyl, pteridinyl, carbazolyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, and phenazinyl. Exemplary 5- or6-memered heteroaryl groups include furanyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrrolyl, imidazolyl (e.g., 2-imidazolyl), pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl (e.g., 4-pyridyl), pyrimidinyl, pyrazinyl, triazinyl, and pyridazinyl. A "substituted heteroaryl" means that one or more (such as 1 to the maximum number of hydrogen atoms bound to a heteroaryl group, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10, such as between 1 to 5, 1 to 4, or 1 to 3, or 1 or 2) hydrogen atoms of the heteroaryl group are replaced with a substituent other than hydrogen (when more than one hydrogen atom is replaced the substituents may be the same or different). In one embodiment, the heteroaryl is substituted with one or more, such as 1 , 2 or 3, such as 1 or 2, such as 1 substituents selected from List A.

[0108] The term "heterocyclyl" or "heterocyclic ring" means a cycloalkyl group as defined above in which from 1 , 2, 3, or 4 carbon atoms in the cycloalkyl group are replaced by heteroatoms of oxygen, nitrogen, silicon, selenium, phosphorus, or sulfur, preferably O, S, or N. A heterocyclyl group has preferably 1 or 2 rings containing from 3 to 10, such as 3, 4, 5, 6, or 7, ring atoms. Preferably, in each ring of the heterocyclyl group the maximum number of O atoms is 1 , the 5 maximum number of S atoms is 1 , and the maximum total number of O and S atoms is 2. The term "heterocyclyl" is also meant to encompass partially or completely hydrogenated forms (such as dihydro, tetrahydro or perhydro forms) of the above-mentioned heteroaryl groups. Exemplary heterocyclyl groups include morpholinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl (also called piperidyl), piperazinyl, di- and tetrahydrofuranyl, di- and tetrahydrothienyl, di- and tetrahydropyranyl, urotropinyl, lactones, lactams, cyclic imides, and cyclic anhydrides. A "substituted heterocyclyl" means that one or more (such as 1 to the maximum number of hydrogen atoms bound to a heterocyclyl group, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to 10, such as between 1 to 5, 1 to 4, or 1 to 3, or 1 or 2) hydrogen atoms of the heterocyclyl group are replaced with a substituent other than hydrogen (when more than one hydrogen atom is replaced the substituents may be the same or different). In one embodiment, the heterocyclyl is substituted with one or more, such as 1 , 2 or 3, such as 1 or 2, such as 1 substituents selected from List A.

[0109] The term "alkylene" refers to a diradical of a saturated straight or branched hydrocarbon. Preferably, the alkylene group comprises from 1 to 40, / .e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40, carbon atoms, such as 1 to 30, such as 1 to 20 carbon atoms, such as 1 to 12 carbon atoms, such as 1 to 10 carbon atoms, such as 1 to 8 carbon atoms, such as 1 to 6or 1 to 4 carbon atoms. Exemplary alkylene groups include methylene, ethylene ( / .e., 1,1-ethylene, 1,2-ethylene), propylene ( / .e., 1,1-propylene, 1,2-propylene (-CH(CH3)CH2-), 2,2-propylene (-C(CH3)2-), and 1,3-propylene), the butylene isomers (e.g., 1,1-butylene, 1,2-butylene, 2,2-butylene, 1,3-butylene, 2,3-butylene (c / s or trans or a mixture thereof), 1,4-butylene, 1,1-iso-butylene, 1,2-iso-butylene, and 1,3-iso-butylene), the pentylene isomers (e.g., 1,1-pentylene, 1,2-pentylene, 1,3-pentylene, 1,4-pentylene, 1,5-pentylene, 1,1-iso-pentylene, 1,1 -sec-pentyl, 1,1-neo-pentyl), the hexylene isomers (e.g., 1,1-hexylene, 1,2-hexylene, 1 ,3-hexylene, 1,4-hexylene, 1,5-hexylene, 1 ,6-hexylene, and 1,1 -isohexylene), the heptylene isomers (e.g., 1,1 -heptylene, 1,2-heptylene, 1,3-heptylene, 1,4-heptylene, 1,5-heptylene, 1,6-heptylene, 1,7-heptylene, and 1,1-isoheptylene), the octylene isomers (e.g., 1,1 -octylene, 1 ,2-octylene, 1 ,3-octylene, 1 ,4-octylene, 1,5-octylene, 1,6-octylene, 1,7-octylene, 1 ,8-octylene, and 1,1-isooctylene), and the like. The straight alkylene moieties having at least 3 carbon atoms and a free valence at each end can also be designated as a multiple of methylene (e.g., 1,4-butylene can also be called tetramethylene). Generally, instead of using the ending "ylene" for alkylene moieties as specified above, one can also use the ending "diyl" (e.g., 1,2-butylene can also be called butan-1,2-diyl). The alkylene groups may be substituted with one or more, preferably 1 to 5, such as 1, 2, or 3 substituents selected from List A.

[0110] The term "cycloalkylene” represents a cyclic non-aromatic version of "alkylene", with preferably 3 to 40, such as 3 to 30, such as 3 to 20, such as 3 to 14 carbon atoms, such as 3 to 12 or 3 to 10 carbon atoms, i.e., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 carbon atoms (such as 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms). More preferably cycloalkylene have 3 to 10, especially 3 to 7, carbon atoms. Exemplary cycloalkylene groups include cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene, cyclooctylene, cyclononylene, and cyclodecylene. The cycloalkylene group may consist of one ring (monocyclic), two rings (bicyclic), or more than two rings (polycyclic). The cycloalkylene group may be substituted with one or more, preferably 1 to 5, such as 1, 2, or 3 substituents selected from List A. The term "partially unsaturated" generally means that the cyclic structure contains at least one double or triple bond between the ring molecules. The term "partially unsaturated" encompasses cyclic structures having multiple sites of unsaturation, but is not intended to include aromatic or heteroaromatic rings defined herein. The term "unsaturated" means that the moiety has one or more degrees of unsaturation.

[0111] The term "halogen" generally refers to fluorine, chlorine, bromine or iodine, and it may be, for example, fluorine or chlorine. The term “hydroxyl” means -OH.In the present application, the term "aliphatic group" generally refers to a linear hydrocarbon, branched hydrocarbon or cyclic hydrocarbon having 1 to 12 carbon atoms, and the hydrocarbon may be either a fully saturated hydrocarbon or a hydrocarbon with one or more unsaturated units, but the unsaturated units are not aromatic groups. For example, suitable aliphatic groups may include substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl, alkynyl and mixtures thereof, such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl. For example, aliphatic groups have 1 to 12, 1 to 8, 1 to 6, 1 to 4 or 1 to 3 carbon atoms.

[0112] In the present application, the term "substituted" generally means that one or more hydrogen atoms in the group, for example, up to 5 (e.g., 1 to 3) hydrogen atoms, are each independently substituted with a corresponding number of substituents. A substituent is only in its possible chemical position, and those skilled in the art will be able to determine (by experiments or theories) possible or impossible substitution without undue efforts. For example, it may be unstable when amino or hydroxy having a free hydrogen is bound to a carbon atom having an unsaturated (such as olefin) bond.

[0113] In the present application, the term "0 or more (e.g., 0 or at least 1, 0 or 1, or 0) methylene units are replaced" generally means that when the structure comprises one or more methylene units, the one or more methylene units may be unsubstituted or replaced by one or more groups that are not methylene (e.g., -NHC(O)-, -C(O)NH-, -C(O)-, -OC(O)-, -C(O)O-, -NH-, -O-, -S-, -SO-, -SO2-, -PH-, -P(=O)H-, -NHSO2-, -SO2NH-, -C(=S)-, -C(=NH)-, -N=N-, -C=N-, -N=C- or-C(=N2)-).

[0114] Preferably substituents are selected from “List A”, consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 6- to 14-membered (such as 6- to 10-membered) aryl, 3- to 14-membered (such as 5- or 6- membered) heteroaryl, 3- to 14-membered (such as 3- to 7-membered) cycloalkyl, 3-to 14-membered (such as 3- to 7-membered) heterocyclyl, halogen, -CN, azido, -NO2, -OR’, -N(R’)2, -S(0)O-2R’, -S(O)I-2OR’, -OS(O)I.2R’, -OS(O)I-2OR’, -S(O)I-2N(R’)2, -OS(O)I-2N(R’)2, -N(R’)S(O)I-2R’, -N(R’)S(O)I-2OR’, -C(=X1)R’, -C(=X1)X1R’, -X1C(=X1)R’, and -X1C(=X1)X1R’, wherein X1is independently selected from O, S, NH and N(CH3); and each R’ is independently selected from the group consisting of H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, 5-or 6-membered cycloalkyl, 5- or 6-membered aryl, 5- or 6-membered heteroaryl, and 5- or 6-membered heterocyclyl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl groups is optionally substituted with one, two or three substituents independently selected from the group consisting of C1-3 alkyl, halogen, -CF3, -CHF2, CH2F, -CN, azido, -NO2, -OH, -O(Ci-3alkyl), -S(Ci-3alkyl), -NH2, -NH(CI_3alkyl), -N(Ci.

[0115] 3 alkyl)2, -NHS(O)2(CI-3alkyl), -S(O)2NH2-Z(CI-3alkyl)z, -C(=O)OH, -C(=O)O(C1.3alkyl), -C(=O)NH2-z(Ci-3alkyl)z, -NHC(=O)(C1-3 alkyl), -NHC(=NH)NHz.2(C1-3 alkyl)z, and -N(CI-3alkyl)C(=NH)NH2.z(Ci-3alkyl)z, wherein each z is independently 0, 1, or 2. In some embodiments, the substituents are selected from List A1, consisting of Ci-3alkyl, phenyl, halogen, -CF3, - CHF2, CH2F, -OH, -OCH3, -SCH3, -NH2-Z(CH3)Z, -C(=O)OH, and -C(=O)OCH3, wherein z is 0, 1, or 2 and Ci-3alkyl is methyl, ethyl, propyl or isopropyl. In some embodiments, the substituents are selected from List A2, consisting of methyl, ethyl, propyl, isopropyl, halogen (such as F, Cl, or Br), -CF3-CHF2, and -CH2F. In some embodiments, the substituents are selected from List A3, consisting of halogen (such as F, Cl, or Br). In some embodiments, the substituents are selected from List A4, consisting of F. The term “pharmaceutical composition” relates to a composition comprising a therapeutically effective agent, preferably together with pharmaceutically acceptable carriers, diluents and / or excipients. Said pharmaceutical composition is useful for treating, preventing, or reducing the severity of a disease by administration of said pharmaceutical composition to a subject.

[0116] The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” means solvents, dispersion media, coatings, antibacterial agents and antifungal agents, isotonic agents, and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. In certain embodiments, the pharmaceutically acceptable carrier or excipient is not naturally occurring.

[0117] As used herein, a “subject” is an animal or human of either gender (a male or a female). The subject may be of any age. In one embodiment, the subject is human. In one embodiment, the subject is female. In another embodiment, the subject is male. In some embodiments, the subject is a subject having cancer, in particular a human subject having cancer.

[0118] The term “treating” or “treatment” when used in the context of a disease or disease condition means ameliorating, improving or remedying a disease, disorder, or symptom of a disease or condition associated with the disease, or can mean completely or partially stopping, on a molecular level, the biochemical basis of the disease, etc. It describes an act that leads to the elimination, reduction, alleviation, reversal, or prevention or delay of onset or recurrence of any symptom of a disease.Compounds - Formulae (l-A) to (l-D)

[0119] Formula (l-A)

[0120] The present invention provides compounds having or comprising a structure shown as formula (l-A) or pharmaceutically acceptable salts or solvates thereof, wherein formula (l-A) is:

[0121]

[0122] wherein:

[0123] Ri and R2are each independently selected from H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, each optionally substituted;

[0124] n and m are each independently from 0 to 20; and

[0125] x is 0, 1, 2, 3, 4, or 5.

[0126] The structure shown as formula (l-A) may be connected via the terminal carbonyl group to any suitable leaving group (LG3) or linker-payload moiety (-L-P), for example any described herein. Throughout the specification, the point of connection is denoted by

[0127]

[0128] . The structure shown as formula (l-A) may be conjugated via the maleimide groups to an antibody or fragment thereof (Ab), for example any described herein.

[0129] Formula (l-B)

[0130] The present invention further provides compounds having a structure shown as formula (l-B) or pharmaceutically acceptable salts or solvates thereof, wherein formula (l-B) is:

[0131]

[0132] wherein:

[0133] Ri and R2are each independently selected from H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, each optionally substituted;

[0134] n and m are each independently from 0 to 20;

[0135] x is 0, 1, 2, 3, 4, or 5; and

[0136] LG3 is a hydroxyl group or a leaving group, for example a halogen.

[0137] The structure shown as formula (l-B) may be added via LG3 to any suitable linker-payload moiety (-L-P), for example any described herein. The structure shown as formula (l-B) may be conjugated via the maleimide groups to an antibody or fragment thereof (Ab), for example any described herein.

[0138] In one preferred embodiment, the compound of formula (l-B) is selected from the following:

[0139]

[0140]

[0141] Formula (l-C)

[0142] The present invention further provides compounds having a structure shown as formula (l-C) or pharmaceutically acceptable salts or solvates thereof, wherein formula (l-C) is:

[0143]

[0144] wherein:

[0145] Ri and R2 are each independently selected from H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, each optionally substituted;

[0146] n and m are each independently from 0 to 20;

[0147] x is 0, 1, 2, 3, 4, or 5;

[0148] L is a linker moiety, for example any described herein; and

[0149] P is a payload moiety, for example any described herein.

[0150] The structure shown as formula (l-C) may be conjugated via the maleimide groups to an antibody or fragment thereof (Ab), for example any described herein.Formula (l-D)

[0151] The present invention further provides compounds having a structure shown as formula (l-D) or pharmaceutically acceptable salts or solvates thereof, wherein formula (l-D) is:

[0152]

[0153] (l-D)

[0154] wherein:

[0155] Ri and R2 are each independently selected from H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, each optionally substituted;

[0156] n and m are each independently from 0 to 20;

[0157] x is 0, 1, 2, 3, 4, or 5;

[0158] L is a linker moiety, for example any described herein;

[0159] P is a payload moiety, for example any described herein;

[0160] Ab is a binding molecule or a fragment thereof, preferably an antibody or a fragment thereof, for example any described herein; and

[0161] q is 1 or 2.

[0162] Substituents

[0163] In formulae (l-A) to (l-D), the substituents may have the meanings defined herein. The general definitions of the substituents are equally applicable to each of formulae (l-A) to (I- D), as appropriate.

[0164] In some embodiments, n and m are each independently 1 or more, 2 or more, 3 or more, 4 or more, or 5 or more. In some embodiments, n and m are each independently 15 or less, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, or 5 or less. In some embodiments, n and mare each independently from 0 to 15, from 0 to 10, from 1 to 10, or from 1 to 5. In some preferred embodiments, n and m are each independently selected from 1, 2, 3, or 4. In some more preferred embodiments, n and m are both 1.

[0165] In some embodiments, x is selected from 0, 1, 2, 3 or 4. In some preferred embodiments, x is selected from 1 , 2, 3 or 4. In some more preferred embodiments, x is 1 or 4. In some embodiments, x is 1. In other embodiments, x is 4.

[0166] In some embodiments, Ri and R2 are each independently selected from H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl. In some preferred embodiments, R1 and R2 are each independently selected from H or a C1-3 alkyl. In some more preferred embodiments, R1 and R2 are both H.

[0167] In some preferred embodiments, the chiral center * is in R configuration.

[0168] In some preferred embodiments, LG3 is a hydroxyl group or a halogen, such as chlorine, bromine, iodine, or a sulfonate, such as tosylate, or mesylate.

[0169] In some preferred embodiments, q is 1.

[0170] In some embodiments, when x is 4, the chiral center * is in R configuration.

[0171] In some embodiments, x is not 4.

[0172] Example compounds

[0173] In some embodiments, the compound of the present invention has or comprises the structure shown as formula (l-A-1) or a pharmaceutically acceptable salt or solvate thereof:

[0174]

[0175] In some embodiments, the compound of the present invention has or comprises the structure shown as formula (l-A-2) or a pharmaceutically acceptable salt or solvate thereof:

[0176]

[0177] In some embodiments, the compound of the present invention has or comprises the structure shown as formula (l-A-3) or a pharmaceutically acceptable salt or solvate thereof:

[0178]

[0179] The structures shown as formulae (l-A-1 ),(l-A-2) and (l-A-3) may be connected via the terminal carbonyl group to any suitable leaving group (LG3) or linker-payload moiety (-L-P), for example any described herein. The structure shown as formulae (l-A-1), (l-A-2) and (l-A-3) may be conjugated via the maleimide groups to an antibody or fragment thereof (Ab), for example any described herein.

[0180] In one embodiment, the compound of the present invention does not have the structure shown as formulae (l-A-4). In one embodiment, the compound of the present invention does not comprise the structure shown as formulae (l-A-4). In one embodiment, the compound of the present invention does not have the structure shown as formulae (l-A-4) or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the compound of the present invention does not comprise the structure shown as formulae (l-A-4) or a pharmaceutically acceptable salt or solvate thereof.

[0181]

[0182] In one embodiment, the compound of the present invention does not have the structure shown as formulae (l-B-4), wherein LG3 is a hydroxyl group or a leaving group. In one embodiment, the compound of the present invention does not have the structure shown as formulae (l-B-4) or a pharmaceutically acceptable salt or solvate thereof, wherein LG3 is a hydroxyl group or a leaving group.

[0183]

[0184] In one embodiment, the compound of the present invention does not have the structure shown as formulae (l-C-4), wherein L is a linker moiety and P is a payload moiety. In one embodiment, the compound of the present invention does not have the structure shown as formulae (l-C-4) or a pharmaceutically acceptable salt or solvate thereof, wherein L is a linker moiety and P is a payload moiety.

[0185]

[0186] In one embodiment, the compound of the present invention does not have the structure shown as formulae (l-D-4), wherein L is a linker moiety; P is a payload moiety; and q is 1 or 2. In one embodiment, the compound of the present invention does not have the structure shown as formulae (l-D-4) or a pharmaceutically acceptable salt or solvate thereof, wherein L is a linker moiety; P is a payload moiety; and q is 1 or 2. In one embodiment, the compound of the present invention does not have the structure shown as formulae (l-D-4), wherein L is a linker moiety; P is a payload moiety; and q is an integer from 1 to 5. In one embodiment, the compound of the present invention does not have the structure shown as formulae (l-D-4) or a pharmaceutically acceptable salt or solvate thereof, wherein L is a linker moiety; P is a payload moiety; and q is an integer from 1 to 5.

[0187]

[0188] (I-D-4)

[0189] In one embodiment, the compound of the present invention is not Bi-MC-Lys-PEG4-Val-Cit-MMAE. In one embodiment, the compound of the present invention does not have the structure shown below. In one embodiment, the compound of the present invention is not Bi-MC-Lys-PEG4-Val-Cit-MMAE or a pharmaceutically acceptable salt or solvate thereof. Inone embodiment, the compound of the present invention does not have the structure shown below or a pharmaceutically acceptable salt or solvate thereof.

[0190]

[0191] HO In one embodiment, the binding molecule conjugate of the present invention does not comprise Trastuzumab conjugated to Bi-MC-Lys-PEG4-Val-Cit-MMAE. In one embodiment, the binding molecule conjugate of the present invention does not comprise an antibody conjugated to Bi-MC-Lys-PEG4-Val-Cit-MMAE. In one embodiment, the compound of the present invention does not have the structure shown below. In one embodiment, the compound of the present invention does not have the structure shown below or a pharmaceutically acceptable salt or solvate thereof.

[0192]

[0193] In one embodiment, the compound of the present invention is not Bi-MC-Lys-TAMRA. In one embodiment, the compound of the present invention does not have the structure shown below. In one embodiment, the compound of the present invention is not Bi-MC-Lys-TAMRA or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the compound of the present invention does not have the structure shown below or a pharmaceutically acceptable salt or solvate thereof.

[0194]

[0195] In one embodiment, the binding molecule conjugate of the present invention does not comprise Trastuzumab conjugated to Bi-MC-Lys-TAMRA. In one embodiment, the binding molecule conjugate of the present invention does not comprise an antibody conjugated to Bi-MC-Lys-TAMRA. In one embodiment, the compound of the present invention does not have the structure shown below. In one embodiment, the compound of the present invention does not have the structure shown below or a pharmaceutically acceptable salt or solvate thereof.

[0196] I

[0197]

[0198] Compounds - Formulae (I l-A) to (ll-D)

[0199] Formula (I l-A)

[0200] The present invention provides compounds having or comprising a structure shown as formula (I l-A) or pharmaceutically acceptable salts or solvates thereof, wherein formula (I l-A) is:

[0201]

[0202] wherein:

[0203] R3, R4, Rs and R6are each independently H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, each optionally substituted;

[0204] LG1 and LG2 are each independently a leaving group;

[0205] R9 and R10 each independently consist of -(EO)s-(CH2)t-, wherein EG is an ethylene glycol moiety, the terminal carbon of which is attached to the group -N(Rs)- or -N(Re)- and the terminal oxygen of which is attached to the group -(CH2)t-, wherein s is from 0 to 10 and t is from 0 to 15, provided that s and t are not both 0;

[0206] u and v are independently from 0 to 10; and

[0207] r is 0, 1, 2, 3, 4, or 5.

[0208] The structure shown as formula (I l-A) may be connected via the terminal carbonyl group to any suitable leaving group (LG3) or linker-payload moiety (-L-P), for example any described herein. The structure shown as formula (I l-A) may be conjugated via the 2-substituted pyrimidine groups to an antibody or fragment thereof (Ab), for example any described herein.

[0209] Formula (ll-B)

[0210] The present invention provides compounds having a structure shown as formula (I l-B) or pharmaceutically acceptable salts or solvates thereof, wherein formula (I l-B) is:

[0211]

[0212] wherein:

[0213] R3, R4, Rs and Re are each independently H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, each optionally substituted;LGi and LG2 are each independently a leaving group;

[0214] R9and R each independently consist of -(EO)s-(CH2)t-, wherein EG is an ethylene glycol moiety, the terminal carbon of which is attached to the group -N(R5)- or -N(R6)- and the terminal oxygen of which is attached to the group -(CH2)t-, wherein s is from 0 to 10 and t is from 0 to 15, provided that s and t are not both 0;

[0215] u and v are independently from 0 to 10;

[0216] r is 0, 1, 2, 3, 4, or 5; and

[0217] LG4 is a hydroxyl group or a leaving group, for example a halogen.

[0218] The structure shown as formula (I l-B) may be added via LG4 to any suitable linker-payload moiety (-L-P), for example any described herein. The structure shown as formula (I l-B) may be conjugated via the 2-substituted pyrimidine groups to an antibody or fragment thereof (Ab), for example any described herein.

[0219] In one preferred embodiment, the compound of formula (ll-B) is selected from the following:

[0220]

[0221] Formula (ll-C)

[0222] The present invention provides compounds having a structure shown as formula (I l-C) or pharmaceutically acceptable salts or solvates thereof, wherein formula (I l-C) is:

[0223]

[0224] wherein:

[0225] R3, R4, Rs and R6are each independently H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, each optionally substituted;

[0226] LG1 and LG2 are each independently a leaving group;

[0227] R9 and R10 each independently consist of -(EO)s-(CH2)t-, wherein EG is an ethylene glycol moiety, the terminal carbon of which is attached to the group -N(Rs)- or -N(Re)- and the terminal oxygen of which is attached to the group -(CH2)t, wherein s is from 0 to 10 and t is from 0 to 15, provided that s and t are not both 0;

[0228] u and v are independently from 0 to 10;

[0229] r is 0, 1, 2, 3, 4, or 5;

[0230] L is a linker moiety, for example any described herein; and

[0231] P is a payload moiety, for example any described herein.

[0232] The structure shown as formula (I l-C) may be conjugated via the 2-substituted pyrimidine groups to an antibody or fragment thereof (Ab), for example any described herein.

[0233] Formula (ll-D)

[0234] The present invention provides compounds having a structure shown as formula (ll-D) or pharmaceutically acceptable salts or solvates thereof, wherein formula (ll-D) is:

[0235]

[0236] wherein:

[0237] R3, R4, Rs and Re are each independently H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, each optionally substituted;

[0238] R9and R each independently consist of -(EO)s-(CH2)t-, wherein EO is an ethylene glycol moiety, the terminal carbon of which is attached to the group -N(R5)- or -N(R6)- and the terminal oxygen of which is attached to the group -(CH2)t, wherein s is from 0 to 10 and t is from 0 to 15, provided that s and t are not both 0;

[0239] u and v are independently from 0 to 10;

[0240] r is 0, 1, 2, 3, 4, or 5;

[0241] L is a linker moiety, for example any described herein;

[0242] P is a payload moiety, for example any described herein;

[0243] Ab is a binding molecule or a fragment thereof, preferably an antibody or a fragment thereof, for example any described herein; and

[0244] q is 1 or 2.

[0245] Substituents

[0246] In formulae (I l-A) to (I l-D), the substituents may have the meanings defined herein. The general definitions of the substituents are equally applicable to each of formulae (I l-A) to (II-D), as appropriate.

[0247] In some embodiments, u and v are each independently 1 or more, 2 or more, 3 or more, 4 or more, or 5 or more. In some embodiments, u and v are each independently 9 or less, 8 or less, 7 or less, 6 or less, or 5 or less. In some embodiments, u and v are each independentlyfrom 0 to 9, from 0 to 8, from 0 to 7, from 0 to 6, from 0 to 5, or from 1 to 5. In some preferred embodiments, u and v are each independently selected from 1, 2, 3, or 4. In some more preferred embodiments, u and v are both 1.

[0248] In some embodiments, r is selected from 0, 1, 2, 3 or 4. In some preferred embodiments, r is selected from 1, 2, 3 or 4. In some more preferred embodiments, r is 1.

[0249] In some embodiments, R3 and R4 are each independently selected from H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl. In some preferred embodiments, R3 and R4 are each independently selected from H or a C1-3 alkyl. In some more preferred embodiments, R3 and R4 are both H.

[0250] In some embodiments, Rs and Rs are each independently selected from H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-6 cycloalkyl. In some preferred embodiments, Rs and Rs are each independently selected from H or a C1-3 alkyl. In some more preferred embodiments, R5and R6are both methyl.

[0251] In some embodiments, LG1 is a sulfonate having formula -SO2R7 and LG2 is a sulfonate having formula -SO2R8, wherein R7 and Rs are each independently C1-6 alkyl or substituted C1-6 alkyl. In some preferred embodiments, R7 and Rs are each independently selected from H or a C1-3 alkyl. In some more preferred embodiments, LG1 is a sulfonate having formula -SO2CH3 and LG2 is a sulfonate having formula -SO2CH3.

[0252] In some preferred embodiments, the chiral center * is in R configuration.

[0253] In some embodiments, s is from 1 to 10 and t is from 0 to 10, preferably wherein s is from 1 to 3 and t is from 0 to 2. In some preferred embodiments, s is 2 and t is 1.

[0254] In other embodiments, s is from 0 to 10 and t is from 0 to 15, preferably wherein s is 0 and t is from 0 to 15 or from 0 to 6. In some embodiments, R9 and Rware each independently selected from 01-015 alkylene, preferably 01-6 alkylene, more preferably wherein R9 and R10 are both 02 alkylene or 03 alkylene.

[0255] In some preferred embodiments, LG4 is a hydroxyl group or a halogen, such as chlorine, bromine, iodine, or a sulfonate, such as tosylate, or mesylate.

[0256] In some preferred embodiments, q is 1.

[0257] In some embodiments, when u is 0, R3 is not H. In some embodiments, when v is 0, R4 is not H.

[0258] In some embodiments, when u is 0, R3 is not H, and that when v is 0, R4 is not H.Example compounds where s > 0

[0259] In some embodiments, s is from 1 to 10 and t is from 0 to 15. In some embodiments, s is from 1 to 10 and t is from 0 to 10, from 0 to 5, from 0 to 4, from 0 to 3, or from 0 to 2. In some embodiments, s is 2 and t is 1.

[0260] In some embodiments, the compound of the present invention has or comprises the structure shown as formula (ll-A-2) or pharmaceutically acceptable salts or solvates thereof:

[0261]

[0262] wherein R3, R4, Rs, Rs, u, v, r, LG1, LG2 are as defined for formula (ll-A) above.

[0263] In some embodiments, the compound of the present invention has or comprises the structure shown as formula (ll-A-2) or a pharmaceutically acceptable salt or solvate thereof:

[0264]

[0265] The structures shown as formulae (ll-A-1) and (ll-A-2) may be connected via the terminal carbonyl group to any suitable leaving group (LG3) or linker-payload moiety (-L-P), for example any described herein. The structure shown as formulae (ll-A-1) and (ll-A-2) may be conjugated via the 2-substituted pyrimidine groups to an antibody or fragment thereof (Ab), for example any described herein.

[0266] Example compounds where s = 0

[0267] In some embodiments, s is 0 and t is from 1 to 15. In some embodiments, s is from 0 and t is from 0 to 10, from 0 to 5, from 0 to 4, or from 0 to 3. In some embodiments, s is 0 and t is 2. In some embodiments, s is 0 and t is 3.

[0268] In some embodiments, the compound of the present invention has or comprises the structure shown as formula (ll-A-3) or pharmaceutically acceptable salts or solvates thereof:

[0269]

[0270] wherein:

[0271] R3, R4, Rs, Re, u, v, r, LG1, and LG2 are as defined above for formula (ll-A); and

[0272] x and y are each independently from 1 to 15, preferably x and y are each independently from 1 to 6, preferably wherein x and y are both 2 or both 3.

[0273] In some embodiments, the compound of the present invention has or comprises the structure shown as formula (ll-A-4) or a pharmaceutically acceptable salt or solvate thereof:

[0274]

[0275] In some embodiments, the compound of the present invention has or comprises the structure shown as formula (ll-A-5) or a pharmaceutically acceptable salt or solvate thereof:

[0276]

[0277] (ll-A-5)

[0278] The structures shown as formulae (ll-A-3) to (ll-A-5) may be connected via the terminal carbonyl group to any suitable leaving group (LG3) or linker-payload moiety (-L-P), for example any described herein. The structure shown as formulae (ll-A-3) to (ll-A-5) may be conjugated via the 2-substituted pyrimidine groups to an antibody or fragment thereof (Ab), for example any described herein.

[0279] Payload moieties (P)

[0280] The compound of the present invention may comprise any suitable payload moiety. The payload moiety may be referred to herein as substituent P.

[0281] Suitable payloads are well-known in the art (see e.g. Conilh, L. et al. 2023. Journal of Hematology & Oncology, 16(1), p.3). Suitable examples of payloads are also described herein and are also generally described in WO2022 / 068878, WO2022 / 170971 and W02004 / 010957, and national applications deriving therefrom.In one embodiment, the payload is a cytotoxic drug. In one embodiment, the payload is an immunomodulator. In one embodiment, the cytotoxic drug is a tubulin polymerisation inhibitor, a DNA damaging agent, a TOPO1 inhibitor, an auristatin, a maytansinoid, a maytansine, or a calicheamicin. In one embodiment, the cytotoxic drug is a TOPO1 inhibitor. In one embodiment, the TOPO1 inhibitor is a camptothecin or an exatecan, or a derivative thereof.

[0282] In one embodiment, the payload is a topoisomerase inhibitor, preferably a topoisomerase 1 (TOPO1) inhibitor.

[0283] In one embodiment, the payload is exatecan, or a derivative thereof. In one embodiment, the payload is exatecan. In one embodiment, the payload is deruxtecan.

[0284] In one embodiment, the payload is an auristatin.

[0285] In one embodiment, the payload is not monomethyl auristatin E (MMAE). In one embodiment, the payload is not an auristatin.

[0286] In other embodiments, the payload is a diagnostic marker, e.g. selected from a radionuclide suitable for radio imaging. For diagnostic purposes, the payload as defined herein may be a radionuclide suitable for radio imaging.

[0287] In one embodiment, the payload is not 5-Carboxytetramethylrhodamine (TAMRA). In one embodiment, the payload is not a fluorescent dye.

[0288] In one embodiment, the payload is not monomethyl auristatin E (MMAE) or 5-Carboxytetramethylrhodamine (TAMRA). In one embodiment, the payload is not an auristatin or a fluorescent dye.

[0289] Linker moieties (L)

[0290] The compound of the present invention may further comprise any suitable linker moiety. The linker moiety may be referred to herein as substituent L.

[0291] Suitable linkers are well-known in the art (see e.g. Su, Z. et al., 2021. Acta Pharmaceutica Sinica B, 11(12), pp.3889-3907).

[0292] The combination of a linker moiety and a payload moiety may be referred to herein as a “linker-payload moiety”. Typically, when an antibody-drug conjugate is administered to a subject, the linker-payload moiety is released by breakdown of the antibody-drug conjugate in vivo. The linker-payload moiety then typically breaks down to release the payload in vivo. Suitable examples of linker-payload moieties are also described herein and are alsogenerally described in WO2022 / 068878, WO2022 / 170971 and WG2004 / 010957, and national applications deriving therefrom.

[0293] In some embodiments, the linker is a cleavable linker. In some embodiments, the linker is a linker cleavable by a lysosomal peptidase.

[0294] In some embodiments, the linker comprises a peptide linker. In some embodiments, the linker consists essentially of a peptide linker. In some embodiments, the linker consists of a peptide linker. Typically, the peptide linker comprises, essentially of or consist of 1 to 10 amino acid residues. The peptide linker may comprise, consist essentially of or consist of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid residues. In some embodiments, the peptide linker comprises, consists essentially of or consists of 1 to 6 amino acid residues. In some embodiments, the peptide linker comprises, consists essentially of or consists of 1 to 5 amino acid residues. In some embodiments, the peptide linker comprises, consists essentially of or consists of 2 amino acid residues. In some embodiments, the peptide linker comprises, consists essentially of or consists of 3 amino acid residues. In some embodiments, the peptide linker comprises, consists essentially of or consists of 4 amino acid residues. In some embodiments, the peptide linker comprises, consists essentially of or consists of 5 amino acid residues.

[0295] In one embodiment, the linker is selected from the group consisting of AA1, AA1-Gly, Val-Cit, Vai-Ala, Val-AA1, Val-AA1-Gly, AA1-Ala-Asn, Ala-Ala-Ala, Ala-Ala-Asn and Gly-Gly-Phe-Gly.

[0296] In one embodiment, the amino acid residue represented by AA1 is selected from the group consisting of:

[0297]

[0298]

[0299]

[0300] , where position 1 is connected, via a conjugation moiety, to the portion of the molecule bearing the antibody or fragment thereof and position 2 is connected, optionally via a further moiety, to the portion of the molecule bearing the payload compound.

[0301] In some embodiments, the peptide linker comprises, consists essentially of, or consists of a Gly-Gly-Phe-Gly (GGFG) peptide moiety. In some embodiments, the peptide linker comprises a Gly-Gly-Phe-Gly (GGFG) peptide moiety. In some embodiments, the peptide linker comprises, consists essentially of, or consists of a Val-Cit peptide moiety.

[0302] In one embodiment, the linker comprises a spacer moiety. In one embodiment, the linker comprises a peptide moiety and the spacer moiety is conjugated to the C-terminus of the peptide moiety. In one embodiment, the linker-payload moiety comprises a payload moiety, a spacer moiety and a peptide moiety, and the spacer moiety is present between the peptide moiety and the payload moiety.

[0303] In one embodiment, the spacer moiety has the structure:

[0304]

[0305] In some embodiments, the peptide linker comprises, consists essentially of, or consists of a Val-Cit moiety, the spacer moiety has the structure:

[0306] o

[0307]

[0308] H , the -NH- moiety thereof being conjugated to the C-terminus of the Cit residue of the peptide moiety.

[0309] In some embodiments, the peptide moiety comprises, consists essentially of, or consists of a Val-Cit moiety, the spacer moiety has the structure:o

[0310]

[0311] H , the -NH- moiety thereof being conjugated to the C-terminus of the Cit residue of the peptide moiety and the C(=O)- moiety thereof being conjugated to the payload moiety.

[0312] In some embodiments, the peptide moiety comprises, consists essentially of, or consists of a Val-Cit moiety, the spacer moiety has the structure:

[0313] O

[0314]

[0315] H , the -NH- moiety thereof being conjugated to the C-terminus of the Cit residue of the peptide moiety and the C(=O)- moiety thereof being conjugated to an N atom on the payload moiety.

[0316] In one embodiment, the linker moiety does not comprise a Val-Cit peptide moiety.

[0317] Example linker and payload moieties

[0318] Examples of suitable payload moieties, linker moieties, spacer moieties and payload-linker moieties are described herein.

[0319] Linker-payload structures containing a 6-ring exatecan moiety linked via an open-chain group

[0320] For each of the formulae described below the definitions are self-contained.

[0321] In one embodiment, the payload moiety comprises a structure shown as formula (lll-A):

[0322]

[0323] or a tautomer, mesomer, enantiomer, a diastereoisomer thereof, or a pharmaceutically acceptable salt thereof wherein,

[0324] II is O or S; and

[0325] V is (C1-6) alkylene, (C3-10) cycloalkylene, or (C1-6) alkylene-(C3-10) cycloalkylene.

[0326] In one embodiment, II is O. In one embodiment, II is S.

[0327] In one embodiment, V is (C1-6) alkylene. In one embodiment, V is (C1-4) alkylene. In one embodiment, V is (C1-3) alkylene. In one embodiment, V is methylene. In one embodiment, V is ethylene. In one embodiment, V is methylmethylene. In one embodiment, V is trimethylene. In one embodiment, V is (S)-methylethylene. In one embodiment, V is ( / ?)-methylethylene.

[0328] In one embodiment, V is (C3-10) cycloalkylene. In one embodiment, V is (C3-6) cycloalkylene. In one embodiment, V is (C3-5) cycloalkylene. In one embodiment, V is cyclopropylene. In one embodiment, V is 1,1 -cyclopropylene. In one embodiment, V is cis- 1.2-cyclopropylene. In one embodiment, V is trans-1,2-cyclopropylene. In one embodiment, V is cyclobutylene. In one embodiment, V is 1,1 -cyclobutylene. In one embodiment, V is cis- 1.2- cyclobutylene. In one embodiment, V is trans- 1,2-cyclobutylene. In one embodiment, V is cis-1,3-cyclobutylene. In one embodiment, V is trans-1,3-cyclobutylene.

[0329] In one embodiment, the linker-payload moiety comprises a structure shown as formula (III-B):

[0330]

[0331] or a tautomer, mesomer, enantiomer a diastereoisomer thereof, or a pharmaceutically acceptable salt thereof wherein,

[0332] L is -Lb-Lc-;-Lb- represents a peptide residue consisting of 2 to 7 amino acids;

[0333] -Lc- is selected from the group consisting of:

[0334]

[0335] wherein RL1and RL2are each independently selected from the group consisting of: hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H and a C1-6 aliphatic group;

[0336] II is O or S; and

[0337] V is (C1-6) alkylene, (C3-10) cycloalkylene, or (C1-6) alkylene-(C3-10) cycloalkylene.

[0338] In one embodiment, -Lb- is:

[0339]

[0340] In one embodiment, -

[0341]

[0342] Lc- is

[0343] In one embodiment, II is O. In one embodiment, II is S.

[0344] In one embodiment, V is (C1-6) alkylene. In one embodiment, V is (C1-4) alkylene. In one embodiment, V is (C1-3) alkylene. In one embodiment, V is methylene. In one embodiment, V is ethylene. In one embodiment, V is methylmethylene. In one embodiment, V is trimethylene. In one embodiment, V is (S)-methylethylene. In one embodiment, V is ( / ?)-methylethylene.

[0345] In one embodiment, V is (C3-10) cycloalkylene. In one embodiment, V is (C3-6) cycloalkylene. In one embodiment, V is (C3-5) cycloalkylene. In one embodiment, V is cyclopropylene. In one embodiment, V is 1,1 -cyclopropylene. In one embodiment, V is cis- 1,2-cyclopropylene. In one embodiment, V is trans-1,2-cyclopropylene. In one embodiment, V is cyclobutylene. In one embodiment, V is 1,1 -cyclobutylene. In one embodiment, V is cis-1,2- cyclobutylene. In one embodiment, V is trans- 1,2-cyclobutylene. In one embodiment, V is cis-1,3-cyclobutylene. In one embodiment, V is trans-1,3-cyclobutylene.

[0346] In one embodiment, the payload moiety comprises a structure shown as formula (IV-A):

[0347]

[0348] or a tautomer, mesomer, enantiomer, a diastereoisomer thereof, or a pharmaceutically acceptable salt thereof wherein,

[0349] R1’ is selected from the group consisting of: -O-, -(R2’)N-, -P(=O)(R2’)- and -S-;

[0350] X is -L1-CH2-C(O)-;

[0351] L1is -(C(R3a)(R3b))m-, wherein 0 or at least 1 methylene unit of L1is independently replaced by -C(O)-, -C(=S)-, -C(=NR4b)- or -C(=N2)-;

[0352] wherein each R2’, each R3a, each R3band each R4bare each independently hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OR, -SR, -N(Ra)(Rb), -C(O)R, -CO2R, -C(O)C(O)R, -C(O)CH2C(O)R, -S(O)R, -S(O)2R, -C(O)N(Ra)(Rb), -SO2N(Ra)(Rb), -OC(O)R, -N(R)SO2R,

[0353] or a C1-6 aliphatic group optionally substituted with R;

[0354] wherein each R, each Raand each Rbare each independently hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H or a C1-6 aliphatic group;

[0355] m is selected from the group consisting of integers > 0,

[0356] when R1’ is -O- or -HN-, at least 1 methylene unit of L1is independently replaced by -C(O)-, -C(=S)-, -C(=NR4b)- or -C(=N2)-, or each R3aand each R3bare not both hydrogen.In one embodiment, the linker-payload moiety comprises a structure shown as formula (IV-B):

[0357]

[0358] (IV-B)

[0359] or a tautomer, mesomer, enantiomer a diastereoisomer thereof, or a pharmaceutically acceptable salt thereof wherein,

[0360] L is -Lb-Lc-;

[0361] -Lb- represents a peptide residue consisting of 2 to 7 amino acids;

[0362] -Lc- is selected from the group consisting of:

[0363]

[0364] wherein RL1and RL2are each independently selected from the group consisting of: hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H and a C1-6 aliphatic group.

[0365] In one embodiment, -Lb- is:

[0366]

[0367] In one embodiment, -Lc- is

[0368] In one embodiment, the payload moiety has a structure selected from the group consisting of:

[0369]

[0370] IV-A-16 IV-A-17

[0371] In one embodiment, the payload moiety has the following structure:

[0372]

[0373] Payload and linker-payload moieties having the above structures are described in WO2022 / 068878 and national applications deriving therefrom.

[0374] Linker-payload structures containing a 6-ring exatecan moiety linked via a cyclic group

[0375] In one embodiment, the payload moiety has a structure shown as formula (V-A):

[0376]

[0377] or a tautomer, a mesomer, an enantiomer or a diastereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein

[0378] X1is saturated C, and X1is substituted with Rn;

[0379] ring A is selected from the group consisting of: 3-10 membered saturated or partially unsaturated heterocyclyl and 3-10 membered saturated or partially unsaturated carbocyclyl, wherein ring A is substituted with 0 or at least 1 substituent R1a;

[0380] when ring A is 3-10 membered saturated or partially unsaturated carbocyclyl, ring A is substituted with p L2, and L2is not Rn;

[0381] or, when ring A is 3-10 membered saturated or partially unsaturated heterocyclyl, ring A is substituted with p L2;

[0382] L2is -R2x-L3-, and R2xis used for direct or indirect linking of a ligand;

[0383] L3is -(C(R3a)(R3b))m-, wherein when L3 comprises a methylene unit, 0 or at least 1 methylene unit of L3is independently replaced by -N(R4’)C(O)-, -C(O)N(R4’)-, -C(O)-, -OC(O)-, -C(O)O-, -NR4’-, -O-, -S-, -SO-, -SO2-, -P(R4’)-, -P(=O)(R4’)-, -N(R4’)SO2-, -SO2N(R4’)-, -C

[0384]

[0385] (=S)-, -C(=NR4’)-, -N=N-, -C=N-, -N=C- or -C(=N2)-; R2xis selected from the group consisting of: -O-, -(R2a)N-, -S- and -P(=O)(R2a)-;L1is -(C(R5a)(R5b))n-, wherein when L1comprises a methylene unit, 0 or at least 1 methylene unit of L1is independently replaced by -N(R6’)C(O)-, -C(O)N(R6’)-, -C(O)-, -OC(O)-, -C(O)O-, -NR6’-, -O-, -S-, -SO-, -SO2-, -P(R6’)-, -P(=O)(R6’)-, -N(R6’)SO2-, -SO2N(R6’)-, -C(=S)-, -C(=NR6’)-, -N=N-, -C=N-, -N=C- or-C(=N2)-;

[0386] wherein each R1a, each R2a, each R3a, each R3b, each R4’, each R5a, each R5b, each R6’ and each Rnare each independently hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OR, -SR, -N(Ra)(Rb), -C(O)R, -CO2R, -C(O)C(O)R, -C(O)CH2C(O)R, -S(O)R, -S(O)2R, -C(O)N(Ra)(Rb), -SO2N(Ra)(Rb), -OC(O)R, -N(R)SO2R, or a C1-6 aliphatic group optionally substituted with R;

[0387] wherein each R, each Raand each Rbare each independently hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H or a C1-6 aliphatic group;

[0388] m and n are each independently selected from the group consisting of integers > 0, and p is an integer > 1.

[0389] In one embodiment, the linker-payload moiety has a structure shown as formula (V-B):

[0390]

[0391] or a tautomer, a mesomer, an enantiomer or a diastereoisomer thereof, or a pharmaceutically acceptable salt thereof wherein,

[0392] L is -Lb-Lc-;

[0393] -Lb- represents a peptide residue consisting of 2 to 7 amino acids;

[0394] -Lc- is selected from the group consisting of:

[0395]

[0396] wherein RL1and RL2are each independently selected from the group consisting of: hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H and a C1-6 aliphatic group.

[0397] In one embodiment, -Lb- represents a peptide residue consisting of 2 to 7 amino acids, and the peptide residue of -Lb- is a peptide residue formed of amino acids selected from the group consisting of: phenylalanine, glycine, alanine, valine, citrulline, lysine, serine, glutamic acid and aspartic acid; -Lc- is selected from the group consisting of:

[0398]

[0399] wherein RL1and RL2are each independently selected from the group consisting of: hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H and a C1-6 aliphatic group.

[0400] In one embodiment, -Lb- represents a peptide residue consisting of 2 to 4 amino acids, and the peptide residue of -Lb- is a peptide residue formed of amino acids selected from the group consisting of: phenylalanine, glycine, alanine, valine, citrulline and lysine.

[0401] In one embodiment, -Lb- is selected from the group consisting of:In one embodiment, -Lb- is

[0402]

[0403] In one embodiment, -Lc- is selected from the group consisting of:

[0404]

[0405] wherein RL1and RL2are each independently selected from the group consisting of: hydrogen, halogen, -OH and a C1-6 aliphatic group.

[0406] In one embodiment, -Lc- is

[0407]

[0408] wherein RL1and RL2are each independently selected from the group consisting of: hydrogen, halogen, -OH and a C1-6 aliphatic group.

[0409] In one embodiment, -Lc- is - .

[0410] In one embodiment, ring A is selected from the group consisting of: 3-10 membered saturated heterocyclyl and 3-10 membered saturated carbocyclyl.

[0411] In one embodiment, ring A is 3-10 membered saturated carbocyclyl.In one embodiment, ring A is 3-6 membered saturated carbocyclyl, preferably wherein ring A is 4 membered saturated carbocyclyl. In one embodiment, ring A is 6 membered saturated carbocyclyl.

[0412] In one embodiment, ring A is 3-10 membered saturated heterocyclyl. In one embodiment, ring A is 3-6 membered saturated heterocyclyl. In one embodiment, ring A is 3 membered saturated heterocyclyl.

[0413] In one embodiment, ring A comprises 1 heteroatom. In one embodiment, ring A comprises 1 nitrogen atom.

[0414] In one embodiment, ring A is substituted with 0 substituent R1a.

[0415] In one embodiment, the payload moiety comprises a structure selected from the following (wherein R2is replaced with R2x):

[0416]

[0417] V-A-10 V-A-11 V-A-12

[0418] In one embodiment, the payload moiety comprises the structure (wherein R2is replaced with R2x):In some embodiments, the payload moiety comprises the structure:

[0419]

[0420] Payload and linker-payload moieties having the above structures are described in WO2022 / 068878 and national applications deriving therefrom.

[0421] Linker-payload structures containing a 5- or 6- ring camptothecin or exatecan moiety linked using alternative open-chain or cyclic structures

[0422] In one embodiment, the payload moiety has the structure represented by formula (Vl-A):

[0423]

[0424] fVI-A|■anc| / or

[0425] the linker-payload moiety has the structure represented by formula (Vl-B):

[0426]

[0427] (VI-B)

[0428] wherein,

[0429] L3 is selected from an amino acid residue or a short peptide consisting of 2-10 amino acid residues; preferably wherein the amino acid residue is selected from natural amino acid residues, non-natural amino acid residues, or selected from amino acid residue represented by AA1or stereoisomer thereof;

[0430] o

[0431]

[0432] AA1

[0433] in the amino acid residue represented by AA1, any one of Raand Rbis H, and the other is H,

[0434]

[0435] ; or, Raand Rb, together with the carbon atom to which they are both attached, form a 5-6 membered heterocyclic ring, and said 5-6 membered heterocyclic ring is piperidine ring or piperazine ring.

[0436] r, r1, r1aand r1bare each independently 0, 1, 2, 3, 4 or 5;

[0437] Rm1, Rn1, Rm1a, Rn1a, Rm1band Rn1bare each independently H, C1-6 alkyl or-COORx1, wherein, Rx1is C1-6 alkyl;

[0438] or, Rm1and Rn1, Rm1aand Rn1a, and Rm1band Rn1b, together with the nitrogen atom to which they are both attached, form a 5-6 membered heterocyclic ring, and of said 5-6 membered heterocyclic ring, the heteroatom is selected from 1 or 2 N atoms; the said 5-6 membered heterocyclic ring is optionally substituted with one or more R0’;R°” is selected from C1-6 alkyl, -NRm2Rn2or 5-6 membered heterocyclyl optionally substituted with C1-6 alkyl; of said 5-6 membered heterocyclyl, the heteroatom is selected from 1 or 2 N atoms;

[0439] Rm2and Rn2are each independently selected from H and C1-6 alkyl;

[0440] * N N L4 is absent or present, when L4 is present, L4 is selected from H

[0441]

[0442] position 2 is attached to W;

[0443] R1” and R2”are each independently selected from H, halogens and C1-4 alkyl; or, R1” and R2”, together with the carbon atom to which they are both attached form a 5-6 membered heterocyclic ring, the heterocyclic ring contains 1, 2, or 3 of O, S, or N or any combination thereof;

[0444] R3’’ is selected from H and C1-4 alkyl; or R3’’ and X, together with the carbon atom to which they are both attached, form a 5-6 membered carbon ring;

[0445] W is absent or present, when W is present, W is selected from -O-, -S-, -NR4”-,

[0446]

[0447] and RS , position 1 is attached to X, and position 2 is attached to L4or L3;

[0448] T' R / ’ >

[0449] R / 4faR / ' X is selected from optionally substituted -(CH2)ni-,

[0450]

[0451] R?,R?” , * position 1 is attached to the parent ring and position 2 is attached to W or L4; the substituent is selected from one or two C1-4 alkyls;

[0452] R4”, R5”, and R7’’ are each independently selected from H and C1-4 alkyl;n”, n1, n2, n3 are each independently selected from any integer between 0 and 6.

[0453] In one embodiment, L3is selected from AA1, AA1-Gly, Val-Cit, Val-Ala, Val-AA1, Val-AA1-Gly, AA1-Ala-Asn, Ala-Ala-Ala, Ala-Ala-Asn and Gly-Gly-Phe-Gly.

[0454] In one embodiment, L3is selected from AA1, AA1-Gly, Val-Cit, Val-AA1-Gly, AA1-Ala-Asn and Gly-Gly-Phe-Gly.

[0455] In one embodiment, L3is Val-AA1-Gly.

[0456] In one embodiment, the amino acid residue represented by AA1is selected from

[0457]

[0458] In one embodiment, the amino acid residue represented b

[0459]

[0460] y AA1is

[0461]

[0462] In one embodiment, L4is selected from H ' , and

[0463]

[0464] In one embodiment,

[0465]

[0466] L4is H

[0467] In one embodiment, W is O.

[0468] In one embodiment, X is -(CH2)ni-.

[0469] In one embodiment, n1 is 2, 3 or 4. In one embodiment, n1 is 3.

[0470] In one embodiment, the structural fragment represented by; and position 1 is attached to L4.

[0471] In o

[0472]

[0473] ne embodiment, the structural fragment

[0474]

[0475] Payload and linker-payload moieties having the above structures are described generally in WO2022 / 170971 and national applications deriving therefrom.

[0476] Linker-payload structures containing auristatin moieties

[0477] In one embodiment, the payload is monomethyl auristatin E (MMAE). MMAE has the IIIPAC name (S)-N-((3 / ?,4S,5S)-1-((S)-2-((1 / ?,2 / ?)-3-(((1S,2 / ?)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide and has the following structure:

[0478]

[0479] In one embodiment, the payload is MMAE and the linker-payload moiety is formed by the conjugation of a linker, as defined herein, to the N-terminal of the MMAE moiety.Thus, in one embodiment, the payload moiety is of formula (Vll-A):

[0480]

[0481] In one embodiment, the payload is monomethyl auristatin F (MMAF). MMAF has the IIIPAC name (S)-2-((2F?,3F?)-3-((S)-1-((3F?,4S,5S)-4-((S)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoic acid and has the following structure:

[0482]

[0483] In one embodiment, the payload is MMAF and the linker-payload moiety is formed by the conjugation of a linker, as defined herein, to the N-terminal of the MMAF moiety.

[0484] Thus, in one embodiment, the payload moiety is of formula (Vlll-A):

[0485]

[0486] In one embodiment, the payload moiety is MMAE or MMAF and the linker comprises a spacer moiety. In one embodiment, the payload is MMAE or MMAF, the linker comprises a peptide moiety and the spacer moiety is conjugated to the C-terminus of the peptide moiety. In one embodiment, the linker-payload moiety comprises a payload moiety, a spacer moietyand a peptide moiety, the payload moiety is MMAE or MMAF, and the spacer moiety is present between the peptide moiety and the payload moiety. In one embodiment, the linkerpayload moiety comprises a payload moiety, a spacer moiety and a peptide moiety, the payload is MMAE or MMAF, and the spacer moiety is present between the peptide moiety and the payload moiety.

[0487] In some embodiments, the payload is MMAE or MMAF, the peptide linker comprises, consists essentially of, or consists of a Val-Cit moiety, the spacer moiety has the structure:

[0488] O

[0489]

[0490] the -NH- moiety of the spacer moiety being conjugated by an amide bond to the C-terminus of the Cit residue of the peptide moiety and the C(=O)- moiety of the spacer moiety being conjugated by an amide bond to the N-terminus of the MMAE or MMAF payload moiety. In some embodiments, the payload is MMAE or MMAF, the linker comprises a maleimide moiety, the peptide moiety is a Val-Cit moiety, the spacer moiety has the structure:

[0491] o

[0492]

[0493] the -NH- moiety of the spacer moiety being conjugated by an amide bond to the C-terminus of the Cit residue of the peptide moiety and the C(=O)- moiety of the spacer moiety being conjugated by an amide bond to the N-terminus of the MMAE or MMAF payload moiety. Payload and linker-payload moieties having the above structures are described generally in W02004 / 010957 and national applications deriving therefrom.

[0494] In one embodiment, the compound of the invention does not comprise a linker-payload moiety in which the payload is MMAE and in which the linker comprises a Val-Cit moiety. Binding molecules (Ab)

[0495] The compound of the present invention may comprise any suitable binding molecule or a fragment thereof, preferably any suitable antibody or fragment thereof. The binding molecule or fragment thereof (e.g. antibody or fragment thereof) may be referred to herein as substituent Ab.In some embodiments, the binding molecule or fragment thereof comprises one or more, two or more, three or more, or four or more cysteine residues (e.g. 32 cysteine residues in a full-length IgG antibody). In some embodiments, the binding molecule or fragment thereof comprises one or more, two or more, three or more, or four or more disulfide bonds (e.g. 16 disulfide bonds in a full-length IgG antibody). In some embodiments, the binding molecule or fragment thereof comprises one or more, two or more, three or more, or four or more interchain disulfide bonds (e.g. 4 inter-chain disulfide bonds in a full-length IgG antibody).

[0496] In some embodiments, the binding molecule may be an antibody or a fragment thereof. In some embodiments, the fragment is an antigen-binding fragment.

[0497] The antibody or fragment thereof may be selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, a monoclonal antibody, a polyclonal antibody, and fragments thereof.

[0498] In some embodiments, the antibody or fragment thereof is a full-length antibody, such as a human antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, a monoclonal antibody, ora polyclonal antibody. In some embodiments, the antibody or fragment thereof that specifically binds to a target expressed on the surface of a tumour cell is a human antibody, a humanized antibody, or a chimeric antibody. In some embodiments, the antibody or fragment thereof that specifically binds to a target expressed on the surface of a tumour cell is a monoclonal antibody, for example a monoclonal human antibody, a monoclonal humanized antibody, ora monoclonal chimeric antibody.

[0499] In other embodiments, the antibody or fragment thereof is a human antibody fragment, a humanized antibody fragment, or a chimeric antibody fragment. In other embodiments, the antibody or fragment thereof is an antibody fragment, such as a Fab, a Fab', a F(ab')2, an Fv, an scFv, a Fab'-SH, an sdAb, or a VHH.

[0500] In some embodiments, the antibody or fragment thereof comprises an immunoglobulin constant region. In some embodiments, the immunoglobulin constant region is a human IgG constant region, for example a human lgG1, lgG2, lgG3 or lgG4 constant region. In some embodiments, the immunoglobulin constant region is a human lgG1 constant region.

[0501] In some embodiments, the antibody or fragment thereof comprises an Fc region. In some embodiments, the Fc region is a human Fc region, for example a human lgG1, lgG2, lgG3 or lgG4 Fc region. In some embodiments, the antibody or fragment thereof comprises a human lgG1 Fc region.In some embodiments, the antibody or fragment thereof comprises an Fc region comprising one or more mutations which reduce or abolish immune effect functions. Suitable mutations are known in the art and may include one or more amino acid substitutions (see e.g.

[0502] Wilkinson, I., et al., 2021. FcPLoS One, 16(12), p.e0260954; and Liu, R., et al., 2020.

[0503] Antibodies, 9(4), p.64). In some embodiments, the antibody or fragment thereof comprises an IgG 1 Fc region comprising a L234A and / or a L235A mutation. In some embodiments, the antibody or fragment thereof comprises an I gG 1 Fc region comprising L234A and L235A mutations. Amino acids are numbered according to the Eu numbering (Eu-index) as set forth in Kabat (Kabat, E.A.; National Institutes of Health (U.S.) Office of the Director. Sequences of Proteins of Immunological Interest, 5th ed.; DIANE Publishing: Collingdale, PA, USA, 1991).

[0504] In some embodiments, the antibody or fragment thereof specifically binds to a target expressed on the surface of a tumour cell. Targets which are expressed on the surface of a tumour cell may be identified by means of various molecular biological and immunological methods known in the art (see e.g. Carter, P., et al., 2004. Endocrine-related cancer, 11(4), pp.659-687). An ideal expression profile is abundant and homogeneous antigen expression on the external surface of all tumour cells for multiple tumour types with the majority of subject for each tumour type, and absent from normal tissue. In some embodiments, the target is expressed on the surface of solid tumour cells.

[0505] In some embodiments, the target is expressed with higher expression on the surface of tumour cells as compared to healthy cells. In some embodiments, the target is expressed at a level sufficient to distinguish a tumour cell from healthy cells. Evaluation of antigen expression on the surface may be determined by any suitable method, for example by immunohistochemistry e.g. tissue microarray immunohistochemistry (see e.g. Hoos, A. and Cordon-Cardo, C., 2001. Laboratory investigation, 81(10), pp.1331-1338).

[0506] Example targets may include B7H3, TROP2, HER2, HER3, ALK receptor (pleiotrophin receptor); ovarian carcinoma antigen (CA125); prostate-specific antigen (PSA); melanoma-associated antigen p97; melanoma antigen gp75; high molecular weight melanoma antigen (HMW-MAA); prostate-specific membrane antigen (PSMA); carcinoembryonic antigen (CEA); polymorphic epithelial mucin antigen; CD19; human B-lymphoma antigen-CD20; CD33; melanoma-specific antigens such as ganglioside GD2, ganglioside GD3, ganglioside GM2, and ganglioside GM3; epidermal growth factor receptor (EGFR); NY-BR-16; NY-BR-16; polymorphic epithelial mucin (PEM); malignant human lymphocyte antigen-APO-1; SSEA-1; SCP-1; SSEA-3; SSEA-4; sialyl Tn (STn); colon cancer antigen NY-CO-45; lung cancer antigen NY-LU-12 variant A; adenocarcinoma antigen ART1; Neuro-oncologicalventral antigen 2 (NOVA2); tumour-associated antigens MAGE-C1 (cancer / testis antigen CT7), MAGE-B1 (MAGE-XP antigen), MAGE-B2 (DAM6), MAGE-2, MAGE-4a, MAGE-4b and MAGE-X2; Cancer-Testis Antigen (NY-EOS-1); YKL-40; EpCAM; EREG; CA15-3; sialyl SSEA-I(SLX); and Mesothelin. Other example targets may include CD30, Nectin-4, TF, B7-H4 and ITGB6.

[0507] In some embodiments, the target expressed on the surface of a tumour cell is HER2, B7H3, TROP2, HER3, CD30, Nectin-4, TF, B7-H4, and / or ITGB6.

[0508] In some embodiments, the target expressed on the surface of a tumour cell is HER2, B7H3, TROP2 and / or HER3. In some embodiments, the target expressed on the surface of a tumour cell is HER2, B7H3 or TROP2. In some embodiments, the target expressed on the surface of a tumour cell is HER3. In some embodiments, the target expressed on the surface of a tumour cell is CD30, Nectin-4, TF, B7-H4, ITGB6, and / or HER2. In some embodiments, the target expressed on the surface of a tumour cell is CD30, Nectin-4, TF, B7-H4, ITGB6, or HER2.

[0509] Examples of suitable antibodies or fragments thereof are described herein. However, the present invention is not limited to any particular antibody or fragment thereof.

[0510] Anti-B7H3 antibodies and fragments thereof

[0511] In some embodiments, the compound of the invention comprises an anti-B7H3 antibody or fragment thereof. B7H3 is a protein that in humans is encoded by the CD276 gene and which may also be known as Cluster of Differentiation 276 (CD276) and B7 Homolog 3 (B7-H3).

[0512] The anti-B7H3 antibody or fragment thereof may specifically bind B7H3. The anti-B7H3 antibody may be a monoclonal antibody. In some embodiments, the anti-B7H3 antibody or fragment thereof is a humanized antibody. In some embodiments, the anti-B7H3 antibody or fragment thereof is a monoclonal humanized antibody. The fragment thereof may be any antigen-binding fragment thereof, for example a Fab, a Fab', a F(ab')2, a Fv, a scFv, a Fab'-SH, an sdAb, or a VHH. In some embodiments, the anti-B7H3 antibody or fragment thereof is a full-length anti-B7H3 antibody.

[0513] Example anti-B7H3 antibody CDRs, variable region sequences, and heavy and light chain sequences are provided below.Example anti-B7H3 antibody sequences 1

[0514] Kabat HCDR1 GDYAWN (SEQ ID NO: 1)

[0515] Kabat HCDR2 YISYSGSTSYNPSLQS (SEQ ID NO: 2)

[0516] Kabat HCDR3 SLGRRWYFW (SEQ ID NO: 3)

[0517] Kabat LCDR1 KSSQSLLNSSNQKNYLA (SEQ ID NO: 4)

[0518] Kabat LCDR2 FASTRES (SEQ ID NO: 5)

[0519] Kabat LCDR3 QQHYSAPWT (SEQ ID NO: 6)

[0520] IMGT HCDR1 DYSITGDYA (SEQ ID NO: 7)

[0521] IMGT HCDR2 ISYSGST (SEQ ID NO: 8)

[0522] IMGT HCDR3 ARSLGRRWYFVV (SEQ ID NO: 9)

[0523] IMGT LCDR1 QSLLNSSNQKNY (SEQ ID NO: 10)

[0524] IMGT LCDR2 FAS (SEQ ID NO: 11)

[0525] IMGT LCDR3 QQHYSAPWT (SEQ ID NO: 12)

[0526] VH DVQLQESGPGLVKPSQSLSLTCTVTDYSITGDYAWNWIRQFPGNKLEWM GYISYSGSTSYNPSLQSRISITRDTSKNQFFLQLNSVTSEDTATYFCARSLG RRWYFVVWGAGTTVTVSA (SEQ ID NO: 13)

[0527] VL DIVMTQSPSSLAMSVGQKVTMSCKSSQSLLNSSNQKNYLAWYQQKPGQS PKLLIYFASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLTDYFCQQHYSAP WTFGGGTKLEIK (SEQ ID NO: 14)

[0528] Heavy chain DVQLQESGPGLVKPSQSLSLTCTVTDYSITGDYAWNWIRQFPGNKLEWM GYISYSGSTSYNPSLQSRISITRDTSKNQFFLQLNSVTSEDTATYFCARSLG RRWYFVVWGAGTTVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI CNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPI EKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

[0529] (SEQ ID NO: 15)

[0530] Light chain DIVMTQSPSSLAMSVGQKVTMSCKSSQSLLNSSNQKNYLAWYQQKPGQS PKLLIYFASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLTDYFCQQHYSAP WTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASWCLLNNFYPREAKV QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE

[0531]

[0532] VTHQGLSSPVTKSFNRGEC (SEQ ID NO: 16)

[0533] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 2; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 3; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 4; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 5; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 6, wherein the CDRs are defined according to the Kabat numbering system.In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 7; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 8; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 9; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 10; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 11 ; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 12, wherein the CDRs are defined according to the IMGT numbering system.

[0534] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 13, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or 7; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 2 or 8; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 3 or 9; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 14 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 4 or 10; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 5 or 11 ; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 6 or 12.

[0535] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 13; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 14.

[0536] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 15, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or 7; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 2 or 8; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 3 or 9; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 16 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the light chain variable regioncomprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 4 or 10; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 5 or 11 ; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 6 or 12. In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 15; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 16. In some embodiments, the antibody or fragment thereof comprises or consists of two heavy chains comprising or consisting of the amino acid sequence of SEQ ID NO: 15; and two light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 16.

[0537] Example anti-B 7H3 antibody sequences 2

[0538] Kabat HCDR1 GDYAWN (SEQ ID NO: 17)

[0539] Kabat HCDR2 YISYSGSTSYNPSLQS (SEQ ID NO: 18)

[0540] Kabat HCDR3 SLGRRWYFW (SEQ ID NO: 19)

[0541] Kabat LCDR1 KSSQSLLQSSNQKNYLA (SEQ ID NO: 20)

[0542] Kabat LCDR2 FASTRES (SEQ ID NO: 21)

[0543] Kabat LCDR3 QQHYSAPWT (SEQ ID NO: 22)

[0544] IMGT HCDR1 DYSITGDYA (SEQ ID NO: 23)

[0545] IMGT HCDR2 ISYSGST (SEQ ID NO: 24)

[0546] IMGT HCDR3 ARSLGRRWYFVV (SEQ ID NO: 25)

[0547] IMGT LCDR1 QSLLQSSNQKNY (SEQ ID NO: 26)

[0548] IMGT LCDR2 FAS (SEQ ID NO: 27)

[0549] IMGT LCDR3 QQHYSAPWT (SEQ ID NO: 28)

[0550] VH QVQLQESGPGLVKPSQTLSLTCTVTDYSITGDYAWNWIRQHPGKGLEWIG YISYSGSTSYNPSLQSRVTISRDTSKNQFSLKLSSVTAADTAVYFCARSLG RRWYFVVWGQGTTVTVSS (SEQ ID NO: 29)

[0551] VL DIVMTQSPDSLAVSLGERATINCKSSQSLLQSSNQKNYLAWYQQKPGQPP KLLIYFASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYSAP WTFGGGTKVEIK (SEQ ID NO: 30)

[0552] Heavy chain QVQLQESGPGLVKPSQTLSLTCTVTDYSITGDYAWNWIRQHPGKGLEWIG YISYSGSTSYNPSLQSRVTISRDTSKNQFSLKLSSVTAADTAVYFCARSLG RRWYFVVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI CNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPI EKTISKAKGQPREPQ VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

[0553] K (SEQ ID NO: 31)

[0554] Light chain DIVMTQSPDSLAVSLGERATINCKSSQSLLQSSNQKNYLAWYQQKPGQPP KLLIYFASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYSAP WTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASWCLLNNFYPREAKV QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE

[0555]

[0556] VTHQGLSSPVTKSFNRGEC (SEQ ID NO: 32)

[0557] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO:17; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 18; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 19; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 20; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 21 ; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 22, wherein the CDRs are defined according to the Kabat numbering system.

[0558] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 23; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 24; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 25; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 26; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 27; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 28, wherein the CDRs are defined according to the IMGT numbering system.

[0559] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 29, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 17 or 23; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 18 or 24; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 19 or 25; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 30 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 20 or 26; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 21 or 27; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 22 or 28.

[0560] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 29; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 30.

[0561] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 31, or an amino acid sequence havingat least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 17 or 23; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 18 or 24; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 19 or 25; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 32 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 20 or 26; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 21 or 27; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 22 or 28.

[0562] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 31 ; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 32. In some embodiments, the antibody or fragment thereof comprises or consists of two heavy chains comprising or consisting of the amino acid sequence of SEQ ID NO: 31 ; and two light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 32.

[0563] Anti-TROP2 antibodies and fragments thereof

[0564] In some embodiments, the compound of the invention comprises an anti-TROP2 antibody or fragment thereof. TROP2 is a protein that in humans is encoded by the TACSTD2 and which may also be known as Tumour-associated calcium signal transducer 2, epithelial glycoprotein- 1 antigen (EGP-1), orTrop-2.

[0565] The anti-TROP2 antibody or fragment thereof may specifically bind TROP2. The anti-TROP2 antibody may be a monoclonal antibody. In some embodiments, the anti-TROP2 antibody or fragment thereof is a humanized antibody. In some embodiments, the anti-TROP2 antibody or fragment thereof is a monoclonal humanized antibody. The fragment thereof may be any antigen-binding fragment thereof, for example a Fab, a Fab', a F(ab')2, a Fv, a scFv, a Fab'-SH, an sdAb, or a VHH. In some embodiments, the anti-TROP2 antibody or fragment thereof is a full-length anti-TROP2 antibody.

[0566] Example anti-TROP2 antibody CDRs, variable region sequences, and heavy and light chain sequences are provided below.

[0567] Kabat HCDR1 NYGMN (SEQ ID NO: 33)

[0568] Kabat HCDR2 WINTYTGEPTYTDDFKG (SEQ ID NO: 34)

[0569]

[0570] Kabat HCDR3 GGFGSSYWYFDV (SEQ ID NO: 35)Kabat LCDR1 KASQDVSIAVA (SEQ ID NO: 36)

[0571] Kabat LCDR2 SASYRYT (SEQ ID NO: 37)

[0572] Kabat LCDR3 QQHYITPLT (SEQ ID NO: 38)

[0573] IMGT HCDR1 GYTFTNYG (SEQ ID NO: 39)

[0574] IMGT HCDR2 INTYTGEP (SEQ ID NO: 40)

[0575] IMGT HCDR3 ARGGFGSSYWYFDV (SEQ ID NO: 41)

[0576] IMGT LCDR1 QDVSIA (SEQ ID NO: 42)

[0577] IMGT LCDR2 SAS (SEQ ID NO: 43)

[0578] IMGT LCDR3 QQHYITPLT (SEQ ID NO: 44)

[0579] VH QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKW MGWINTYTGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCAR GGFGSSYWYFDVWGQGSLVTVSS (SEQ ID NO: 45)

[0580] VL DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSA SYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAGT KVEIK (SEQ ID NO: 46)

[0581] Heavy chain QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKW MGWINTYTGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCAR GGFGSSYWYFDVWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALG CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL GTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLF PPKPKDTLMISRTPEVTCWVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP REPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS LSPGK (SEQ ID NO: 47)

[0582] Light chain DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSA SYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAGT KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNA LQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS

[0583]

[0584] PVTKSFNRGEC (SEQ ID NO: 48)

[0585] In some embodiments, the anti-TROP2 antibody or fragment thereof is derived from sacituzumab.

[0586] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 33; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 34; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 35; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 36; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 37; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 38, wherein the CDRs are defined according to the Kabat numbering system.In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 39; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 40; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 41; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 42; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 43; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 44, wherein the CDRs are defined according to the IMGT numbering system.

[0587] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 45, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 33 or 39; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 34 or 40; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 35 or 41; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 46 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 36 or 42; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 37 or 43; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 38 or 44.

[0588] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 45; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 46.

[0589] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 47, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 33 or 39; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 34 or 40; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 35 or 41; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 48 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the light chain variableregion comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 36 or 42; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 37 or 43; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 38 or 44.

[0590] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 47; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 48. In some embodiments, the antibody or fragment thereof comprises or consists of two heavy chains comprising or consisting of the amino acid sequence of SEQ ID NO: 47; and two light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 48.

[0591] Anti-HER2 antibodies and fragments thereof

[0592] In some embodiments, the compound of the invention comprises an anti-HER2 antibody or fragment thereof. HER2 is a protein that in humans is encoded by the ERBB2 gene and which may also be known as human epidermal growth factor receptor 2 (HER-2), Receptor tyrosine-protein kinase erbB-2 and CD340 (Cluster of Differentiation 340).

[0593] The anti-HER2 antibody or fragment thereof may specifically bind HER2. The anti-HER2 antibody may be a monoclonal antibody. In some embodiments, the anti-HER2 antibody or fragment thereof is a humanized antibody. In some embodiments, the anti-HER2 antibody or fragment thereof is a monoclonal humanized antibody. The fragment thereof may be any antigen-binding fragment thereof, for example a Fab, a Fab', a F(ab')2, a Fv, an ScFv, a Fab'-SH, an sdAb, or a VHH. In some embodiments, the anti-HER2 antibody or fragment thereof is a full-length anti-HER2 antibody.

[0594] Example anti-HER2 antibody CDRs, variable region sequences, and heavy and light chain sequences are provided below.

[0595] Example anti-HER2 antibody sequences 1 - Trastuzumab

[0596] Kabat HCDR1 DTYIH (SEQ ID NO: 49)

[0597] Kabat HCDR2 RIYPTNGYTRYADSVKG (SEQ ID NO: 50)

[0598] Kabat HCDR3 WGGDGFYAMDY (SEQ ID NO: 51)

[0599] Kabat LCDR1 RASQDVNTAVA (SEQ ID NO: 52)

[0600] Kabat LCDR2 SASFLYS (SEQ ID NO: 53)

[0601] Kabat LCDR3 QQHYTTPPT (SEQ ID NO: 54)

[0602] IMGT HCDR1 GFNIKDTY (SEQ ID NO: 55)

[0603] IMGT HCDR2 IYPTNGYT (SEQ ID NO: 56)

[0604] IMGT HCDR3 SRWGGDGFYAMDY (SEQ ID NO: 57)

[0605] IMGT LCDR1 QDVNTA (SEQ ID NO: 58)

[0606] IMGT LCDR2 SAS (SEQ ID NO: 59)

[0607]

[0608] IMGT LCDR3 QQHYTTPPT (SEQ ID NO: 60)VH EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVA RIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRW GGDGFYAMDYWGQGTLVTVSS (SEQ ID NO: 61)

[0609] VL DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYS ASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQ GTKVEIK (SEQ ID NO: 62)

[0610] Heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVA RIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRW GGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCWVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPG (SEQ ID NO: 63)

[0611] Light chain DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYS ASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQ GTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGL

[0612]

[0613] SSPVTKSFNRGEC (SEQ ID NO: 64)

[0614] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 49; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 50; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 51; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 52; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 53; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 54, wherein the CDRs are defined according to the Kabat numbering system.

[0615] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 55; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 56; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 57; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 58; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 59; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 60, wherein the CDRs are defined according to the IMGT numbering system.

[0616] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 61, or an amino acidsequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 49 or 55; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 50 or 56; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 51 or 57; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 62 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 52 or 58; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 53 or 59; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 54 or 60.

[0617] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 61; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 62.

[0618] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 63, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 49 or 55; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 50 or 56; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 51 or 57; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 64 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 52 or 58; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 53 or 59; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 54 or 60.

[0619] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 63; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 64. In some embodiments, the antibody or fragment thereof comprises or consists of two heavy chains comprising or consisting of the amino acid sequence of SEQ ID NO: 63; and two light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 64.

[0620] In one embodiment, the antibody or fragment thereof is not Trastuzumab.Example anti-HER2 antibody sequences 2 - Pertuzumab

[0621] Kabat HCDR1 DYTMD (SEQ ID NO: 65)

[0622] Kabat HCDR2 DVNPNSGGSIYNQRFKG (SEQ ID NO: 66)

[0623] Kabat HCDR3 NLGPSFYFDY (SEQ ID NO: 67)

[0624] Kabat LCDR1 KASQDVSIGVA (SEQ ID NO: 68)

[0625] Kabat LCDR2 SASYRYT (SEQ ID NO: 69)

[0626] Kabat LCDR3 QQYYIYPYT (SEQ ID NO: 70)

[0627] IMGT HCDR1 GFTFTDYT (SEQ ID NO: 71)

[0628] IMGT HCDR2 VNPNSGGS (SEQ ID NO: 72)

[0629] IMGT HCDR3 ARNLGPSFYFDY (SEQ ID NO: 73)

[0630] IMGT LCDR1 QDVSIG (SEQ ID NO: 74)

[0631] IMGT LCDR2 SAS (SEQ ID NO: 75)

[0632] IMGT LCDR3 QQYYIYPYT (SEQ ID NO: 76)

[0633] VH EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWV ADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCAR NLGPSFYFDYWGQGTLVTVSS (SEQ ID NO: 77)

[0634] VL DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSA SYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGT KVEIK (SEQ ID NO: 78)

[0635] Heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWV ADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCAR NLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ TYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP

[0636] G (SEQ ID NO: 79)

[0637] Light chain DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSA SYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGT KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNA LQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS

[0638]

[0639] PVTKSFNRGEC (SEQ ID NO: 80)

[0640] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 65; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 66; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 67; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 68; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 69; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 70, wherein the CDRs are defined according to the Kabat numbering system.

[0641] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO:71 ; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 72; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 73; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 74; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 75; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 76, wherein the CDRs are defined according to the IMGT numbering system.

[0642] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 77, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 65 or 71 ; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 66 or 72; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 67 or 73; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 78 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 68 or 74; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 69 or 75; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 70 or 76.

[0643] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 77; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 78.

[0644] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 79, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 65 or 71 ; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 66 or 72; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 67 or 73; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 80 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 68 or 74; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO:69 or 75; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 70 or 76.

[0645] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 79; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 80. In some embodiments, the antibody or fragment thereof comprises or consists of two heavy chains comprising or consisting of the amino acid sequence of SEQ ID NO: 79; and two light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 80.

[0646] Example anti-HER2 antibody sequences 3

[0647] Kabat HCDR1 DYYIH (SEQ ID NO: 81)

[0648] Kabat HCDR2 RVNPDHGDSYYNQKFKD (SEQ ID NO: 82)

[0649] Kabat HCDR3 NYLFDH (SEQ ID NO: 83)

[0650] Kabat LCDR1 KASQDVGTAVA (SEQ ID NO: 84)

[0651] Kabat LCDR2 WASIRHT (SEQ ID NO: 85)

[0652] Kabat LCDR3 HQFATYT (SEQ ID NO: 86)

[0653] IMGT HCDR1 GYTFTDYY (SEQ ID NO: 87)

[0654] IMGT HCDR2 VNPDHGDS (SEQ ID NO: 88)

[0655] IMGT HCDR3 ARNYLFDH (SEQ ID NO: 89)

[0656] IMGT LCDR1 QDVGTA (SEQ ID NO: 90)

[0657] IMGT LCDR2 WAS (SEQ ID NO: 91)

[0658] IMGT LCDR3 HQFATYT (SEQ ID NO: 92)

[0659] VH EVQLVQSGAEVKKPGATVKISCKVSGYTFTDYYIHWVQQAPGKGLEWMG RVNPDHGDSYYNQKFKDKATITADKSTDTAYMELSSLRSEDTAVYFCARN YLFDHWGQGTLVTVSS (SEQ ID NO: 93)

[0660] VL DIQMTQSPSSVSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYW ASIRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQFATYTFGGGTK VEIK (SEQ ID NO: 94)

[0661] Heavy chain EVQLVQSGAEVKKPGATVKISCKVSGYTFTDYYIHWVQQAPGKGLEWMG RVNPDHGDSYYNQKFKDKATITADKSTDTAYMELSSLRSEDTAVYFCARN YLFDHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0662] (SEQ ID NO: 95)

[0663] Light chain DIQMTQSPSSVSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYW ASIRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQFATYTFGGGTK VEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL QSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP

[0664]

[0665] VTKSFNRGEC (SEQ ID NO: 96)

[0666] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 81 ; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 82;and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 83; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 84; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 85; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 86, wherein the CDRs are defined according to the Kabat numbering system.

[0667] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 87; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 88; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 89; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 90; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 91 ; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 92, wherein the CDRs are defined according to the IMGT numbering system.

[0668] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 93, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 81 or 87; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 82 or 88; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 83 or 89; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 94 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 84 or 90; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 85 or 91; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 86 or 92.

[0669] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 93; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 94.

[0670] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 95, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the heavy chainvariable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 81 or 87; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 82 or 88; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 83 or 89; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 96 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 84 or 90; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 85 or 91; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 86 or 92.

[0671] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 95; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 96. In some embodiments, the antibody or fragment thereof comprises or consists of two heavy chains comprising or consisting of the amino acid sequence of SEQ ID NO: 95; and two light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 96.

[0672] Anti-HER3 antibodies and fragments thereof

[0673] In some embodiments, the compound of the invention comprises an anti-HER3 antibody or fragment thereof. HER3 is a protein that in humans is encoded by the ERBB3 gene and which may also be known as human epidermal growth factor receptor 3 (HER-3) and Receptor tyrosine-protein kinase erbB-3.

[0674] The anti-HER3 antibody or fragment thereof may specifically bind HER3. The anti-HER3 antibody may be a monoclonal antibody. In some embodiments, the anti-HER3 antibody or fragment thereof is a humanized antibody. In some embodiments, the anti-HER3 antibody or fragment thereof is a monoclonal humanized antibody. In some embodiments, the anti-HER3 antibody or fragment thereof is a human antibody. In some embodiments, the anti-HER3 antibody or fragment thereof is a monoclonal human antibody. The fragment thereof may be any antigen-binding fragment thereof, for example a Fab, a Fab', a F(ab')2, a Fv, a scFv, a Fab'-SH, an sdAb, or a VHH. In some embodiments, the anti-HER3 antibody or fragment thereof is a full-length anti-HER3 antibody.

[0675] Example anti-HER3 antibody CDRs, variable region sequences, and heavy and light chain sequences are provided below.Kabat HCDR1 TYGMH (SEQ ID NO: 97)

[0676] Kabat HCDR2 VIWYDVSHKYYADSVKG (SEQ ID NO: 98)

[0677] Kabat HCDR3 DWGDPDAFDI (SEQ ID NO: 99)

[0678] Kabat LCDR1 RASQGISSYLA (SEQ ID NO: 100)

[0679] Kabat LCDR2 AASTLQS (SEQ ID NO: 101)

[0680] Kabat LCDR3 QQLNSYPLT (SEQ ID NO: 102)

[0681] IMGT HCDR1 GFTFSTYG (SEQ ID NO: 103)

[0682] IMGT HCDR2 IWYDVSHK (SEQ ID NO: 104)

[0683] IMGT HCDR3 ARDWGDPDAFDI (SEQ ID NO: 105)

[0684] IMGT LCDR1 QGISSY (SEQ ID NO: 106)

[0685] IMGT LCDR2 AAS (SEQ ID NO: 107)

[0686] IMGT LCDR3 QQLNSYPLT (SEQ ID NO: 108)

[0687] VH EVQLVESGGGWQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWV AVIWYDVSHKYYADSVKGRFTISRDNSKNTLSLQMNSLRAEDTAVYYCAR DWGDPDAFDI WGQGTMVTVSS (SEQ ID NO: 109)

[0688] VL DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAAS TLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGT KVEIK (SEQ ID NO: 110)

[0689] Heavy chain EVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWV AVIWYDVSHKYYADSVKGRFTISRDNSKNTLSLQMNSLRAEDTAVYYCAR DWGDPDAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK (SEQ ID NO: 111)

[0690] Light chain DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAAS TLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGT KVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNA LQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS

[0691]

[0692] PVTKSFNRGEC (SEQ ID NO: 112)

[0693] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 97; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 98; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 99; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 100; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 101; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 102, wherein the CDRs are defined according to the Kabat numbering system.

[0694] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 103; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 104;and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 105; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 106; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 107; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 108, wherein the CDRs are defined according to the IMGT numbering system.

[0695] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 109, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 97 or 103; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 98 or 104; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 99 or 105; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 110 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 100 or 106; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 101 or 107; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 102 or 108. In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 109; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 110.

[0696] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 111, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 97 or 103; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 98 or 104; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 99 or 105; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 112 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 100 or 106; a LCDR2 comprising or consisting of the amino acid sequence of SEQ IDNO: 101 or 107; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 102 or 108.

[0697] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 111; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 112. In some embodiments, the antibody or fragment thereof comprises or consists of two heavy chains comprising or consisting of the amino acid sequence of SEQ ID NO: 111; and two light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 112.

[0698] Anti-CD30 antibodies and fragments thereof

[0699] In some embodiments, the compound of the invention comprises an anti-CD30 antibody or fragment thereof. CD30 is a protein that in humans is encoded by the TNFRSF8 gene and which may also be known as TNFRSF8 (TNF receptor superfamily member 8).

[0700] The anti-CD30 antibody or fragment thereof may specifically bind CD30. The anti-CD30 antibody may be a monoclonal antibody. In some embodiments, the anti-CD30 antibody or fragment thereof is a humanized antibody. In some embodiments, the anti-CD30 antibody or fragment thereof is a monoclonal humanized antibody. The fragment thereof may be any antigen-binding fragment thereof, for example a Fab, a Fab', a F(ab')2, a Fv, an ScFv, a Fab'-SH, an sdAb, or a VHH. In some embodiments, the anti-CD30 antibody or fragment thereof is a full-length anti-CD30 antibody.

[0701] Example anti-CD30 antibody CDRs, variable region sequences, and heavy and light chain sequences are provided below.

[0702] Kabat HCDR1 DYYIT (SEQ ID NO: 113)

[0703] Kabat HCDR2 WIYPGSGNTKYNEKFKG (SEQ ID NO: 114)

[0704] Kabat HCDR3 YGNYWFAY (SEQ ID NO: 115)

[0705] Kabat LCDR1 KASQSVDFDGDSYMN (SEQ ID NO: 116)

[0706] Kabat LCDR2 AASNLES (SEQ ID NO: 117)

[0707] Kabat LCDR3 QQSNEDPWT (SEQ ID NO: 118)

[0708] IMGT HCDR1 GYTFTDYY (SEQ ID NO: 119)

[0709] IMGT HCDR2 IYPGSGNT (SEQ ID NO: 120)

[0710] IMGT HCDR3 ANYGNYWFAY (SEQ ID NO: 121)

[0711] IMGT LCDR1 QSVDFDGDSY (SEQ ID NO: 122)

[0712] IMGT LCDR2 AAS (SEQ ID NO: 123)

[0713] IMGT LCDR3 QQSNEDPWT (SEQ ID NO: 124)

[0714] VH QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGW IYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYG NYWFAYWGQGTQVTVSA (SEQ ID NO: 125)

[0715] VL DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPK VLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPW

[0716]

[0717] TFGGGTKLEIK (SEQ ID NO: 126)Heavy chain QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGW IYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYG NYWFAYWGQGTQVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCWVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

[0718] (SEQ ID NO: 127)

[0719] Light chain DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPK VLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPW TFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASWCLLNNFYPREAKVQ WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVT

[0720]

[0721] HQGLSSPVTKSFNRGEC (SEQ ID NO: 128)

[0722] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 113; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 114; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 115; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 116; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 117; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 118, wherein the CDRs are defined according to the Kabat numbering system.

[0723] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 119; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 120; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 121 ; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 122; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 123; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 124, wherein the CDRs are defined according to the IMGT numbering system.

[0724] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 125, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 113 or 119; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 114 or 120; and a HCDR3 comprising or consistingof the amino acid sequence of SEQ ID NO: 115 or 121 ; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 126 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 116 or 122; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 117 or 123; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 118 or 124. In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 125; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 126.

[0725] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 127, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 113 or 119; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 114 or 120; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 115 or 121; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 128 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 116 or 122; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 117 or 123; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 118 or 124.

[0726] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 127; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 128. In some embodiments, the antibody or fragment thereof comprises or consists of two heavy chains comprising or consisting of the amino acid sequence of SEQ ID NO: 127; and two light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 128.

[0727] Anti-Nectin-4 antibodies and fragments thereof

[0728] In some embodiments, the compound of the invention comprises an anti-Nectin-4 antibody or fragment thereof. Nectin-4 is a protein that in humans is encoded by the NECTIN4 gene and which may also be known as Nectin Cell Adhesion Molecule 4.The anti-Nectin-4 antibody or fragment thereof may specifically bind Nectin-4. The anti-Nectin-4 antibody may be a monoclonal antibody. In some embodiments, the anti-Nectin-4 antibody or fragment thereof is a human antibody. In some embodiments, the anti-Nectin-4 antibody or fragment thereof is a monoclonal human antibody. The fragment thereof may be any antigen-binding fragment thereof, for example a Fab, a Fab', a F(ab')2, a Fv, an ScFv, a Fab'-SH, an sdAb, or a VHH. In some embodiments, the anti-Nectin-4 antibody or fragment thereof is a full-length anti-Nectin-4 antibody.

[0729] Example anti-Nectin-4 antibody CDRs, variable region sequences, and heavy and light chain sequences are provided below.

[0730] Kabat HCDR1 SYNMN (SEQ ID NO: 129)

[0731] Kabat HCDR2 YISSSSSTIYYADSVKG (SEQ ID NO: 130)

[0732] Kabat HCDR3 AYYYGMDV (SEQ ID NO: 131)

[0733] Kabat LCDR1 RASQGISGWLA (SEQ ID NO: 132)

[0734] Kabat LCDR2 AASTLQS (SEQ ID NO: 133)

[0735] Kabat LCDR3 QQANSFPPT (SEQ ID NO: 134)

[0736] IMGT HCDR1 GFTFSSYN (SEQ ID NO: 135)

[0737] IMGT HCDR2 ISSSSSTI (SEQ ID NO: 136)

[0738] IMGT HCDR3 ARAYYYGMDV (SEQ ID NO: 137)

[0739] IMGT LCDR1 QGISGW (SEQ ID NO: 138)

[0740] IMGT LCDR2 AAS (SEQ ID NO: 139)

[0741] IMGT LCDR3 QQANSFPPT (SEQ ID NO: 140)

[0742] VH EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYNMNWVRQAPGKGLEWV SYISSSSSTIYYADSVKGRFTISRDNAKNSLSLQMNSLRDEDTAVYYCARA YYYGMDVWGQGTTVTVSS (SEQ ID NO: 141)

[0743] VL DIQMTQSPSSVSASVGDRVTITCRASQGISGWLAWYQQKPGKAPKFLIYA ASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGG GTKVEIK (SEQ ID NO: 142)

[0744] Heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYNMNWVRQAPGKGLEWV SYISSSSSTIYYADSVKGRFTISRDNAKNSLSLQMNSLRDEDTAVYYCARA YYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI CNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD TLMISRTPEVTCWVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK, wherein the terminal lysine residue is present or absent (SEQ ID NO: 143) Light chain DIQMTQSPSSVSASVGDRVTITCRASQGISGWLAWYQQKPGKAPKFLIYA ASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGG GTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGL

[0745]

[0746] SSPVTKSFNRGEC (SEQ ID NO: 144)

[0747] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 129; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 130;and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 131; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 132; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 133; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 134, wherein the CDRs are defined according to the Kabat numbering system.

[0748] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 135; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 136; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 137; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 138; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 139; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 140, wherein the CDRs are defined according to the IMGT numbering system.

[0749] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 141, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 129 or 135; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 130 or 136; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 131 or 137; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 142 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 132 or 138; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 133 or 139; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 134 or 140. In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 141; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 142.

[0750] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 143, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the heavy chainvariable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 129 or 135; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 130 or 136; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 131 or 137; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 144 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 132 or 138; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 133 or 139; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 134 or 140.

[0751] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 143; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 144. In some embodiments, the antibody or fragment thereof comprises or consists of two heavy chains comprising or consisting of the amino acid sequence of SEQ ID NO: 143; and two light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 144.

[0752] Anti-TF antibodies and fragments thereof

[0753] In some embodiments, the compound of the invention comprises an anti-TF antibody or fragment thereof. Tissue factor (TF) is a protein that in humans is encoded by the F3 gene and which may also be known as platelet tissue factor or Coagulation factor III.

[0754] The anti-TF antibody or fragment thereof may specifically bind TF. The anti-TF antibody may be a monoclonal antibody. In some embodiments, the anti-TF antibody or fragment thereof is a human antibody. In some embodiments, the anti-TF antibody or fragment thereof is a monoclonal human antibody. The fragment thereof may be any antigen-binding fragment thereof, for example a Fab, a Fab', a F(ab')2, a Fv, an ScFv, a Fab'-SH, an sdAb, or a VHH. In some embodiments, the anti-TF antibody or fragment thereof is a full-length anti-TF antibody.

[0755] Example anti-TF antibody CDRs, variable region sequences, and heavy and light chain sequences are provided below.

[0756] Kabat HCDR1 NYAMS (SEQ ID NO: 145)

[0757] Kabat HCDR2 SISGSGDYTYYTDSVKG (SEQ ID NO: 146)

[0758] Kabat HCDR3 SPWGYYLDS (SEQ ID NO: 147)

[0759] Kabat LCDR1 RASQGISSRLA (SEQ ID NO: 148)

[0760] Kabat LCDR2 AASSLQS (SEQ ID NO: 149)

[0761]

[0762] Kabat LCDR3 QQYNSYPYT (SEQ ID NO: 150)IMGT HCDR1 GFTFSNYA (SEQ ID NO: 151)

[0763] IMGT HCDR2 ISGSGDYT (SEQ ID NO: 152)

[0764] IMGT HCDR3 ARSPWGYYLDS (SEQ ID NO: 153)

[0765] IMGT LCDR1 QGISSR (SEQ ID NO: 154)

[0766] IMGT LCDR2 AAS (SEQ ID NO: 155)

[0767] IMGT LCDR3 QQYNSYPYT (SEQ ID NO: 156)

[0768] VH EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWV SSISGSGDYTYYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR SPWGYYLDSWGQGTLVTVSS (SEQ ID NO: 157)

[0769] VL DIQMTQSPPSLSASAGDRVTITCRASQGISSRLAWYQQKPEKAPKSLIYAA SSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQG TKLEIK (SEQ ID NO: 158)

[0770] Heavy chain EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWV SSISGSGDYTYYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR SPWGYYLDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ TYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPK PKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK (SEQ ID NO: 159)

[0771] Light chain DIQMTQSPPSLSASAGDRVTITCRASQGISSRLAWYQQKPEKAPKSLIYAA SSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQG TKLEI KRTVAAPSVFI FPPSDEQLKSGTASVVCLLN N FYPREAKVQWKVDN ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLS

[0772]

[0773] SPVTKSFNRGEC (SEQ ID NO: 160)

[0774] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 145; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 146; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 147; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 148; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 149; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 150, wherein the CDRs are defined according to the Kabat numbering system.

[0775] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 151; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 152; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 153; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 154; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 155; and (iii) a LCDR3comprising or consisting of the amino acid sequence of SEQ ID NO: 156, wherein the CDRs are defined according to the IMGT numbering system.

[0776] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 157, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 145 or 151; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 146 or 152; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 147 or 153; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 158 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 148 or 154; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 149 or 155; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 150 or 156. In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 157; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 158.

[0777] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 159, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 145 or 151; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 146 or 152; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 147 or 153; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 160 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 148 or 154; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 149 or 155; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 150 or 156.

[0778] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 159; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 160. Insome embodiments, the antibody or fragment thereof comprises or consists of two heavy chains comprising or consisting of the amino acid sequence of SEQ ID NO: 159; and two light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 160.

[0779] Anti-B7-H4 antibodies and fragments thereof

[0780] In some embodiments, the compound of the invention comprises an anti-B7-H4 antibody or fragment thereof. B7-H4 is a protein that in humans is encoded by the VTCN1 gene and which may also be known as V-Set Domain Containing T Cell Activation Inhibitor 1.

[0781] The anti-B7-H4 antibody or fragment thereof may specifically bind B7-H4. The anti-B7-H4 antibody may be a monoclonal antibody. In some embodiments, the anti-B7-H4 antibody or fragment thereof is a human antibody. In some embodiments, the anti-B7-H4 antibody or fragment thereof is a monoclonal human antibody. The fragment thereof may be any antigen-binding fragment thereof, for example a Fab, a Fab', a F(ab')2, a Fv, an ScFv, a Fab'-SH, an sdAb, or a VHH. In some embodiments, the anti-B7-H4 antibody or fragment thereof is a full-length anti-B7-H4 antibody.

[0782] Example anti-B7-H4 antibody CDRs, variable region sequences, and heavy and light chain sequences are provided below.

[0783] Kabat HCDR1 SGSYYWG (SEQ ID NO: 161)

[0784] Kabat HCDR2 NIYYSGSTYYNPSLRS (SEQ ID NO: 162)

[0785] Kabat HCDR3 EGSYPNQFDP (SEQ ID NO: 163)

[0786] Kabat LCDR1 RASQSVSSNLA (SEQ ID NO: 164)

[0787] Kabat LCDR2 GASTRAT (SEQ ID NO: 165)

[0788] Kabat LCDR3 QQYHSFPFT (SEQ ID NO: 166)

[0789] IMGT HCDR1 GGSIKSGSYY (SEQ ID NO: 167)

[0790] IMGT HCDR2 IYYSGST (SEQ ID NO: 168)

[0791] IMGT HCDR3 AREGSYPNQFDP (SEQ ID NO: 169)

[0792] IMGT LCDR1 QSVSSN (SEQ ID NO: 170)

[0793] IMGT LCDR2 GAS (SEQ ID NO: 171)

[0794] IMGT LCDR3 QQYHSFPFT (SEQ ID NO: 172)

[0795] VH QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWI GNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREG SYPNQFDPWGQGTLVTVSS (SEQ ID NO: 173)

[0796] VL EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYG ASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGG TKVEIK (SEQ ID NO: 174)

[0797] Heavy chain QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWI GNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREG SYPNQFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP

[0798]

[0799] QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GK (SEQ ID NO: 175)

[0800] Light chain EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYG ASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGG TKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLS

[0801]

[0802] SPVTKSFNRGEC (SEQ ID NO: 176)

[0803] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 161; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 162; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 163; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 164; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 165; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 166, wherein the CDRs are defined according to the Kabat numbering system.

[0804] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 167; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 168; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 169; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 170; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 171; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 172, wherein the CDRs are defined according to the IMGT numbering system.

[0805] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 173, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 161 or 167; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 162 or 168; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 163 or 169; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 174 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 164 or 170; a LCDR2comprising or consisting of the amino acid sequence of SEQ ID NO: 165 or 171; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 166 or 172. In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 173; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 174.

[0806] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 175, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 161 or 167; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 162 or 168; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 163 or 169; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 176 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 164 or 170; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 165 or 171; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 166 or 172.

[0807] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 175; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 176. In some embodiments, the antibody or fragment thereof comprises or consists of two heavy chains comprising or consisting of the amino acid sequence of SEQ ID NO: 175; and two light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 176.

[0808] Anti-ITGB6 antibodies and fragments thereof

[0809] In some embodiments, the compound of the invention comprises an anti-ITGB6 antibody or fragment thereof. Integrin beta-6 (ITGB6) is a protein that in humans is encoded by the ITGB6 gene.

[0810] The anti-ITGB6 antibody or fragment thereof may specifically bind ITGB6. The anti-ITGB6 antibody may be a monoclonal antibody. In some embodiments, the anti-ITGB6 antibody or fragment thereof is a human antibody. In some embodiments, the anti-ITGB6 antibody or fragment thereof is a monoclonal human antibody. The fragment thereof may be anyantigen-binding fragment thereof, for example a Fab, a Fab', a F(ab')2, a Fv, an ScFv, a Fab'-SH, an sdAb, or a VHH. In some embodiments, the anti-ITGB6 antibody or fragment thereof is a full-length anti-ITGB6 antibody.

[0811] Example anti-ITGB6 antibody CDRs, variable region sequences, and heavy and light chain sequences are provided below.

[0812] Kabat HCDR1 DYNVN (SEQ ID NO: 177)

[0813] Kabat HCDR2 VINPKYGTTRYNQKFKG (SEQ ID NO: 178)

[0814] Kabat HCDR3 GLNAWDY (SEQ ID NO: 179)

[0815] Kabat LCDR1 GASENIYGALN (SEQ ID NO: 180)

[0816] Kabat LCDR2 GATNLED (SEQ ID NO: 181)

[0817] Kabat LCDR3 QNVLTTPYT (SEQ ID NO: 182)

[0818] IMGT HCDR1 GYSFTDYN (SEQ ID NO: 183)

[0819] IMGT HCDR2 INPKYGTT (SEQ ID NO: 184)

[0820] IMGT HCDR3 TRGLNAWDY (SEQ ID NO: 185)

[0821] IMGT LCDR1 ENIYGA (SEQ ID NO: 186)

[0822] IMGT LCDR2 GAT (SEQ ID NO: 187)

[0823] IMGT LCDR3 QNVLTTPYT (SEQ ID NO: 188)

[0824] VH QFQLVQSGAEVKKPGASVKVSCKASGYSFTDYNVNWVRQAPGQGLEWI GVINPKYGTTRYNQKFKGRATLTVDKSTSTAYMELSSLRSEDTAVYYCTR GLNAWDYWGQGTLVTVSS (SEQ ID NO: 189)

[0825] VL DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGA TNLEDGVPSRFSGSGSGRDYTFTISSLQPEDIATYYCQNVLTTPYTFGQGT KLEIK (SEQ ID NO: 190)

[0826] Heavy chain QFQLVQSGAEVKKPGASVKVSCKASGYSFTDYNVNWVRQAPGQGLEWI GVINPKYGTTRYNQKFKGRATLTVDKSTSTAYMELSSLRSEDTAVYYCTR GLNAWDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI CNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD TLMISRTPEVTCWVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0827] (SEQ ID NO: 191)

[0828] Light chain DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGA TNLEDGVPSRFSGSGSGRDYTFTISSLQPEDIATYYCQNVLTTPYTFGQGT KLEIKRTVAAPSVFIFPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNA LQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS

[0829]

[0830] PVTKSFNRGEC (SEQ ID NO: 192)

[0831] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 177; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 178; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 179; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 180; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 181; and (iii) a LCDR3comprising or consisting of the amino acid sequence of SEQ ID NO: 182, wherein the CDRs are defined according to the Kabat numbering system.

[0832] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises: (i) a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 183; (ii) a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 184; and (iii) a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 185; and a light chain variable region of the antibody or fragment thereof comprises: (i) a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 186; (ii) a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 187; and (iii) a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 188, wherein the CDRs are defined according to the IMGT numbering system.

[0833] In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 189, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 177 or 183; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 178 or 184; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 179 or 185; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 190 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, optionally wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 180 or 186; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 181 or 187; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 182 or 188. In some embodiments, a heavy chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 189; and a light chain variable region of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 190.

[0834] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 191, or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the heavy chain variable region comprises: a HCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 177 or 183; a HCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 178 or 184; and a HCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 179 or 185; and a light chain of the antibody or fragment thereof comprisesor consists of the amino acid sequence of SEQ ID NO: 192 or an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity thereto, wherein the light chain variable region comprises: a LCDR1 comprising or consisting of the amino acid sequence of SEQ ID NO: 180 or 186; a LCDR2 comprising or consisting of the amino acid sequence of SEQ ID NO: 181 or 187; and a LCDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 182 or 188.

[0835] In some embodiments, a heavy chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 191; and a light chain of the antibody or fragment thereof comprises or consists of the amino acid sequence of SEQ ID NO: 192. In some embodiments, the antibody or fragment thereof comprises or consists of two heavy chains comprising or consisting of the amino acid sequence of SEQ ID NO: 191; and two light chain comprising or consisting of the amino acid sequence of SEQ ID NO: 192.

[0836] Variants, derivatives, homologues and fragments

[0837] In addition to the specific antibodies and fragments described herein, the present invention also encompasses variants thereof.

[0838] In the context of the invention, a “variant” of any given sequence is a sequence in which the specific sequence of amino acid residues has been modified in such a manner that the antibodies or fragment in question retains the ability to specifically bind an antigen of interest. A variant sequence can be obtained by addition, deletion, substitution, modification, replacement and / or variation of at least one residue present in the given sequence.

[0839] Although a variant can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties / functions), in the context of the present invention it is preferred to express it in terms of sequence identity. In the present context, a variant sequence is taken to include an amino acid sequence which may be at least 90% identical, suitably at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the subject sequence.

[0840] Calculation of maximum percent identity firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (see e.g. Devereux, J., et al., 1984. Nucleic acids research, 12(1), pp.387-395). Examples of other software that can perform sequence comparisons include, but are not limited to, the BLAST package (see e.g. Altschul, S.F., et al., 1990. Journal of molecular biology, 215(3), pp.403-410), BLAST 2 (see e.g. Tatusova, T.A. and Madden, T.L., 1999. FEMS microbiology letters, 174(2), pp.247-250), FASTA (see e.g. Pearson, W.R. and Lipman, D.J., 1988. PNAS, 85(8), pp.2444-2448.), EMBOSS Needle (Madeira, F., et al., 2019. Nucleic acids research, 47(W1), pp.W636-W641) and the GENEWORKS suite of comparison tools. For some applications, it is preferred to use EMBOSS Needle. Once the software has produced an optimal alignment, it is possible to calculate percent sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result. The percent sequence identity may be calculated as the number of identical residues as a percentage of the total residues in the SEQ ID NO referred to.

[0841] Example variants of the specific antibodies and fragments described herein comprise one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid additions, deletions and / or substitutions in a framework region. Example variants of the specific antibodies and fragments described herein comprise one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid substitutions in a framework region. Example variants of the specific antibodies and fragments described herein include those which differ mainly by conservative substitutions; for example, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 of the substitutions in the variant are conservative amino acid residue replacements.

[0842] In the context of the present disclosure, a "conservative substitution" is a substitution of one amino acid with another amino acid having similar structural and / or chemical characteristics, such substitution of one amino acid residue for another amino acid residue of the same class. For example, leucine may be substituted with isoleucine as they are both aliphatic, branched hydrophobes. Similarly, aspartic acid may be substituted with glutamic acid since they are both small, negatively charged residues. Naturally occurring amino acids may also be generally divided into four families: acidic (aspartate, glutamate), basic (lysine, arginine, histidine), non-polar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. In one embodiment, conservative amino acid substitutions include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

[0843] Binding molecule conjugates

[0844] The present invention provides a binding molecule conjugate, such as an antibody-drug conjugate, obtained or obtainable by conjugating a compound of the present invention to a binding molecule or a fragment thereof, preferably an antibody or a fragment thereof.Examples of such binding molecule conjugates, preferably ADCs, are provided in Formulae (l-D) and (ll-D).

[0845] As used herein, the term “binding molecule conjugate” encompasses both specific binding molecule conjugates having a connection number which is integral and compositions containing a mixture of binding molecule conjugates having different connection numbers, resulting in an average connection number which can be non-integral. As used herein, the term “binding molecule conjugate” applies irrespective of whether the binding moiety is a binding molecule or a fragment thereof.

[0846] In preferred embodiments, the binding molecule conjugate of the present invention is an antibody-drug conjugate. As used herein, the term “antibody-drug conjugate” encompasses both specific antibody-drug conjugates having a DAR which is integral and compositions containing a mixture of antibody-drug conjugates having different DARs, resulting in an average DAR which can be non-integral. As used herein, the term “antibody-drug conjugate” applies irrespective of whether the binding moiety is an antibody or a fragment thereof.

[0847] Typically, in the antibody-drug conjugates of the present invention, one or more payloads or payload moieties are linked, preferably covalently linked to an antibody or fragment thereof via a linker to form an antibody-drug conjugate. The moiety linked to the antibody or fragment thereof is generally referred to herein as the “linker-payload moiety”. The linkerpayload moiety comprises a linker, as defined herein, and a payload, as defined herein. The drug-antibody ratio (DAR) is the number of linker-payload molecules attached to each binding molecule conjugate e.g. each antibody or fragment thereof (it can be understood that the term “drug-antibody ratio” applies equally whether the linker-payload molecule is attached to an antibody or to a fragment thereof). In this specification the terms “drugantibody ratio”, “DAR” and “connection number” are synonymous.

[0848] In some preferred embodiments, the DAR is an integer of 1 or 2. In some more preferred embodiments, the DAR is 1. In other embodiments, the DAR is 2.

[0849] Compositions comprising binding molecule conjugates

[0850] The present invention also provides a composition which comprises one or more binding molecule conjugates (e.g. one or more antibody-drug conjugates) as defined herein.

[0851] As indicated above, the drug-antibody ratio (DAR) of the binding molecule conjugates (e.g. antibody-drug conjugates) as described herein may vary. Consequently, the composition may comprise a mixture of binding molecule conjugates (e.g. antibody-drug conjugates)having a number of different DARs, and may therefore have an average DAR which is nonintegral. In this specification “average DAR” and “average connection number” are synonymous.

[0852] In some preferred embodiments, the average DAR is an integer or decimal from about 0.5 to about 2.0, from about 0.5 to about 1.5, from about 0.6 to about 1.4, from about 0.7 to about 1.3, from about 0.8 to about 1.2, or from about 0.9 to 1.1. In some preferred embodiments, the average DAR is about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0. In some preferred embodiments, the average DAR is about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, or about 1.5. In some more preferred embodiments, the average DAR is an integer or decimal from about 0.8 to 1.2. In some embodiments, the average DAR is about 0.8. In some embodiments, the average DAR is about 0.9. In some embodiments, the average DAR is about 1.0. In some embodiments, the average DAR is about 1.1. In some embodiments, the average DAR is about 1.2.

[0853] In some even more preferred embodiments, the average DAR is an integer or decimal from about 0.9 to 1.1. In some even more preferred embodiments, the average DAR is about 0.9. In some even more preferred embodiments, the average DAR is about 1.0. In some even more preferred embodiments, the average DAR is about 1.1.

[0854] In some embodiments, the composition comprises one or more binding molecule conjugates, preferably one or more antibody-drug conjugates having the structure shown as formula (l-D’) or a pharmaceutically acceptable salt thereof:

[0855]

[0856] " (l-D')

[0857] wherein Ri, R2, n, m, x, L, P and Ab are as defined for formula (l-D), either in its broadest aspect or a preferred aspect, and wherein q’ is an average connection number and is aninteger or decimal from about 0.5 to about 2.0. In some preferred embodiments, q’ is an integer or decimal from about 0.5 to about 1.5, from about 0.6 to about 1.4, from about 0.7 to about 1.3, from about 0.8 to about 1.2, or from about 0.9 to 1.1.

[0858] In some embodiments, the composition comprises one or more binding molecule conjugates, preferably one or more antibody-drug conjugates having the structure shown as formula (I l-D’) or a pharmaceutically acceptable salt thereof:

[0859]

[0860] wherein R3, R4, Rs, Rs, R9, R10, u, v, r, LG1, LG2, L, P and Ab are as defined for formula (II-D), either in its broadest aspect or a preferred aspect, and wherein q’ is an average connection number and is an integer or decimal from about 0.5 to about 2.0. In some preferred embodiments, q’ is an integer or decimal from about 0.5 to about 1.5, from about 0.6 to about 1.4, from about 0.7 to about 1.3, from about 0.8 to about 1.2, or from about 0.9 to 1.1.

[0861] General Methods

[0862] Synthesis of compounds of formula (l-A) and (ll-A)

[0863] The compounds of formula (l-A) and (I l-A) may be synthesized by any suitable method. Example methods for synthesizing a compound of formula (l-A) are provided in Examples 1 and 2. An example method for synthesizing a compound of formula (I l-A) is provided in Example 3.

[0864] Preparation of binding molecule conjugates

[0865] The binding molecule conjugates (e.g. antibody-drug conjugates) may be formed by conjugating a compound of formula (l-C) or (I l-C) to a binding molecule or a fragment thereof (e.g. an antibody or fragment thereof). This can be carried out by a number of methods well known to those skilled in the art.In one embodiment of such a method, the method comprises:

[0866] (a) reducing the disulphide bonds on the relevant amino acid residues (typically cysteine residues) on the binding molecule or fragment thereof (e.g. antibody or fragment thereof) (Ab), to generate an activated form of Ab in which the thiol groups on the relevant amino acids are free; and

[0867] (b) reacting the activated form of Ab with the compound of formula (l-C) or (I l-C), thereby conjugating the compound of formula (l-C) or (I l-C) to Ab to form the compound of formula (I-D) or (ll-D).

[0868] In some embodiments, the method further comprises selective reduction / oxidation of the disulphide bonds to generate an activated form of Ab in which the thiol groups in the hinge region are free, but in which other thiol groups form disulphide bonds. Any suitable method may be used to selectively reduce / oxidise the disulphide bonds. Such methods may enable further control of the DAR, for example providing a DAR of from about 0.5 to about 2.0, from about 0.5 to about 1.5, from about 0.6 to about 1.4, from about 0.7 to about 1.3, from about 0.8 to about 1.2, or from about 0.9 to 1.1. In some embodiments, the DAR is an integer of 1. In some embodiments, the method further comprises: (i) incubating Ab with metal ions, either during or after step (a); (ii) an oxidation step to re-form the disulphide bonds between steps (a) and (b); and (iii) a step of adding a chelator to remove the metal ions prior to step (b).

[0869] In one embodiment, the method comprises:

[0870] (i) reducing disulphide bonds of Ab in the presence of metal ions, where the metal ions bind to certain sulfur atoms in the hinge region of Ab;

[0871] (ii) an oxidation step to re-form the disulphide bonds;

[0872] (iii) a step of adding a chelator to remove the metal ions; and

[0873] (iv) a step of adding the compound of formula (l-C) or (I l-C), thereby conjugating the compound to the sulfur atoms that were protected by the metal ions to form the compound of formula (l-D) or (ll-D).

[0874] In one embodiment, the method comprises:

[0875] (i) reducing disulphide bonds of Ab and, following the reduction step, Ab is then incubated with metal ions in a separate step, where the metal ions bind to certain sulfur atoms in the hinge region of Ab;(ii) an oxidation step to re-form the disulphide bonds;

[0876] (iii) a step of adding a chelator to remove the metal ions; and

[0877] (iv) a step of adding the compound of formula (l-C) or (I l-C), thereby conjugating the compound to the sulfur atoms that were protected by the metal ions to form the compound of formula (l-D) or (ll-D).

[0878] Any suitable reaction conditions and amounts of reducing agent, metal ions, oxidation agent, and chelator may be used. Any suitable reducing agent may be used, for example tris(2-carboxyethyl)phosphine (TCEP), optionally in a TCEP:Ab ratio of from about 4:1 to about 16:1, for example about 8:1. Any suitable metal ions may be used, for example zinc ions, optionally in a zinc:Ab ratio of from about 2:1 to about 8:1, for example about 4:1. Any suitable oxidising agent may be used, for example DHAA, optionally in a DHAA:Ab ratio of from about 8:1 to about 32:1, for example about 16:1. Any suitable chelator may be used, for example EDTA, optionally in a concentration of from about 1 mM to about 20 mM, for example about 5 mM. The ratio of compound of formula (l-C) or (I l-C) :Ab may be from about 5: 1 to about 20: 1 , for example about 10:1.

[0879] An example method for conjugating a compound of formula (l-C) or (I l-C) to Ab is provided in Example 4.

[0880] Synthesis and conjugation of payload compounds

[0881] The compounds of formulae (l-C) and (l-C) may be formed by conjugating payload moieties (P) to compounds comprising linker moieties (L). This can be carried out by a number of methods well known to those skilled in the art. For example, when the linker moiety L contains a peptide linker, part of the linker may be synthesised by standard peptide synthetic methods well known to those skilled in the art. The payload can subsequently be conjugated by standard peptide coupling.

[0882] Examples methods for synthesising and conjugating a payload moiety to a compound comprising a peptide linker are provided in the accompanying examples.

[0883] Salts, Solvates, Polymorphs, Enantiomers, Isotopically Labelled Derivatives

[0884] Pharmaceutically acceptable salts of the compounds of formulae (l-A) to (l-D) and (ll-A) to (ll-D) include the acid addition and base salts thereof.

[0885] Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate / carbonate,bisulphate / sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogen phosphate / dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate and xinafoate salts.

[0886] Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.

[0887] Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.

[0888] For a review on suitable salts, see Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth (Wiley-VCH, 2002).

[0889] Pharmaceutically acceptable salts of compounds of formulae (l-A) to (l-D) and (ll-A) to (ll-D) may be prepared by one or more of three methods:

[0890] (i) by reacting the compound of formulae (l-A) to (l-D) and (ll-A) to (ll-D) with the desired acid or base;

[0891] (ii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound of formulae (l-A) to (l-D) and (ll-A) to (ll-D) or by ring-opening a suitable cyclic precursor, for example, a lactone or lactam, using the desired acid or base; or

[0892] (iii) by converting one salt of the compound of formulae (l-A) to (l-D) and (ll-A) to (ll-D) to another by reaction with an appropriate acid or base or by means of a suitable ion exchange column.

[0893] All three reactions are typically carried out in solution. The resulting salt may precipitate out and be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionisation in the resulting salt may vary from completely ionised to almost non-ionised. The compounds of the invention may exist in a continuum of solid states ranging from fully amorphous to fully crystalline. The term 'amorphous' refers to a state in which the material lacks long range order at the molecular level and, depending upon temperature, may exhibit the physical properties of a solid or a liquid. Typically, such materials do not give distinctive X-ray diffraction patterns and, while exhibiting the properties of a solid, are more formallydescribed as a liquid. Upon heating, a change from solid to liquid properties occurs which is characterised by a change of state, typically second order ('glass transition').

[0894] The term 'crystalline' refers to a solid phase in which the material has a regular ordered internal structure at the molecular level and gives a distinctive X-ray diffraction pattern with defined peaks. Such materials when heated sufficiently will also exhibit the properties of a liquid, but the change from solid to liquid is characterised by a phase change, typically first order ('melting point').

[0895] The compounds of the invention may also exist in unsolvated and solvated forms. The term “solvate” is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term “hydrate” is employed when said solvent is water.

[0896] A currently accepted classification system for organic hydrates is one that defines isolated site, channel, or metal-ion coordinated hydrates - see Polymorphism in Pharmaceutical Solids by K. R. Morris (Ed. H. G. Brittain, Marcel Dekker, 1995). Isolated site hydrates are ones in which the water molecules are isolated from direct contact with each other by intervening organic molecules. In channel hydrates, the water molecules lie in lattice channels where they are next to other water molecules. In metal-ion coordinated hydrates, the water molecules are bonded to the metal ion. When the solvent or water is tightly bound, the complex will have a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water / solvent content will be dependent on humidity and drying conditions. In such cases, non- stoichiometry will be the norm.

[0897] In this specification all references to compounds of formulae (l-A) to (l-D) and (I l-A) to (I l-D) include references to pharmaceutically acceptable salts and solvates thereof.

[0898] The compounds of the invention include compounds of formulae (l-A) to (l-D) and (ll-A) to (I l-D) as hereinbefore defined, including all polymorphs and crystal habits thereof, prodrugs and isomers thereof (including optical, geometric and tautomeric isomers) as hereinafter defined and isotopically-labelled compounds of formulae (l-A) to (l-D) and (ll-A) to (ll-D). Compounds of formulae (l-A) to (l-D) and (ll-A) to (ll-D) containing one or more asymmetric carbon atoms can exist as two or more stereoisomers. Where structural isomers are interconvertible via a low energy barrier, tautomeric isomerism ('tautomerism') can occur. This can take the form of proton tautomerism in compounds of formula I containing, for example, an imino, keto, or oxime group, or so-called valence tautomerism in compoundswhich contain an aromatic moiety. It follows that a single compound may exhibit more than one type of isomerism.

[0899] Included within the scope of the present invention are all stereoisomers, geometric isomers and tautomeric forms of the compounds of formulae (l-A) to (l-D) and (I l-A) to (ll-D), including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof. Also included are acid addition or base salts wherein the counterion is optically active, for example, d-lactate or / - lysine, or racemic, for example, d-tartrate or dAarginine. Cis / trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of formulae (l-A) to (l-D) and (I l-A) to (ll-D) contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid. The resulting diastereomeric mixture may be separated by chromatography and / or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person. Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and from 0 to 5% by volume of an alkylamine, typically 0.1% diethylamine. Concentration of the eluate affords the enriched mixture.

[0900] When any racemate crystallises, crystals of two different types are possible. The first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts. The second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer.

[0901] While both of the crystal forms present in a racemic mixture have identical physical properties, they may have different physical properties compared to the true racemate.

[0902] Racemic mixtures may be separated by conventional techniques known to those skilled inthe art - see, for example, Stereochemistry of Organic Compounds by E. L. Eliel and S. H. Wilen (Wiley, 1994).

[0903] The present invention includes all pharmaceutically acceptable isotopically-l abelled compounds of formulae (l-A) to (l-D) and (I l-A) to (I l-D), wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.

[0904] Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as2H and3H, carbon, such as11C,13C and14C, chlorine, such as36CI, fluorine, such as18F, iodine, such as123l and125l, nitrogen, such as13N and15N, and oxygen, such as15O,17O and18O.

[0905] Certain isotopically-labelled compounds of formulae (l-A) to (l-D) and (ll-A) to (ll-D), for example, those incorporating a radioactive isotope, are useful in drug and / or substrate tissue distribution studies. The radioactive isotopes tritium, i.e.3H, and carbon-14, i.e.14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.

[0906] Substitution with heavier isotopes such as deuterium, i.e.2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. Substitution with positron emitting isotopes, such as11C,18F,15O and13N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labelled compounds of formulae (l-A) to (l-D) and (ll-A) to (ll-D) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Intermediates using an appropriate isotopically-labelled reagent in place of the non-labelled reagent previously employed.

[0907] Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, d6-acetone, d6-DMS.

[0908] Pharmaceutical Compositions

[0909] The present invention also provides a pharmaceutical composition which comprises a compound of formulae (l-A) to (l-D) and (ll-A) to (ll-D) according to the invention, together with a pharmaceutically acceptable carrier, diluent or excipient.In some embodiments, the compositions described herein may further comprise one or more selected from this list consisting of: an adjuvant, salt, active polypeptide, compound, component and active agent.

[0910] Compositions typically should be sterile and stable under the conditions of manufacture and storage. The composition according to the invention may be produced using current good manufacturing practices (CGMP).

[0911] The pharmaceutical composition may be formulated to be suitable for administration to a subject in order to prevent and / or treat disease. Pharmaceutical compositions can be formulated for administration by different routes, for example, for oral, parenteral, topical, inhalative, intravenous, intramuscular, rectal, sublingual, transdermal, subcutaneous, intratumoral application routes, according to their chemical and physical properties.

[0912] The pharmaceutical composition may be in the form of a tablet, a coated tablet, powder, granulate, a pellet, a capsule, an effervescent tablet or a transdermal therapeutic system. The pharmaceutical composition may be in the form of a liquid composition, selected from the group consisting of a solution, a syrup, an infusion, an extract, a solution for intravenous application, or a solution for infusion. The pharmaceutical composition may be in the form of a semisolid composition such as an emulsion, a suspension, a cream, a lotion, a gel, a globule, a buccal tablet or a suppository.

[0913] The term “carrier”, as used herein, may refer to a diluent, adjuvant, excipient, or vehicle. Such carriers can be sterile liquids, such as saline solutions in water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil. A sterile saline solution is a preferred carrier.

[0914] Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers. Suitable excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.

[0915] The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. The composition of the invention can be formulated as neutral or salt forms. Salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.In some embodiments, the salt may comprise a metal cation, such as a sodium salt or a potassium salt.

[0916] In some embodiments, the composition may comprise an aqueous diluent or solvent. In some embodiments, the aqueous diluent or solvent may be a phosphate buffered saline solution, such as a sterile phosphate buffered saline solution.

[0917] In some embodiments, the composition may comprise one or more vesicles, nanoparticles, lipid nanoparticle (LNPs), liposomes or polymeric mixtures.

[0918] Kit

[0919] The present invention also provides a kit which comprises a compound of formulae (l-A) to (l-D) and (I l-A) to (ll-D) according to the invention. The present invention also provides a kit comprising the composition according to the invention.

[0920] In some embodiments, the kit further comprises instructions for use. As used herein, an "instructional material" or "instructions" includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the compositions and methods described herein. The instructional material of the kit of the disclosure may, for example, be affixed to a container which contains the compositions of the disclosure or be shipped together with a container which contains the compositions. Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and the compositions be used cooperatively by the recipient.

[0921] Medical Uses and Methods of Treatment

[0922] The compounds of the invention are indicated as pharmaceuticals. According to a further aspect of the invention there is provided a compound of the invention, as hereinbefore defined, for use as a pharmaceutical.

[0923] The disorders / conditions that the compounds of the invention may be useful in treating hence include cancer (such as lymphomas, solid tumours or a cancer as described hereinafter), inflammatory and autoimmune diseases, for example rheumatoid arthritis, psoriasis, psoriatic arthritis, osteoarthritis, ankylosing spondylitis, atopic dermatitis, inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease, systemic lupus erythematosus, lupus nephritis, multiple sclerosis, peanut allergy, asthma and celiac disease).According to a further aspect of the present invention, there is provided a compound of the invention, as hereinbefore defined, for use in the treatment of cancer.

[0924] According to a further aspect of the present invention, there is provided use of a compound of the invention, as hereinbefore defined, in the manufacture of a medicament for the treatment of cancer.

[0925] According to a further aspect of the present invention, there is provided a method of treatment of cancer, which method comprises administration of a therapeutically effective amount of a compound of the invention, as hereinbefore defined, to a subject suffering from, or susceptible to, such a condition.

[0926] According to a further aspect of the present invention, there is provided a compound of the invention, as hereinbefore defined, for use in the treatment of cancer.

[0927] As stated above, the compounds of the invention may be useful in the treatment of cancer. More, specifically, the compounds of the invention may therefore be useful in the treatment of a variety of cancer including, but not limited to: carcinoma such as cancer of the bladder, breast, colon, kidney, liver, lung (including non-small cell cancer and small cell lung cancer), oesophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, skin, squamous cell carcinoma, testis, genitourinary tract, larynx, glioblastoma, neuroblastoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, non-small cell lung carcinoma, small cell lung carcinoma, lung adenocarcinoma, bone, adenoma, adenocarcinoma, follicular carcinoma, undifferentiated carcinoma, papilliary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, myeloid disorders, lymphoid disorders, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, Hodgkin’s and leukaemia; hematopoietic tumours of lymphoid lineage, including leukaemia, acute lymphocitic leukaemia, acute lymphoblastic leukaemia, B-cell lymphoma, T-cell-lymphoma, mantle cell lymphoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumours of myeloid lineage, including acute and chronic myelogenous leukaemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumours of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; and other tumours, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi’s sarcoma.According to a further aspect of the present invention, there is provided use of a compound of the invention, as hereinbefore defined, in the manufacture of a medicament for the treatment of an autoimmune disease or an inflammatory disease.

[0928] According to a further aspect of the present invention, there is provided a method of treatment of an autoimmune disease or an inflammatory disease, which method comprises administration of a therapeutically effective amount of a compound of the invention, as hereinbefore defined, to a subject suffering from, or susceptible to, such a condition.

[0929] According to a further aspect of the present invention, there is provided a compound of the invention, as hereinbefore defined, for use in the treatment of an autoimmune disease or an inflammatory disease.

[0930] Examples of autoimmune disease and / or inflammatory diseases include but are not limited to coeliac disease, psoriasis, inflammatory bowel diseases such as colitis and Crohn’s disease, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, aplastic anaemia, myocarditis, autoimmune hepatitis, primary biliary cholangitis, alopecia areata, autoimmune urticaria, perphigus vulgaris, autoimmune polyendocrine syndrome (APS), autoimmune pancreatitis, type 1 diabetes, autoimmune thyroiditis, Sjogren’s syndrome, autoimmune haemolytic anaemia, gastritis vasculitis, granlumatosis with polyangitis, autoimmune uveitis, myasthenia gravis, acute disseminated encephalomyelitis, relapsing polychrondritis, Lambert-Eaton myasthenic syndrome, Hashimoto’s encephalopathy, Felty syndrome, autoimmune thyroiditis, Graves’ disease, nephritis, bullous pemphigoid, dermatitis, epidermolysis bullosa acquisita, linear IgA disease, autoimmune lymphoprolifeative syndrome, autoimmune neutropenia, autoimmune thrombocytopenis purpura, cold agglutinin disease, Evans syndrome, pernicious anaemia, Still’s disease, psoriatic arthritis, rheumatic fever, Guillain-Barre syndrome, Ord’s thyroiditis, ankylosing spondylitis, atopic dermatitis, systemic sclerosis (scleroderma), hidradenitis suppurativa, lupus nephritis, peanut allergy, and asthma.

[0931] Compounds of the invention are indicated both in the therapeutic and / or prophylactic treatment of the above-mentioned conditions. For the avoidance of doubt, references herein to "treatment" include references to curative, palliative and prophylactic treatment.

[0932] As used herein the term, “subjects” or “patients” include mammalian (including human) subject. Hence, the method of treatment discussed above may include the treatment of a human or animal body. In some embodiments, the subject is a human subject.The term “effective amount” refers to an amount of a compound, which confers a therapeutic effect on the treated subject. The effect may be objective (e.g. measurable by some test or marker) or subjective (e.g. the subject gives an indication of or feels an effect).

[0933] For administration to human subjects, the total daily dose of the compounds of the invention is typically in the range 1 mg to 5000 mg, preferably 10 mg to 2000 mg, more preferably 50 mg to 1500 mg, and still more preferably 100 to 500 mg depending, of course, on the mode of administration. The total daily dose may be administered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein. These dosages are based on an average human subject having a weight of about 60kg to 70kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.

[0934] EXAMPLES

[0935] The invention will now be further described by way of Examples, which are meant to serve to assist one of ordinary skill in the art in carrying out the invention and are not intended in any way to limit the scope of the invention.

[0936] Example 1 - (3-maleimidopropanoyl)2-Lys-Gly-Gly-Phe-OH

[0937]

[0938] 0.25 mmol of unloaded 2-chlorotrityl chloride resin (0.53 mmol / g substitution on polystyrene crosslinked with 1% divinylbenzene was weighed into a 50 mL conical tube and swollen in a minimal volume of dichloromethane (DCM). 2 eq. relative to the resin substitution of Fmoc-L-Phenylalanine-OH (Phe) was weighed into a separate 50 mL conical tube and dissolved in DCM (~10 mL / g resin). 4 eq. N,N-diisopropylethylamine (DIEA) was pipetted into the amino acid solution, then sonicated and vortexed to mix. The solution was transferred to the resin conical, which was agitated via orbital shaking at room temperature for 4-12 hours. The resin was then transferred to a 20 mL polypropylene fritted syringe and rinsed with DCM. The resin was then treated with a solution comprising 17:2:1 DCM:MeOH:DIEA (~15 mL / g resin) at room temperature for 15 minutes, after which the liquid was ejected and the resin rinsed1x with DMF, 3x with DCM, and then transferred to a new 50mL conical tube. The resin was suspended in 10 mL of 1:1 DMF:DCM and loaded onto the Liberty Blue microwave synthesizer.

[0939] The Liberty Blue was set up with the following reagent configurations: N,N-dimethylformamide (DMF) as the main solvent, 0.3 M solutions of Fmoc-L-Lys(Fmoc)-OH and Fmoc-Gly-OH in DMF, 1.0 M N,N’-diisopropylcarbodiimide (DIG) in DMF as the Activator solution, 1.0M ethyl (cyanohydroxyimino)acetate (Oxyma) + 0.1 M DIEA in DMF as the Activator Base solution, and 20% v / v piperidine in DMF as the Deprotection solution. The instrument was programmed to use 1:1 DMF:DCM to transfer the resin to the 50 mL reaction vessel (RV). The automation method was set to perform Fmoc removal via adding 10 mL of Deprotection solution and microwaving at 60 °C for 3 minutes, followed by washing 3x with DMF. Each coupling was performed by adding 6 eq. of the amino acid (5 mL), 8 eq. of DIG (2 mL), 4 eq. / 0.4 eq. Oxyma / DIEA (1 mL) to the RV and microwaving at 50 °C for 10 minutes. After draining and washing with DMF, the coupling was repeated. After final Fmoc deprotection, the peptide was transferred back to the HT. The resin was rinsed into a 20 mL fritted syringe with DCM and dried on a vacuum manifold.

[0940] The resin in the syringe was swollen in DMF while reagents were prepared for maleimide coupling and the DMF then ejected. 6 eq. of 3-maleimidopropionic acid (3mp) and 6 eq. Oxyma was weighed into a 50mL conical tube and dissolved in 1:1 DMF:NMP (~5mL / g resin). 6 eq. DIEA was added and the conical was vortexed / sonicated to mix. Separately, 6 eq. of [Ethyl cyano(hydroxyimino)acetato-O2]tri-1-pyrrolidinylphosphonium hexafluorophosphate (PyOxim) was weighed into another 50 mL conical tube and dissolved in 1:1 DMF:NMP. The solution of 3mp / Oxyma / DIEA was added to the resin and swirled for 30 seconds, followed by addition of the PyOxim solution. The syringe was agitated at room temperature for 2-16 hours, after which the liquid was ejected and the resin washed 3x with DMF, 3x with DCM, 3x with MeOH and dried in vacuo.

[0941] Final cleavage was performed by adding a solution of 20% v / v 1,1, 1,3,3, 3-hexafluoro-2-propanol (HFIP) in DCM (~15mL / g resin) to the resin and allowing it to stand at room temperature for 15 minutes. The liquid was collected in a round bottom flask and this step was repeated twice, collecting the liquid and a final DCM rinse into the flask. Most of the solvent was removed in vacuo using a rotary evaporator to yield a yellow liquid, which was then transferred to a fared 20mL scintillation vial using a minimal volume of DCM. All DCM was then removed via rotary evaporation to yield a yellow residue. The compound was resuspended in ~3 mL of 1:1 ACN:H2O (0.1% TFA), frozen at -80 °C, and lyophilized for 2 days to yield the crude product. The molecular weight was confirmed by UPLC-MS (ESI+).The crude sample was dissolved in 75:25 water: acetonitrile with 0.05% TFA and transferred to an HPLC injection rack. The crude compound was loaded onto the preparative HPLC column (Phenomenex Luna C18(2) LC Column, 100 A pore size, 10 pm particle size, 30 mm x 250 mm) with an automatic injector through a 10 mL sample loop. Sample loading was done in 95% mobile phase A (0.05% TFA in water), 5% mobile phase B (0.05% TFA in acetonitrile). Elution was performed in a 36-minute linear gradient of 15 - 30 %B. The flow rate was 30 mL / min. A single quadrupole mass spectrometer with ESI+ was used to trigger fraction collection automatically based on the M+1H and M+2H values for the target compound. Aliquots of selected HPLC fractions were injected on a Waters H-Class UPLC-MS system to determine purity by UV214 %area using a linear gradient from 10 to 80% B in 8 minutes with flow rate of 0.5mL / min, where mobile phase A was 0.100% TFA in water and mobile phase B was 0.085% TFA in acetonitrile. The column (ACQUITY UPLC Peptide BEH C18 Column, 130 A, 1.7 pm, 2.1 mm X 100 mm) temperature was 40 °C. Fractions with measured or estimated purity > 90% were pooled into 50 mL polypropylene tubes and concentrated via rotary evaporator. Concentrated fraction pools were transferred to a fared glass tube, and an aliquot was taken for final purity measurement using the aforementioned UPLC-MS method. The bulk compound was frozen on dry ice and isolated via lyophilization. The final purity by UPLC-UV214 was 98.9%.

[0942] Example 2 - (3-maleimidopropanoyl)2-D-Dap-Gly-Gly-Phe-OH

[0943]

[0944] 0.25 mmol of unloaded 2-chlorotrityl chloride resin (0.53 mmol / g substitution on polystyrene crosslinked with 1% divinylbenzene) was weighed into a 50mL conical tube and swollen in a minimal volume of DCM. 2 eq. relative to the resin substitution of Fmoc-L-Phenylalanine-OH (Phe) was weighed into a separate 50 mL conical tube and dissolved in DCM (~10 mL / g resin). 4 eq. DIEA was pipetted into the amino acid solution, then sonicated and vortexed to mix. The solution was transferred to the resin conical, which was agitated via orbital shaking at room temperature for 4-12 hours. The resin was then transferred to a 20 mL polypropylene fritted syringe and rinsed with DCM. The resin was then treated with asolution comprising 17:2:1 DCM:MeOH:DIEA (~15 mL / g resin) at room temperature for 15 minutes, after which the liquid was ejected and the resin rinsed Ixwith DMF, 3x with DCM, and then transferred to a new 50mL conical tube. The resin was suspended in 10 mL of 1 :1 DMF:DCM and loaded onto the Liberty Blue HT12 module.

[0945] The Liberty Blue was set up with the following reagent configurations: DMF as the main solvent, 0.3 M Fmoc-Gly-OH in DMF, 1.0 M DIG in DMF as the Activator solution, 1.0 M Oxyma + 0.1 M DIEA in DMF as the Activator Base solution, and 20% v / v piperidine in DMF as the Deprotection solution. The instrument was programmed to use 1:1 DMF:DCM to transfer the resin to the 50 mL RV. The automation cycle was set to perform Fmoc removal via adding 10 mL of Deprotection solution and microwaving at 60 °C for 3 minutes, followed by washing 3x with DMF. Each coupling was performed by adding 6 eq. of the amino acid (5mL), 8eq of DIG (2 mL), 4 eq. / 0.4 eq. Oxyma / DIEA (1 mL) to the RV and microwaving at 50 °C for 10 minutes. After draining and washing with DMF, the coupling was repeated. After final Fmoc deprotection, the peptide was transferred back to the HT. The resin was rinsed into a 20mL fritted syringe with DCM and rinsed with DMF.

[0946] Fmoc-D-Dap(Fmoc)-OH was coupled by hand. 1.1 eq. of Fmoc-D-Dap(Fmoc)-OH and 1.1 eq. 1-Hydroxy-7-azabenzotriazole (HOAt) were weighed into a 50 mL conical and dissolved in 1:1 DMF:NMP (~5 mL / g resin). 4.4 eq. DIEA was added to the conical, which was sonicated / vortexed to mix. Separately, 1.1 eq. of (7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP) was weighed into another 50 mL conical tube and dissolved in 1:1 DMF:NMP. The solution of DDap / HOAt / DIEA was added to the resin and swirled for 30 seconds, followed by the addition of the PyAOP solution. The resin was agitated at room temperature for 1 hour via the orbital shaker, after which the resin was washed 3x with DMF, 3x with DCM, and 3x with MeOH and dried on the vacuum manifold.

[0947] Final Fmoc deprotection was performed by adding 10 mL 20% v / v piperidine in DMF and agitating at room temperature for 15 minutes, twice. This was followed by washing 3x with DMF and Ixwith DCM. The resin in the syringe was swollen in DMF while reagents were prepared for maleimide coupling and the DMF then ejected. 6 eq. of 3-maleimidopropionic acid (3mp) and 6eq Oxyma was weighed into a 50mL conical tube and dissolved in 1:1 DMF:NMP (~5 mL / g resin). 6 eq. DIEA was added and the conical was vortexed / sonicated to mix. Separately, 6eq of PyOxim was weighed into another 50 mL conical tube and dissolved in 1:1 DMF:NMP. The solution of 3mp / Oxyma / DIEA was added to the resin and swirled for 30 seconds, followed by addition of the PyOxim solution. The syringe wasagitated at room temperature for 2 hours - overnight, after which the liquid was ejected and the resin washed 3x with DMF, 3x with DCM, 3x with MeOH and dried in vacuo.

[0948] Final cleavage was performed by adding a solution of 20% v / v 1,1, 1,3,3, 3-hexafluoro-2-propanol (HFIP) in DCM (~15 mL / g resin) to the resin and allowing it to stand at room temperature for 15 minutes. The liquid was collected in a round bottom flask and this step was repeated twice more, collecting the liquid and a final DCM rinse into the flask. Most of the solvent was removed in vacuo using a rotary evaporator to yield a yellow liquid, which was then transferred to a fared 20mL scintillation vial using a minimal volume of DCM. All DCM was then removed via rotary evaporation to yield a yellow residue. The peptide was resuspended in ~3 mL of 1:1 AC kbhO (0.1% TFA), frozen at -80 °C, and lyophilized for 2 days to yield the crude product. The molecular weight was confirmed by UPLC-MS (ESI+). The crude sample was dissolved in 75:25 water: acetonitrile with 0.05% TFA and transferred to an HPLC injection rack. The crude compound was loaded onto the preparative HPLC column (Phenomenex Luna C18(2) LC Column, 100 A pore size, 10 pm particle size, 30 mm x 250 mm) with an automatic injector through a 5 mL sample loop. Sample loading was done in 95% mobile phase A (0.05% TFA in water), 5% mobile phase B (0.05% TFA in acetonitrile). Elution was performed in a 36-minute linear gradient of 15 - 30 %B. The flow rate was 30 mL / min. A single quadrupole mass spectrometer with ESI+ was used to trigger fraction collection automatically based on the M+1H and M+2H values for the target compound. Aliquots of selected HPLC fractions were injected on a Waters H-Class UPLC-MS system to determine purity by UV214 %area using a linear gradient from 10 to 80% B in 8 minutes with flow rate of 0.5mL / min, where mobile phase A was 0.100% TFA in water and mobile phase B was 0.085% TFA in acetonitrile. The column (ACQUITY UPLC Peptide BEH C18 Column, 130 A, 1.7 pm, 2.1 mm X 100 mm) temperature was 40 °C. Fractions with measured or estimated purity >90% were pooled into 50 mL polypropylene tubes and concentrated via rotary evaporator. Concentrated fraction pools were transferred to a fared glass tube, and an aliquot was taken for final purity measurement using the aforementioned UPLC-MS method. The bulk compound was frozen on dry ice and isolated via lyophilization. The final purity by UPLC-UV214 was 100.0%.Example 3 - (MSP-N-Me-AEEA)2-D-Dap-Gly-Gly-Phe-OH

[0949]

[0950] 0.25 mmol of unloaded 2-chlorotrityl chloride resin (0.53 mmol / g substitution on polystyrene crosslinked with 1% divinylbenzene) was weighed into a 50 mL conical tube and swollen in a minimal volume of dichloromethane (DCM). 2 eq. relative to the resin substitution of Fmoc-L-Phenylalanine-OH (Phe) was weighed into a separate 50 mL conical tube and dissolved in DCM (~10mL / g resin). 4 eq / V, / V-diisopropylethylamine (DIEA) was pipetted into the amino acid solution, then sonicated and vortexed to mix. The solution was transferred to the resin conical, which was agitated via orbital shaking at room temperature for 4-12 hours. The resin was then transferred to a 20 mL polypropylene fritted syringe and rinsed with DCM. The resin was then treated with a solution comprising 17:2:1 DCM:MeOH:DIEA (~15 mL / g resin) at room temperature for 15 minutes, after which the liquid was ejected and the resin rinsed 1x with DMF, 3x with DCM, and then transferred to a new 50 mL conical tube. The resin was suspended in 10 mL of 1:1 DMF:DCM and loaded onto the Liberty Blue HT12 module.

[0951] The Liberty Blue was set up with the following reagent configurations: DMF as the main solvent, 0.3 M Fmoc-Gly-OH in DMF, 1.0M DIC in DMF as the Activator solution, 1.0 M Oxyma + 0.1M DIEA in DMF as the Activator Base solution, and 20% v / v piperidine in DMF as the Deprotection solution. The instrument was programmed to use 1:1 DMF:DCM to transfer the resin to the 50 mL RV. The automation Cycle was set to perform Fmoc removal via adding 10 mL of Deprotection solution and microwaving at 60 °C for 3 minutes, followed by washing 3x with DMF. Each coupling was performed by adding 6 eq. of the amino acid (5 mL), 8eq of DIC (2 mL), 4eq / 0.4eq Oxyma / DIEA (1mL) to the RV and microwaving at 50 °C for 10 minutes. After draining and washing with DMF, the coupling was repeated. After final Fmoc deprotection, the peptide was transferred back to the HT. The resin was rinsed into a 20mL fritted syringe with DCM and rinsed with DMF.Fmoc-D-Dap(Fmoc)-OH was coupled by hand. 1.1 eq of Fmoc-D-Dap(Fmoc)-OH and 1.1 eq HOAt were weighed into a 50mL conical and dissolved in 1:1 DMF:NMP (~5mL / g resin). 3.3eq DIEA was added to the conical, which was sonicated / vortexed to mix. Separately, 1.1 eq of PyAOP was weighed into another 50mL conical tube and dissolved in 1:1 DMF:NMP. The solution of D-Dap / HOAt / DIEA was added to the resin and swirled for 30 seconds, followed by the addition of the PyAOP solution. The resin was agitated at room temperature for 1 hour via the orbital shaker, after which the resin was washed 3x with DMF, 3x with DCM, and 3xwith MeOH and dried on the vacuum manifold.

[0952] Both Fmoc groups were deprotected by adding 10mL 20% v / v piperidine in DMF to the resin and agitating at room temperature for 15 minutes, twice. This was followed by washing 3x with DMF and 1x with DCM. The resin in the syringe was swollen in DMF while reagents were prepared for Fmoc-N-methyl AEEA coupling and the DMF then ejected. Fmoc-N-methyl AEEA-OH (NMeAEEA) was coupled by hand. 2.2 eq. of NMeAEEA and 2.2 eq. HOAt were weighed into a 50mL conical and dissolved in 1:1 DMF:NMP (~5 mL / g resin). 8.8eq DIEA was added to the conical, which was sonicated / vortexed to mix. Separately, 2.2 eq. of PyAOP was weighed into another 50 mL conical tube and dissolved in 1 :1 DMF:NMP. The solution of NMeAEEA / HOAt / DIEA was added to the resin and swirled for 30 seconds, followed by the addition of the PyAOP solution. The resin was agitated at room temperature for 2 hours via the orbital shaker, after which the resin was washed 3x with DMF, 3x with DCM, and 3x with MeOH and dried on the vacuum manifold. A test cleavage was performed to confirm complete coupling. Then, final Fmoc deprotection was performed by adding 10mL 20% v / v piperidine in DMF to the resin and agitating at room temperature for 15 minutes, twice. This was followed by washing 3x with DMF and 1x with DCM.

[0953] 7.5 eq. 2-(Methylsulfonyl)pyrimidine-5-carboxylic acid (MSP) and 7.2 eq. of 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) was weighed into a 50mL conical tube and dissolved in ~10 mL of 2-methyltetrahydrofuran (2MeTHF). 10 eq. of N-methylmorpholine (NMM) was added to the conical, followed by 1-2 mL of / V, / V-dimethylacetamide (DMAc) to assist in solubilizing the mixture. The solution was agitated at RT for approximately 2 hours. The resin was swollen in a minimal volume of 2MeTHF, after which the preactivated mixture was added to the syringe and agitated on an orbital shaker for 4 hours. The resin was rinsed 3x with 2-MeTHF, 3xwith DMF, 3xwith DCM, and 3xwith MeOH and dried on the vacuum manifold.

[0954] Final cleavage was performed by adding a solution of 20% v / v 1,1, 1,3,3, 3-hexafluoro-2-propanol (HFIP) in DCM (~15mL / g resin) to the resin and allowing it to stand at room temperature for 15 minutes. The liquid was collected in a round bottom flask and this stepwas repeated twice more, collecting the liquid and a final DCM rinse into the flask. Most of the solvent was removed in vacuo using a rotary evaporator to yield a yellow liquid, which was then transferred to a fared 20 mL scintillation vial using a minimal volume of DCM. All DCM was then removed via rotary evaporation to yield a yellow residue. The compound was resuspended in ~3 mL of 1:1 ACIXLF (0.1% TFA), frozen at -80 °C, and lyophilized for 2 days to yield the crude product. The molecular weight was confirmed by UPLC-MS (ESI+). The crude sample was dissolved in 75:25 water: acetonitrile with 0.05% TFA and transferred to an HPLC injection rack. The crude compound was loaded onto the preparative HPLC column (Phenomenex Luna C18(2) LC Column, 100 A pore size, 5 pm particle size, 30 mm x 250 mm) with an automatic injector through a 10 mL sample loop. Sample loading was done in 95% mobile phase A (0.05% TFA in water), 5% mobile phase B (0.05% TFA in acetonitrile). Elution was performed in a 36-minute linear gradient of 15 - 30 %B. The flow rate was 30 mL / min. A single quadrupole mass spectrometer with ESI+ was used to trigger fraction collection automatically based on the M+1H, M+2H, and M+3H values for the target compound. Aliquots of selected HPLC fractions were injected on a Waters H-Class UPLC-MS system to determine purity by UV214 %area using a linear gradient from 10 to 80% B in 8 minutes with flow rate of 0.5mL / min, where mobile phase A was 0.100% TFA in water and mobile phase B was 0.085% TFA in acetonitrile. The column (ACQUITY UPLC Peptide BEH C18 Column, 130 A, 1.7 pm, 2.1 mm X 100 mm) temperature was 40 °C. Fractions with measured or estimated purity >90% were pooled into 50 mL polypropylene tubes and concentrated via rotary evaporator. Concentrated fraction pools were transferred to a fared glass tube, and an aliquot was taken for final purity measurement using the aforementioned UPLC-MS method. The bulk compound was frozen on dry ice and isolated via lyophilization. The final purity by UPLC-UV214 was 98.1%.

[0955] Example 4 - Protocol for preparing Linker Payloads

[0956] Any suitable payload may be attached to the molecules described above in Examples 1-3 via the free carboxyl group using standard conditions known in the art. The skilled person would be familiar with suitable reagents and conditions for this reaction. Suitable examples of such payloads are described above and are also generally described in WO2022 / 068878, WO2022 / 170971 and W02004 / 010957, and national applications deriving therefrom.Example 5 - Protocol for preparing Antibody-Drug Conjugates (ADCs) using selective reduction / oxidation

[0957] A method for preparing antibody-drug conjugates involves the coupling of a linker-payload (for example, as prepared according to Example 4) to reduced, inter-chain disulphide-forming cysteine residues of an antibody.

[0958] An example protocol for preparing such ADCs is described below. The example protocol comprises selective reduction / oxidation of the disulphide bonds:

[0959] 1. Antibody Reduction and Zn(ll) Chelation:

[0960] • Reduction of the antibody (e.g. Trastuzumab) is performed at a concentration of 5-8 mg / mL using TCEP in the presence of ZnCh.

[0961] • Conditions: 12 °C for 20 hours in 40 mM sodium phosphate buffer, pH 6.9.

[0962] • Molar ratios: TCEP to antibody was 8:1, ZnCI2 to antibody was 4:1.

[0963] 2. Oxidation:

[0964] • DHAA was added to the reduced antibody solution.

[0965] • Conditions: Incubated at 22 °C for 2 hours.

[0966] • Molar ratio: DHAA to antibody was 16:1.

[0967] 3. DHAA Removal:

[0968] • The intermediate product was purified using a spin desalting column (40 kDa) with 40 mM sodium phosphate buffer, pH 6.9.

[0969] 4. Conjugation:

[0970] • The linker payload was slowly added to the purified mAb-Zn(ll) complex.

[0971] • After thorough mixing, EDTA was added to chelate Zn(ll), allowing the linker payload to react with the protected two cysteine residues.

[0972] • Conditions: Incubated at 4 °C for 2 hours.

[0973] • Molar ratio: Linker-payload to mAb was 10:1.

[0974] • EDTA final concentration: 5 mM.

[0975] 5. Quench Reaction:

[0976] N-acetylcysteine (NAC) was used to quench the reactions.

[0977] Molar ratio: NAC to antibody was 16:1.

[0978] Conditions: Incubated at 4 °C for 30 minutes.6. Purification:

[0979] • The final ADC product was purified using a spin desalting column (40 kDa) with formulation buffer containing 20 mM Histidine, 120 mM Sodium Chloride, 50 mM Sucrose, pH 6.0, 0.02% polysorbate 20.

[0980] Example 6 - Determination of drug-to-antibody ratio (DAR) for method of Example 5

[0981] Antibody-Drug Conjugates (ADCs) were prepared by the method described in Example 5, using the compounds of Examples 1-4.

[0982] To determine the drug-antibody ratio (DAR) of antibody-drug conjugates (ADCs), the samples were analyzed under denaturing reverse-phase liquid chromatography-mass spectrometry (RPLC-MS) conditions. RPLC effectively separates chains with various payloads.

[0983] Each sample was prepared by diluting 1.0 mg / mL of ADCs to 0.1 mg / mL in 1% acetic acid. The mixture was analyzed using a MAb Pac RP column (4.0 pm, 2.1 x 50 mm, Thermo Fisher Scientific, USA, PN 088648) connected to a Shimadzu LC40 HPLC system equipped with a binary gradient pump, temperature-controlled column compartment, autosampler, and diode array detector.

[0984] The system conditions were as follows: Flow rate: 0.4 mL / min at 60°C; Mobile phase A (MPA): 0.1% formic acid in water; Mobile phase B (MPB): 0.1% formic acid in acetonitrile / Absorbance was monitored at 280 nm (reference wavelength at 450 nm) for the naked antibody, and at 370 nm for ADCs with various payloads. Each ADC sample (0.5 pg) was injected into the system and eluted over a 9-minute run, consisting of:

[0985] 1. 1 -minute isocratic hold at 25% MPB

[0986] 2. 5-minute linear gradient from 25% to 95% MPB

[0987] 3. 1-minute wash using 95% MPB

[0988] 4. A 2-minute re-equilibration at 25% MPB

[0989] The results are shown in Figure 1. Each of the ADCs had an average DAR of around 1. The ADCs prepared using the compounds of Examples 1-3 had a tightly controlled DAR, with >83% ADCs having a DAR of 1, and 0.0% ADCs having a DAR of 0.

[0990] All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope andspirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in chemistry, biochemistry, molecular biology, biotechnology or related fields are intended to be within the scope of the following claims.

Claims

CLAIMS1. A compound comprising a structure shown as formula (l-A) or formula (I l-A) or pharmaceutically acceptable salts or solvates thereof:(i) wherein formula (l-A) is:wherein:Ri and R2 are each independently selected from H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, each optionally substituted;n and m are each independently from 0 to 20; andx is 0, 1, 2, 3, 4, or 5; and(ii) wherein formula (ll-A) is:wherein:R3, R4, Rs and R6are each independently H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, each optionally substituted;LG1 and LG2 are each independently a leaving group;Rg and Rweach independently consist of -(EO)s-(CH2)t-, wherein EO is an ethylene glycol moiety, the terminal carbon of which is attached to the group -N(Rs)- or -N(Re)- and the terminal oxygen of which is attached to the group -(CH2)t-, wherein s is from 0 to 10 and t is from 0 to 15, provided that s and t are not both 0;u and v are independently from 0 to 10; andr is 0, 1, 2, 3, 4, or 5.

2. The compound according to claim 1 , wherein the compound comprises the structure shown as formula (l-A).

3. The compound according to claim 2, wherein n and m are each independently selected from 1, 2, 3, or 4, preferably wherein n and m are both 1.

4. The compound according to claim 2 or 3, wherein x is 0, 1, 2, 3, or 4, preferably wherein x is 1 or 4.

5. The compound according to any of claims 2-4, wherein Ri and R2are each independently selected from H or a C1-3 alkyl, preferably wherein Ri and R2are both H.

6. The compound according to any of claims 2-5, wherein the chiral center * is in R configuration.

7. The compound according to any of claims 2-6, wherein the compound comprises the structure shown as formula (l-A-1) or formula (l-A-2) or formula (l-A-3) or pharmaceutically acceptable salts or solvates thereof:

8. The compound according to claim 1 , wherein the compound comprises the structure shown as formula (ll-A).

9. The compound according to claim 8, wherein u and v are independently selected from 1 , 2, 3, or 4, preferably wherein u and v are both 1.

10. The compound according to claim 8 or 9, wherein r is 0, 1, 2, 3, or 4, preferably wherein r is 1.

11. The compound according to any of claims 8-10, wherein R3 and R4 are each independently selected from H or a C1-3 alkyl, preferably wherein R3 and R4 are both H.

12. The compound according to any of claims 8-11 , wherein R5and R6are each independently selected from H or a C1-3 alkyl, preferably wherein R5and R6are both methyl.

13. The compound according to any of claims 8-12, wherein LG1 is a sulfonate having formula -SO2R7 and LG2 is a sulfonate having formula -SO2R8, wherein R7 and Rs are each independently C1-6 alkyl or substituted C1-6 alkyl, preferably wherein R7and R8are each independently selected from H or a C1-3 alkyl, more preferably wherein R7and R8are both methyl.

14. The compound according to any of claims 8-13, wherein the chiral center * is in R configuration.

15. The compound according to any of claims 8-14, wherein s is from 1 to 10 and t is from 0 to 10, preferably wherein s is 2 and t is 1.

16. The compound according to claim 15, wherein the compound comprises the structure shown as formula (ll-A-1) or a pharmaceutically acceptable salt or solvate thereof:wherein:Rs, R4, Rs, Re, u, v, r, LG1, and LG2 are as defined for formula (ll-A) in claim 1.

17. The compound according to claim 16, wherein the compound comprises the structure shown as formula (ll-A-2) or a pharmaceutically acceptable salt or solvate thereof:

18. The compound according to any of claims 8-14, wherein R9and R10are each independently selected from 01-015 alkylene.

19. The compound according to claim 18, wherein the compound comprises the structure shown as formula (ll-A-3) or a pharmaceutically acceptable salt or solvate thereof:wherein:Rs, R4, Rs, Re, u, v, r, LG1, and LG2 are as defined for formula (ll-A) in claim 1; and x and y are each independently from 1 to 15, preferably x and y are each independently from 1 to 6, preferably wherein x and y are both 2 or both 3.

20. The compound according to claim 19, wherein the compound comprises the structure shown as formula (ll-A-4) or formula (ll-A-5) or pharmaceutically acceptable salts or solvates thereof:

21. The compound according to any of claims 1-20, wherein the compound further comprises a payload moiety, preferably wherein the payload moiety is a cytotoxic drug.

22. The compound according to claim 21, wherein the payload moiety is a tubulin polymerisation inhibitor, a DNA damaging agent, a TOPO1 inhibitor, an auristatin, a maytansinoid, or a calicheamicin.

23. The compound according to claim 22, wherein the payload moiety is a TOPO1 inhibitor.

24. The compound according to claim 23, wherein the TOPO1 inhibitor is a camptothecin or an exatecan, or a derivative thereof, preferably wherein the TOPO1 inhibitor is exatecan.

25. The compound according to any of claims 21-24, wherein the compound further comprises a linker moiety.

26. The compound according to claim 25, wherein the linker moiety comprises a peptide moiety, preferably wherein the peptide moiety consists of 1 to 10 amino acid residues, more preferably wherein the peptide moiety consists of 1 to 6 amino acid residues.

27. The compound according to claim 26, wherein the linker moiety further comprises a spacer moiety, preferably wherein the spacer moiety is present between the peptide moiety and the payload moiety.

28. The compound according to any of claims 21-27, wherein the compound has a structure shown as formula (l-C) or formula (I l-C) or pharmaceutically acceptable salts or solvates thereof:(i) wherein formula (l-C) is:wherein:Ri, R2, n, m, and xare as defined for formula (l-A) in claim 1;L is a linker moiety; andP is a payload moiety; and(ii) wherein formula (ll-C) is:wherein:Rs, R4, Rs, Re, u, v, r, LG1, and LG2 are as defined for formula (ll-A) in claim 1;L is a linker moiety; andP is a payload moiety.

29. The compound according to any of claims 21-28, wherein the payload moiety has a structure selected from any of formulae (lll-A) to (VI ll-A):wherein formula (lll-A) is:wherein:II is O or S; andV is (C1-6) alkylene, (C3-10) cycloalkylene, or (C1-6) alkylene-(C3-10) cycloalkylene; wherein formula (IV-A) is:(IV-A)wherein:R1’ is selected from the group consisting of: -O-, -(R2’)N-, -P(=O)(R2’)- and -S-;X is -L1-CH2-C(O)-;L1is -(C(R3a)(R3b))m-, wherein 0 or at least 1 methylene unit of L1is independently replaced by -0(0)-, -C(=S)-, -C(=NR4b)- or -C(=N2)-;each R2’, each R3a, each R3band each R4bare each independently hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OR, -SR, -N(Ra)(Rb), -C(O)R, -CO2R, -C(O)C(O)R, -C(O)CH2C(O)R, -S(O)R, -S(O)2R, -C(O)N(Ra)(Rb), -SO2N(Ra)(Rb), -OC(O)R, -N(R)SO2R, or a C1-6 aliphatic group optionally substituted with R;each R, each Raand each Rbare each independently hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H or a C1-6 aliphatic group;m is selected from the group consisting of integers > 0;provided that when R1’ is -O- or -HN-, at least 1 methylene unit of L1is independently replaced by -C(O)-, -C(=S)-, -C(=NR4b)- or -C(=N2)-, or each R3aand each R3bare not both hydrogen;wherein formula (V-A) is:wherein X1is saturated C, and X1is substituted with Rn;ring A is selected from the group consisting of: 3-10 membered saturated or partially unsaturated heterocyclyl and 3-10 membered saturated or partially unsaturated carbocyclyl, wherein ring A is substituted with 0 or at least 1 substituent R1a;provided that when ring A is 3-10 membered saturated or partially unsaturated carbocyclyl, ring A is substituted with p L2, and L2is not Rn; or, when ring A is 3-10 membered saturated or partially unsaturated heterocyclyl, ring A is substituted with p L2;L2is -R2x-L3-, and R2xis used for direct or indirect linking of a ligand;L3is -(C(R3a)(R3b))m-, wherein when L3comprises a methylene unit, 0 or at least 1 methylene unit of L3is independently replaced by -N(R4’)C(O)-, -C(O)N(R4’)-, -C(O)-, -OC(O)-, -C(O)O-, -NR4’-, -O-, -S-, -SO-, -SO2-, -P(R4’)-, -P(=O)(R4’)-, -N(R4’)SO2-, -SO2N(R4’)-, -C(=S)-, -C(=NR4’)-, -N=N-, -C=N-, -N=C- or-C(=N2)-;R2xis selected from the group consisting of: -O-, -(R2a)N-, -S- and -P(=O)(R2a)-;L1is -(C(R5a)(R5b))n-, wherein when L1comprises a methylene unit, 0 or at least 1 methylene unit of L1is independently replaced by -N(R6’)C(O)-, -C(O)N(R6’)-, -C(O)-, -OC(O)-, -C(O)O-, -NR6’-, -O-, -S-, -SO-, -SO2-, -P(R6’)-, -P(=O)(R6’)-, -N(R6’)SO2-, -SO2N(R6’)-, -C(=S)-, -C(=NR6’)-, -N=N-, -C=N-, -N=C- or-C(=N2)-;each R1a, each R2a, each R3a, each R3b, each R4’, each R5a, each R5b, each R6’ and each Rnare each independently hydrogen, protium, deuterium, tritium, halogen, -NO2, -ON, -OR, -SR, -N(Ra)(Rb), -C(O)R, -CO2R, -C(O)C(O)R, -C(O)CH2C(O)R, -S(O)R, -S(O)2R, -C(O)N(Ra)(Rb), -SO2N(Ra)(Rb), -OC(O)R, -N(R)SO2R, or a C1-6 aliphatic group optionally substituted with R;each R, each Raand each Rbare each independently hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H or a C1-6 aliphatic group;m and n are each independently selected from the group consisting of integers > 0, and p is an integer > 1;wherein formula (VI-A) is:(VI-A)wherein:R1” and R2”are each independently selected from H, halogens and C1-4 alkyl; or, R1” and R2”, together with the carbon atom to which they are both attached form a 5-6 membered heterocyclic ring, the heterocyclic ring contains 1, 2, or 3 of O, S, or N or any combination thereof;R3’’ is selected from H and C1-4 alkyl; or R3’’ and X, together with the carbon atom to which they are both attached, form a 5-6 membered carbon ring;W is absent or present, when W is present, W is selected from -O-, -S-, -NR4-,R< Rsand RiRS , wherein position 1 is attached to X;fR?” Rz"R’’-(LR'" X is selected from optionally substituted -(CH2)ni-,Rt,R / , position 1 is attached to the parent ring and position 2 is attached to W; the substituent is selected from one or two C1-4 alkyls;R4”, Rs-, and Ry- are each independently selected from H and C1-4 alkyl;n”, n1, n2, n3 are each independently selected from any integer between 0 and 6; wherein formula (Vll-A) is:and wherein formula (Vlll-A) is:

30. The compound according to any of claims 25-29, wherein the linker moiety comprises or consists of -Lb-Lc- or -L3-L4-, wherein:-Lb- represents a peptide residue consisting of 2 to 7 amino acids;-Lc- is selected from the group consisting of:wherein RL1and RL2are each independently selected from the group consisting of: hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, - C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H and a C1-6 aliphatic group;L3 is selected from an amino acid residue or a peptide consisting of 2-10 amino acid residues;* N * N *■> L4 is absent or present, when L4 is present, L4 is selected from Hposition 2 is attached to the payload moiety.

31. The compound according to any of claims 25-30, wherein the compound comprises a linker-payload moiety having a structure selected from any of formulae (lll-B) to (Vl-B): wherein formula (lll-B) is:wherein:II and V are as defined in claim 29 for formula (lll-A);L is -Lb-Lc- as defined in claim 30;wherein formula (IV-B) is:(IV-B)wherein:R1’ and X are as defined in claim 29 for formula (IV-A);L is -Lb-Lc- as defined in claim 30;wherein formula (V-B) is:wherein:ring A, X1, L1and L2are as defined in claim 29 for formula (V-A); L is -Lb-Lc- as defined in claim 30;and wherein formula (Vl-B) is:(VI-B)wherein:R1”, R2”, R3”, X and W are as defined in claim 29 for formula (Vl-A);-L3-L4- is as defined in claim 30.

32. The compound according to any of claims 1-20, wherein the compound has a structure shown as formula (l-B) or formula (ll-B) or pharmaceutically acceptable salts or solvates thereof:(i) wherein formula (l-B) is:wherein:Ri, R2, n, m, x are as defined for formula (l-A) in claim 1 ; andLG3 is a hydroxyl group or a leaving group, for example a halogen; and(ii) wherein formula (ll-B) is:wherein:Rs, R4, Rs, Re, R9, R10, u, v, r, LG1, and LG2 are as defined for formula (ll-A) in claim 1; and LG4 is a hydroxyl group or a leaving group, for example a halogen.

33. An antibody-drug conjugate obtained or obtainable by conjugating the compound according to any of claims 1-31 to an antibody or a fragment thereof, preferably wherein the antibody-drug conjugate has a Drug-to-Antibody Ratio (DAR) of from 0.5 to 2.0.

34. An antibody-drug conjugate having a structure shown as formula (l-D) or formula (I l-D) or pharmaceutically acceptable salts or solvates thereof:(i) wherein formula (l-D) is:(l-D)wherein:R1 and R2 are each independently selected from H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, each optionally substituted;n and m are each independently from 0 to 20;x is 0, 1, 2, 3, 4, or 5;L is a linker moiety;P is a payload moiety;Ab is an antibody or a fragment thereof; andq is preferably 1 or 2, more preferably wherein q is 1 ; and(ii) wherein formula (ll-D) is:wherein:R3, R4, Rs and R6are each independently H or a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, each optionally substituted;R9 and R10 each independently consist of -(EO)s-(CH2)t-, wherein EO is an ethylene glycol moiety, the terminal carbon of which is attached to the group -N(R5)- or -N(R6)- and the terminal oxygen of which is attached to the group -(CH2)t, wherein s is from 0 to 10 and t is from 0 to 15, provided that s and t are not both 0;u and v are independently from 0 to 10;r is 0, 1, 2, 3, 4, or 5;L is a linker moiety;P is a payload moiety;Ab is an antibody or a fragment thereof; andq is preferably 1 or 2, more preferably wherein q is 1.

35. The antibody-drug conjugate according to 34, wherein the compound conjugated to the antibody or fragment thereof is defined according to any of claims 2-31.

36. The antibody-drug conjugate according to any of claims 33-35, wherein the antibody or fragment thereof specifically binds to a target expressed on the surface of a tumour cell.

37. The antibody-drug conjugate according to claim 36, wherein the target expressed on the surface of a tumour cell is HER2, B7H3, TROP2, HER3, CD30, Nectin-4, TF, B7-H4, and / or ITGB6, preferably HER2, B7H3, TROP2 and / or HER3.

38. The antibody-drug conjugate according to any of claims 33-37, wherein the antibody or fragment thereof is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, a monoclonal antibody, and a polyclonal antibody.

39. The antibody-drug conjugate according to any of claims 33-38, wherein the antibody or fragment thereof is selected from the group consisting of: a Fab, a Fab', a F(ab')2, an Fv, an ScFv, an Fab'-SH, an sdAb, and a VHH.

40. The antibody-drug conjugate according to any of claims 33-39, wherein the antibody or fragment thereof comprises an immunoglobulin constant region, the immunoglobulin constant region being a human IgG constant region, e.g., a human lgG1 constant region.

41. A composition comprising one or more antibody-drug conjugates according to any of claims 33-40.

42. The composition according to claim 41, wherein the composition is a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers, diluents and / or excipients.

43. An antibody-drug conjugate according to any of claims 33-40 or a composition according to claim 41 or 42, for use as a medicament.

44. An antibody-drug conjugate according to any of claims 33-40 or a composition according to claim 41 or 42, for use in treating cancer.

45. Use of an antibody-drug conjugate according to any of claims 33-40 or a composition according to claim 41 or 42 for the manufacture of a medicament for treating cancer.

46. A method of treating cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of an antibody-drug conjugate according to any of claims 33-40 or a composition according to claim 41 or 42 to the subject.

47. An antibody-drug conjugate according to any of claims 33-40 or a composition according to claim 41 or 42, for use in treating an autoimmune disease or an inflammatory disease.

48. Use of an antibody-drug conjugate according to any of claims 33-40 or a composition according to claim 41 or 42 for the manufacture of a medicament for treating an autoimmune disease or an inflammatory disease.

49. A method of treating an autoimmune disease or an inflammatory disease in a subject in need thereof, the method comprising administering a therapeutically effective amount of an antibody-drug conjugate according to any of claims 33-40 or a composition according to claim 41 or 42 to the subject.

50. A method of producing an antibody-drug conjugate, the method comprising conjugating a compound according to any of claims 1-31 to an antibody or fragment thereof.

51. The method according to claim 50, wherein the method comprises:(i) reducing disulphide bonds of an antibody in the presence of metal ions, where the metal ions bind to certain sulfur atoms in the hinge region of the antibody;(ii) an oxidation step to re-form the disulphide bonds;(iii) a step of adding a chelator to remove the metal ions; and(iv) a step of adding the compound according to any of claims 1-31 , which binds to the sulfur atoms that were protected by the metal ions.

52. The method according to claim 50, wherein the method comprises:(i) reducing disulphide bonds of an antibody and, following the reduction step, the antibody is then incubated with metal ions in a separate step, where the metal ions bind to certain sulfur atoms in the hinge region of the antibody;(ii) an oxidation step to re-form the disulphide bonds;(iii) a step of adding a chelator to remove the metal ions; and(iv) a step of adding the compound according to any of claims 1-31 , which binds to the sulfur atoms that were protected by the metal ions.